A

Abdominal pain Causes and risk factors for postoperative... 5 Frequency and characteristics o f . . . 27

ab l gene A novel abl-like gene associated. 329

Abscess, liver Specific diagnosis of amebic l iver . . . 86 Choledochojejunostomy and pyogenic... 1392

Acetaldehyde SEE ALSO Ethanol Hepatitis C virus infection enhances. . . 465 Acetaldehyde and malondialdehyde... 479 IgA, IgG, and IgM antibodies against . . . 480 Acetaldehyde increases transforming... 1461

Acetaminophen Metabolism

Acetaminophen metabolism in patients. . , 1585 Toxicity

OV-6 positive, HepParl negative. . . 496 Incidence of acetaminophen overdose... 1091 Improved outcome from severe. . . 1110 Evaluation of hepatecellular defense.. . 1432

Transport Acetaminophen glucuronide transport . . . 817

Acetic acid Prospective controlled trial o f . . . 357 Development of new therapy targeting 1301

Acetylcysteine Thiol regulation of endotexin-induced... 520

Acid labile subunit The acid-labile subunit in acute . . . 1219

Actin Actin-containing complexes in l iver . . . 168 Endothelin antagonism in experimental.., 460 Hepatic expression of a-smooth.. . 686 Hepatic stellate cell activation... 691 Inhibition of rat Ite cell activation... 705 Early free sermn Gc-globulin i n . . . 1519

Acute hepatic failure Bioartificial liver

Extracorporeal liver perfusion wi th . . . 166 Clinical experience with a bioartificial... 386 Preliminary evaluation of a new. . . 423

Complications Extracellular brain amino acids. . . 216 Correlation of serial cytokine levels. . . 1038 Presence of liver necrosis is needed. . . 1097 Recovery from central pontine.. . 1152

Dialysis Removal of ammonia and nitrogenous... 432 Continuous veno-venous... 1227

Etiology Parvovirus B19 as a possible cause. . . 1351

Experimental models Characterization of early signs. . . 214 A novel experimental anim~ model . . . 1095

Hemodiabsorption The Biologi cv~ sorbent~ and cell-based... 1133 Hemodiabsorption in treatment of . . . . 1134

Hepatocyte transplantation Critical analysis of intra-splenie... 387 Rapid integration and proliferation,.. 499

Liver biopsy Transvenous fiver biopsy in fulminant. . . 1108

Liver regeneration Middle-molecular-weight inhibitor.. , 494

Liver transplantation Tacrolimus (FKS06) versus cyclosporine... 149 Emergency auxiliary liver transplantation. . . 165 Auxiliary liver transplantation... 186 Outcome of liver transplantation.. 407 Inability of intracranial pressure.. 408 Liver transplantation for F H F . . . 410

Outcome Measurement of serum Ge protein. 409 Improved outcome from severe. . . 1110 Common clinical criteria do no t . . . 1135

Pathology Serum isocitrate dehydrogenase a s . , . 1107

S U B J E C T I N D E X Subject index entries denote abstract number.

Acute hepatic failure (continued) Pathophysiology

Bc]-2 protects from lethal hepatic.. . 483 The effect of head elevation o n . . . 729 TNFa-induced apoptesis of . . . 1093 The acid-labile subunit in acute. . . 1219 Cerebrovascular CO z reactivity... 1352 Early free serum Gc-globulin i n . . . 1519

Survival The effect of augmenter of l iver . . . 1094 Does ciprofloxaciu alter survival. . . 1098 Augmentin-induced hepate-renal failure. . . 1173

Acute phase proteins Are acute phase proteins a new biological... 1469

Acute phase response factor APRF, increased nuclear binding,.. 515

Acyltr~n~ferases Hepatic and gallbladde r acyl-CoA... 16

Addressins Expression of E-selectin and E-selectin... 59

S-Adenosylmethionine Improving hepatic hemodynamie and . . . 431 Mechanism of defect in mitechondrial... 521 S-adenosylmethionine deficiency... 1092 S-adenosylmethionine versus. ~. 1153 Bile salt toxicity is reduced b y . . . 1174

S-Adenosylmethionine synthetase Molecular characterization of . . . 343

Adenosine Mechanism of extracellular ATP-induced... 830 Role of adenosine receptors in t he . . . 1473

Adenoviruses Adenovlrus-associated, receptor-mediated... 628

Adrenal glands Increased IL-l~:IL-lra mRNA.. . 1562

Adrenomedullin Effect of adrenomeduUin, a novel. . . 716

Aged Hepatitis C virus infection and . . . 973 Analysis of the anti-HBs response... 1208

Aging Age-dependent repression of a lpha. . . 422 Determinants of biliary bile acid. . . 1274

AIDS SEE HIV infection

Albumin Gene expression

Detection of albumin mRNA in blood... 131 Albumin-mRNA positive circulating... 325 Control of albumin gene expression... 784 Recombinant adenovirus-mediatod... 785 Gap junction's role of differential.,. 1308

Micrvspheres 99m-Tc-labeled human serum albumin,. . 421

Pathophysiology Liver transplantation in familial... 384

Therapeutic use Comparison of albumin, dextran-70... 456 Continuous veno-venous . . . 1227

Alcohol dehydrogenase SE~ ALSO Ethanol Effects of cimetidine on blood ethanol. . . 1322

Alcohol drinking Evidence that increased alcohol... 220 Recidivism following fiver transplantation... 377 Chronic ethanol administration increases... 797 Chronic ethanol consumption impairs . . . 808 Does excessive alcohol consumption... 1544

Alcohol liver disease Diagnosis

Carbohydrate deficient transferrin... 553 Serum andulin and collagen type . , . 720 Clinical significance of elevated... 1111

Drug metabolism Acetaminophen metabolism in patients. . . 1585

Experimental models Polyenylphosphatidylcholine decreases... 475 Treatment with dietary saturated., . 476 Increased in vlvo expression of . . . 543 Effect of thromboxane inhibition... 545 Genetic polymorphism of the r a t . . . 551 Effects of dietary zinc on vitamin. . . 1462

Alcohol liver disease (continued) Hepatitis C

Amelioration of liver damage af ter , . . 265 Hepatitis C virus infection enhances.. . 465

Immunology lmmunoglobulin A antibody to a 140kDa... 82 IgA, IgG, and IgM antibodies against . . . 480 Increased expression of J3 chemokines... 1030 Intrahepatic lymphocyte production... 1033

Iron Hepatic iron concentration in end . . . 676 Red cell ferritin and serum ferrit in. . . 999

Obesity Overweight risk factor of alcoholic... 557

Pathophysiology Increased circulating F2-isoprostanes... 554 Novel expression of a unique I t o . . . 711 S-adenosylmethionine deficiency... 1092 Differential expression of Bcl-2... 1184 Clinical significance of se rum. . . 1589

Pharmacology DB-cAMP treatment of experimental... 1626

Sex differences Increased susceptibility to alcoholic... 555

Alcoholic cirrhosis SEE ALSO Cirrhosis

Gallstone formation Cirrhc~is: a new, but expected cause. •. 7

Hepatitis C Prevalence of hepatitis C v i rus . . . 1186

Liver transplantation De novo malignancy following orthotepic... 375 Recidivism following liver transplantation... 377 Is Mallory's body a prognostic factor ~.. 1477 Liver transplantation for alcoholic... 1490

Pathophysiology Effects of dietary fat on ethanol-induced.,. 477 Estrogenicity of alcoholic beverages.. . 552

Alcoholic hepatitis Nimodipine, a dihydropyridine-type... 548 Overweight risk factor of alcoholic... 557 Amlodipine therapy in acute alcoholic... 558 Liver endothelial cell dysfunction... 1022 Usefulness of technetium-99m GSA. . . 1305 Bacterial infections as bad prognostic... 1555 HMG-CoA reduetase inhibiter.. . 1623

AlcohoHsm Amelioration of ;aver damage af ter . . . 265 In spite of an increased frequency... 376 Prevalence of HCV infection among. . . 972 Carbohydrate-deficient transferrin.. . 1147 Lipid turnover in alcoholics before.. . 1291

Aldehyde dehydrogenase Genetic polymorphism of the r a t . . . 551 Functional analysis of 5' regulatory.. . 775 Models for the dominant negative. . . 1618

Aldolase A Oxygen regulates the expression... 774

Alpha 1-antichymotrypsin a]-antichymotrypsin deficiency... 979

Alpha 1-antitrypsin Unrecognized alpha-l-antitrypsin,. 415 al-antitrypsin reduces transferrin.. 1044 Correlation between serum alpha-1. . . 1185 The acute phase protein alpha-1.. . 1487

Alpha fetoproteins Diagnostic use

Radioisotope scanning of AFP producing... 319 Prognostic value of the lens culinaris.. . 320 Hepatitis C-related hepate-Ca (HCC)... 321 Clinicopathological significance... 322 Clinical features suggesting development.. 1527

Gene expression Clinical implication of circulating... 1330 Heterogeneity in the induction of . . . 1410 Characteristics of hepatecellular... 1431

Ontogeny Gap junction's role of differential. ~. 1308

Transfection Gene therapy of hepatocellular carcinoma.. 206 Adenovirally directed enzyme prodrug.. . 328

Alpha globulins Age-dependent repression of a lpha , . . 422 APRF, increased nuclear binding.. . 515

539A

5 4 0 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

A m i l o r i d e Amiloride, but not DIDS and NPPB.. . 835

A m i n o a c i d s Extracellular brain amino acids. . . 216 Aminoacids subtraction by paracentesis... 1217 Changes in respiratory quotient.. . 1281 Arterial plasma amino acid pat terns. . . 1570

A m i n o t r a n s f e r a s e s SEEALSO Liver function tests Randomized controlled trial of the... 295 Effects of ETOH on mitochondrial... 540 Liver histology in patients wi th . . . 660 Clinical and histological features. . , 661 Hepatitis C virus genotypes, RNA. . . 662 Serum aspartate aminotransferase... 664 Up-regulatlon of mitechondrial aspartate. . . 825 Hepatitis C virus carriers wi th . . . 945 Genomic characterization of HCV. . . 947 A study of unexplained aminotransferases... 989 Viral hepatitis markers and evaluation... 990 Clinical significance of elevated.. . 1111 Phlebotomy reduces transaminase. . . 1207 Female predominance in chronic hepatitis. . . 1256 Mitechondrial aspartate amino . . . . 1269 Liver histology and serum HCV-RNA... 1409

A m l o d i p i n e Amlodipine therapy in acute alcoholic... 558

A m m o n i a The accumulation of glutamine i n . . . 213 Removal of Ammouia and nitrogenous... 482 Platelet concentrates have a ve ry . . . 1515

A m o x i c i l l i n ] c l a v u l a n a t e Augmentin-induced hepato,,renal failure. . . 1173

A m y l o i d p r o t e i n S A A The mechanism of serum amyloid A . . . 1042

A n g i o g e n e s i s Interferon reduces tissular expression... 249 Perisinusoidal cell activation... 315 Expression of vascular endothelial... 339

A n g i o g r a p h y Spiral computed angiography for . . . 154 Clinical and angiographic characteristics... 1325

Angiotensins Altered intracellulas signal transduction... 245

A n n e x i n s Unravelling of the binding mechanism.. . 630

A n t i b o d y t o SEE ALSO Autoantibodies

Acetaldehyde Hepatitis C virus infection enhances. . . 465 IgA, IgG, and IgM antibodies against . . . 480

Asialoglycoprotein receptor Significance of autoantibodies i n . . . 1579

Biliary cholesterol Evidence that cholesterol antibodies... 19

Carbonic anhydrase H Does antibody response to carbonic... 726 Immunization of mice with carbonic... 1261

CD4 Effects of in vivo menoclonal... 429

CD28 Human intrahepatic biliary epithelial . . . . 435

Cholangiocytes Characterization ofintrahepatic.. . 61

Cyclins Cyclin A as molecular target o f . . . 1554

Cytochrome P 45o Microsomal ethanol oxidizing system.. . 1430

Entamoeba histolytica Specific diagnosis of amebic l iver . . . 86

Fab receptors Association of anti-Fab auteantibodies... 263

Fas antigen Bcl-2 protects from lethal hepatic. . . 483 Hepatoproteetive effect of anti-APO-1/Fas... 492 Fas-mediated intracelluiar inactivation.., 629

Ferrit in A novel three-step immunsscintigraphy... 318

Free radicals Human antibodies versus hydroxyethyl... 481

GOR epitope Anti-GOR in patients with chronic... 118

Heat-shock proteins Autoantibody against a heat shock.. . 64

Hepatitis A virus Hepatitis A virus seroprevalence... 1122 Seroepidemiologic study of hepatitis. . . 1546

Hepatitis B core antigens The use of hepatitis B core antibody... 1530

A n t i b o d y t o ( c o n t i n u e d ) Hepatitis B envelope antigens

Clinical, biological and histological... 1131 Hepatitis B surface antigens

Production of antibody te hepatitis,. . 631 Hepatitis C core antigen

Changes in HCV anti-core and anti-F_,2... 258 Determination of serum anti-cere... 259 IgM anti-HCV testing in chronic... 293 Expression and immune response t o . . . 454 Patterns of immune responses t o . . . 921 The significance of IgM antibody... 991 Diagnostic significance of IgM anti-HCV... 992 Improved detection of anti-HCV antibody... 1129 Anti-HCV core antibody levels correspond... 1370 Significance of anti-HCV-core IgM. . . 1498 Hepatitis C virus anti-core IgM. . . 1577 Preliminary study on infection of . . . 1601 Quantitation of anti-cere HCV antibodies.. 1624

Hepatitis C envelope antigens Changes in HCV anti-core and anti-E2.. . 258 E 1 antibody level monitoring predicts... 740 Prognosis of long-term resolvemant... 994 Significance of antibody to anti-envelope... 1613

Hepatitis E virus Do sporadic and asymptematic cases. . . 1390 Prevalence of anti-HEV IgG in Buenos... 1492

ICAM-1 Effects of in vivo monoclonal... 429

Idiotypes Cloning of the variable regions.. . 66

LFA-1 Antibodies against adhesion molecules... 1326

Mitochondria Characterization of intrahepatic... 61 IgG and IgG3 levels of anti-M2... 1593

Nuclear membrane Auteantibodies against inner nuclear. . . 65 Auteantibodies against nucleoporin... 1608

p53 tumor suppressor gene Antibodies to mutant p53 in cirrhotic... 1545

Pyruvate dehydrogenase In situ detection of marker proteins... 57 Characterization ofintrahepatlc... 61

Spleen Precipitating antibodies to splenic... 1176

Transforming growth factor Regulation of TGF-beta expression... 717

Tumor necrosis factor a Antibodies to tumor necrosis facter-a. . . 362

A n t i g e n - p r e s e n t l n g c e l l s Are bile duct epithelial cells capable.. . 10 Effective antigen presentation a n d . . . 81 Production of antibody to hepatitis. . . 631

A n t i g e n s , t u m o r . a s s o c i a t e d CA-125 as a marker for detection... 226 "Pseudo-ovarian carcinoma"... 1240 CA 19-9 is not a reliable test i n . . . 1441

A n t i n e u t r o p h U c y t o p l a s m i c a n t i b o d i e s

SEE ALSO Autoantibodies Biliary atresia - an auteimmune... 87 Antineutrophll cytoplasmic antibody... 89 Chronic HCV hepatitis is associated... 982 Antineutrophll cytoplasmic antibodies... 1139 Detection of antineutrophil cytoplasmic... 1140

Antioxidant response element induction of human hepatic bile... 777 Effect of butylated hydroxyteinene... 781

Antiphospholipid syndrome Clinical and angiographlc characteristics... 1325

Antisense oHgonucleotides SEE ALSO Gene therapy Inhibition of hepatitis B v i rus . . . 473 Adenovirus-associated, recepter-mediatod... 628 Upregulated expression of human . . . 683 Inhibition of protein synthesis... 700 Pharmacokinetics of free and ]iposome.. 889 Inhibition of hepatitis B v i ra l . . . 891 Towards to in vivo gene knock.. . 1132 The effectiveness of antisense... 1285

A p l a s t i c a n e m i a Hepatitis-associated aplastic anemia . . . 1418

A p o l i p o p r o t e i n ( a ) Biliary apolipoprotoin A-I plays . . . 21 Isolation by immobilized artificial... 22 Cypermethrin induces subacute l iver . . . 1124 Is interferon alpha atherogenie?... 1342 Apolipoprotein A-I gene expression... 1434 Viscosity but not colloidosmotic... 1435 Apolipoprotein A-l: in vivo metabolism.. 1520 A new approach to study the metabolic.. 1521

A p o l i p o p r o t e i n ( e ) Role of apolipoprotoin E in intracelhilar... 529 Apolipoprotein E4 genotype is associated... 1484

A p o p t o s i s SEE ALSO Fas antigen

Alcohol liver disease Differential expression of Bcl-2... 1184

Antagonists and inhibitors Bcl-2 protects from lethal hepatic. . . 483 Hepateprotective effect of anti-APO-1/Fas... 492

Carcinogenesis p53 status, pX induced cell cycle... 202 Cancer formation in WAP-HBV-X... 349 Topoisemerase I inhihitors induce. . . 365 e-myc induction of hepatema cell . . . 485

Cholangiocytcs Apoptesis, electrolyte transport. . . 482

Hepatitis, fu lminan t Fas and Fas ligand strongly expressed... 493

Hepatocellular injury Apoptesis of hepatecytes highly. . . 644 TNFa-induced apoptesis o f . . . 1093 Apoptesis in experimental hepatitis. . . 1415 Apoptosis of rat hepatocyte af ter . . . 1533

Hepatocyte growth factor Apoptesis in the liver after discontinuation... 490

Immunology Role of CD8 ÷ lymphocytes and natura l . . . 491 Requirement of Thl-llke l iver . . . 1026 Apoptesis and clonal growth inhibition... 1425 Apoptesis and phagecy~sis of circulating... 1532

Immunosuppressive agents Apeptesis induction in isolated... 489

Liver regeneration Modulation of apoptosis-associated... 487 Apoptosis and ceE proliferation... 1512

Nitric oxide Kupffer cell induces hepatecyte.. . 484 Nitric oxide and tumor necrosis... 485 DNA strand break and fragmentation... 495

p53 tumor suppressor gene p53 and Fas/APO-1 induction in hepatema. . . 200

Primary biliary cirrhosis Nuclear DNA fragmentation in bil iary. . . 58

Transforming growth factor TGF-~I induction of apoptesis... 488 Studies on the fibragenic potential.. . 719

Transplantat ion Immunolocalization ofbcl-2 a n d . . . 122 The role of apoptosis in the ini t ial . . . 128

A r a c h i d o n i c a c i d s Role of interferon alpha on arachidonic... 248

A r g i n i n e L-argiuine minimizes reperfusion... 1099

A s c i t e s Markers

CA-125 as a masker for detection... 226 Paracentesis

Reduction of esophageal vnriceal. . . 195 Sympathoadrenergic deactivation... 223 Hemodynamic changes in patients... 225 Comparison of albumin, dextran-70... 456 Aminoacids subtraction by paracentesis... 1217

Pathophysiology Impaired endothelial function i n . . . 198 Effect of octreotide on endogenous... 222 Variceal bleeding or refractory... 602 Reduced filtration fraction a n d . . . 1163 Elevated levels of natriuretic hormones.. . 1465

TIPS Dissecting the factors involved.. . 229 Increased colloid osmotic pressure. . . 233 Outcome after transjugular intrahepatic.. . 234 TIPSS for refractory ascites and . . • 235 TIPS and paracentesis for the t reatment . . . 762 Effectiveness of transjugular intrahepatic.. . 1531

A s c o r b i c a c i d Estrogen and antioxidante i n . . . 1086 Effects of vitamin E, ascerbic ac id . . . 1617

A s i a l o g l y c o p r o t e i n s Drug effects

Multiple carriers involved in t h e . . . 812 Rapid and sustained de~ease i n . . . 1614

Gene expression intrahepatic MDR3 P-glycoprotein... 1222

Hepatocytes Assessment of isolated rat hepatecyto... 1160

Receptors A novel mRNA cis-acting element. . . 788 Altered asialoglycoprotein receptor.. . 1194 Significance of auteantibodies i n . . . 1579

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 541A

ATP The regulatory mechanism by ex t ra . . . 573 Mechanism of extracellular ATP-induced... 830 Tumor necrosis factor alpha increases.. . 1514

A T P - b i n d i n g c a s s e t t e p r o t e i n s Cloning of a liver-specific MRP. . . 753 Hepatecytes express an array o f . . . 821

A T P - d i p h o s p h o h y d r o l a s e Loss of endothellal cell ecto-ATP... 437

A t r i a l n a t r i u r e t i c f a c t o r Altered pulmonary expression o f . , . 457 Modulation of Kupffer cell function.., 807 Differential gene expression o f . . . 1596

A u g m e n t e r o f l i v e r r e g e n e r a t i o n The effect of augmenter of l iver . . . 1094

A u t o a n t i b o d i e s ANCA

Biliary atresia - an autoimmune.. . 87 Antineutrophil cytoplasmic antibody... 89 Chronic HCV hepatitis is associated... 982 Antineutrophil cytoplasmic antibodies... 1139 Detection of antineutrophil cytoplasmic... 1140

Anticardiolipin Chronic HCV hepatitis is associated... 982 Anticardiolipin antibodies and mixed. . . 1417

Anti-Fab Association of anti-Fab auteantlbodles.., 263

Anti-HSPTO Auteantibody against a heat shock.. . 64

Antimitochondria Characterization of intrahepatic... 61 IgG and IgG3 levels of anti-M2... 1593

Antinuelear Auteantibodies against inner nuclear. . . 65 Genetic predispositions for immunologic... 1198 Prevalence of auteantibodies i n . . . 1547 Cyclin A as molecular target o f . . . 1554 Auteantibodies against nucieoporin... 1608

Antiphospholipid Clinical and angiographic characteristics... 1325

Antipyruvate dehydrogenase In situ detection of marker proteins.. . 57 Characterization ofintrahepatic... 61

Hepatitis C The development of autoantibodies... 262 Comparison of the prevalence o f . . . 1146

Hepatitis, fulminant Significance of auteantibodles i n . . . 1579

A u t o i m m u n e c h r o n i c a c t i v e h e p a t i t i s

Autoantibodies Antineutrophil cytoplasmic antibody,.. 89 Precipitating antibodies to splenic... 1176 Cyciin A as molecular target o f . . . 1554

Drug therapy Treatment of autoimmune hepatitis... 1525

Genetic susceptibility Genetic susceptibility to autoimmune.. . 88

Hepatitis C Comparison of the prevalence o f . . . 1146 Auteimmune hepatitis: clinicopathologic... 1491

Immunology Cloning of the variable regions... 66 Analysis of the T cell antigen receptor... 1474

Liver transplantation Acute cellular rejection of l iver . . . 143 Recurrent auteimmune hepatitis following... 433

Pediatric Validation of a scoring system for . . . 1470

Sclerosing cholangitis Overlap between type 1 autoimmune., . 90

A u t o i m m u n e h e p a t o b i l i a r y o v e r l a p s y n d r o m e

Subtypes of autoimmune hepatebiliary... 1250

A u t o i m m u n i t y SEE .4LSO Autoantibodies

Autoimmune cholangitis Does antibody response to carbonic... 726

Biliary atresia Blliary atresia - an auteimmune.. . 87

Hepatitis C The development of auteantibodies... 262 Association of anti-Fab autoanfibodies... 263 Auteimmunity and thyroid dysfunction... 978 Chronic HCV hepatitis is associated... 982 Rheumatelogic and immunologic... 983 Comparison of the prevalence o f . . . 1146 Alpha-IFN treatment in HCV CAH, . . 1157 Anticardiolipin antibodies and mixed. . . 1417 Prevalence of auteantibodies i n . . . 1547

A u t o i m m u n i t y ( c o n t i n u e d ) Liver transplantation

Significance of immune activation... 189 Does autoimmunity affect the outcome... 1262

Primary biliaPy cirrhosis IgG and IgG3 levels of anti-M2... 1593

Sclerosing eholangitis Immunization of mice with carbonic... 1261

A u t o n o m i c f u n c t i o n t e s t s Assessment of QT interval prolongation... 382 Predictive value of autonomic function.,. 1127

A z a t h i o p r i n e Soluble intercellular adhesion molecule... 72

B

B c e l l l y m p h o m a Infection by HCV and other lymphotropic... 981 Analysis of HCV infection in patients. . . 1629

B c e l l s SEE ALSO Lymphocytes Identification of cross-subtype... 467 Hepatocyte growth facters-scatter... 1027

B 7 antigen Effective antigen presentation and . . . 81 Human intrahepatic biliary epithelial... 435 Expression of CDS0 (B7/BB-1) i n . . . 922

B a c t e r i a l i n f e c t i o n s Bacterial infections as bad prognostic... 1555

B a c t e r i a l t r a n s l o c a t i o n DNA fingerprinting demonstrates... 237 Intestinal bacterial overgrowth... 238 Selective intestinal decontamination... 1268

B a r o r e f l e x Impaired barorecepter sensitivity... 1337

B a s o l a t e r a l m e m b r a n e s SEEALSO Canalicular membranes The glycesyl-phosphatidylinositel-linked,.. 764 High affinity transporter of reduced... 815 Correct targeting of rat liver and. . 846 Increased Na÷/taurocholate... 852

b o x g e n e Modulation of apoptosis-associated. 487

bcl-2 gene SEE ALSO Apoptosis Immunolocalization of bcl-2 and . . . 122 bcl-2 protects from lethal hepatic.. . 483 Modulation of apoptosis-assodated.. 487 Differential expression ofbcl-2.., 1184

bcl-x g e n e Modulation of apoptosis-associatod. 487

Benzodiazepincs Characterization of early signs... 214 Hepatic encephalopathy in patients.. 378 Changes in blood explain increased... 380 A high-affinity peripheral benzo.. . 1354

B e t a a d r e n e r g i c b l o c k e r s The portal pressure-reducing effect... 197 Actions of carvedilol, a vasodllating... 598

B i c a r b o n a t e s vIP is a potent stimulus of bicarbonate... 752 Modulation by endothelin-1 of cyclic... 831 Bicarbonate biliary secretion is... 832 Bombesin stimulates bicarbonate... 833

B i l e a c i d t r a n s p o r t Impairment of taurocholate-dependent... 443 Bile acid uptake in human hepate. . . 750 Metabolism and enterohepatic circulation... 855 Altered hepatecyte transport i n . . . 1159 Bile alcohols undergo an enterohepatic... 1229 Hydrophobic and hydrophilic bi le . . . 1485 Uptake of bile acids by isolated... 1511 Microtubnie-depandent bile acid. . . 1620

B i l e a c i d s a n d s a l t s SEE ALSO more specific entries

Biosynthesis Regulation of cholesterol and bile... 533 Serum concentrations of 7c~-hydroxy... 535 Regulation of stero127-hydroxylase... 857 Clofibrate reduces bile acid synthesis... 860 5cd5~ isomerization during. . . 1273

Metabolism Purification and characterization... 538 Electrosprayionization-mass spectrometry... 856 A mechanism for formation of C2s... 1244 Study of human isoursodeoxycholic... 1389

B i l e a c i d s a n d s a l t s ( c o n t i n u e d ) Pathophysiology

The effect of 2,2'-dihydroxy-di-n-propyl.. 1421 Bile salt toxicity is reduced b y . . . 1174

Signal transduetion Protein kinase C actlvation/cellular... 531

Urine Differential diagnosis ofisckemic... 1538

B i l e a l c o h o l s Bile alcohols undergo an enterohepatic. 1229

B i l e c a n a l i c u l i Involvement of phosphatidylinositel... 809 Maturational increase in canalicular... 814 The mystery ofeanalicular GSH transport. . . 816 Carbon monoxide as an endogenous... 838 Endothelin-1 enhances bile canalicular... 841

B i l e d u c t e p i t h e l i a l c e l l s SEE Cholangiocytes

Bile duet obstruction Reversion by interferon of l iver . . . 684 Expression of the rat liver Na ÷ . . . 850 Hepatic interleukin-10 levels following. 1170

B i l e d u c t s Magnetic resonance cholangio... 1 Largo but not small intrahepatic... 211 In rive contraction of the duct . . . 212 VIP is a potent stimulus of bicarbonate. 752 Co-expression of cytokeratin 7 with... 765 Bombesin stimulates bicarbonate ~.. 833 Pruritus in chronic hepatitis C . . . 975 Hepateeyte differentiation en masse . . . 1125 Immunohistechemical study of F a s . . . 1327 Referral pattern and management. . . 1402

B i l e flow VIP is a potent stimulus of bicarbonate. 752 Involvement of phosphatidylinositel... 309 Bicarbonate biliary secretion i s . . . 832 Nitric oxide stimulates bile f low.. . 834 Nitric oxide-induced choleresis... 836 Choleretic action of glibenclamide... 837 Altered hepatacyte transport i n . . . 1159

B i l e p r o d u c t i o n Large but not small intrahepatie.. . 211 Improving hepatic hemodynamie a n d . . . 431 Amiloride, but not DIDS and NPPB. . . 835

B i l i a r y a t r e s i a Hepatic artery resistance index. . . 11 Blliary atresia - an auteimmune.. . 87 Correlation of plasma fatty acid . . . 1221 Immunohistechemical studies o f . . . 1408

B i l i a r y e x c r e t i o n Acetaminophen

Acetaminophen glucuronide transport. . . 817 Bicarbonates

VIP is a potent stimulus of bicarbonate... 752 Bicarbonate biliary secretion is... 832 Bombesin stimulates bicarbonate... 833

Cholesterol Hepatic transport of unesterifiod... 534 Preferential sterol transport fTom... 536 Minor role of de nero cholesterol ,'.. 1516

Doxorubicin Multiple carriers involved in t h e . . . 812

Genetics Hepatecytes express an array of... 821

Glutathione Maturational increase in cenalicular... 814 High affinity transporter of reduced... 815 The mystery of canalicular GSH... 816 Nitric oxide stimulates bile f low.. . 834 Role of nitric oxide in the hepatic. . . 1016

ICAM.1 Release of soluble intercellular... 1021

Iron Biliary excretion of plasma... 811

Leukotrienes Biliary excretion ofleukotrienes... 1449

Phosphatidylcholine In vitro evidence that sterol. , . 756 Expression of a non-mdr2 coded l iver . . . 820

Phospholipids Demonstration and partial... 791 Bile canalicniar vesicles are markedly, . . 840 Rapid and sustained decrease i n . . . 1614

Physiology Carbon mono~de generated by hems . . . 839 Selectively increased translocation... 863

Prostaglandin F s F2-isoprostane excretion in human... 12

Sex differences Sex differences in membrane binding.. . 1455

542A SUBECT INDEX HEPATOLOGY October 1995

Bil iary fistula The Achilles heel of TIPS, parenchymal.. 763

Biliary lipide Evidence that cholesterol antibodies... 19 Biliary apolipopretein A-I plays. . . 21 The bile canalicular membrane contains. 755 In vitro evidence that sterol. . . 756 Minor role of de nero cholesterol... 1516 Risk factors for gallstone recurrence... 1586 Rapid and sustained decrease i n . . . 1614

Bil iary moti l i ty In vive contraction of the duct . . . 212 Carbon monoxide as an endogenous... 838

Bil iary sludge Cirrhosis: a new, but expected Cause... 7

Biliary s t r ic ture Prospective long-term follow-up... 8 A positive lymphocytetoxic cressmatch... 169

Biliary surgery SEE ALSO Cholecystectomy Choledochocholedochostemy biliary... 1243 One stage operative management of... 1588

Biliary t rac t injuries Trends in biliary tract injuries... 158

Biliary tract neoplasms SEE ALSO Cholangiocarcinoma Staging laparoscopy with laparoscopic... 2 Genetic mechanisms of tumorigenesis. 13 Image analysis of lesions of t h e . . . 155

Bilirubin Amelioration of bilirubin conjugation.. 417 Primary hepatocytes transplanted.. . 419 Oral calcium phosphate lowers serum.. 1069 Correction of bilirubin glucuronidation... 1070 Long-term correction ofbilirubin... 1071

Bioartif icial l iver Extracorporeal liver perfusien wi th . . . 166 Clinical experience with a bioartificial... 386 Preliminary evaluation of a n e w . . . 423 Isolated fetal porcine hepatoeytes... 425 Establishment of 3-dimensienal pr imary. . . 498 Chelate handling by a bioartificial... 1467

Blood donor screening Histological progression of chronic... 657 Liver biopsy discloses occult chronic... 658 Liver biopsy in ani~-HCV(+) blood..'. 659 Hepatitis C virus genotypes, RNA. . . 662 Prevalence Of HCV infection among. . . 961 Viral hepatitis markers and evaluation... 990 Detection of HBV-DNA by PCR in se rum. . . 1242 Significance of anti-HCV in blood... 1509 Analysis OfHCV genotype in blood... 1556

Blood groups ABe blood type and mortality following... 134

Blood t ransfusion Hepatic encephalopathy in patients. . . 378 Infection with the novel GB-C v i rus . . . 448 Mode of transmission of hepatit is. . . 965

Blood volume The effect of posture on central . . . 228

Body fat Pretransplant body fat wasting predicts.. . 396

Bombesin Bombesin stimulates bicarbonate... 833

Bone densi ty Does long-term calcitonin, calcium. •. 77 Mechanisms of bone loss following... 404 Vitamin D receptor polymorphisms... 731 Vitamin D receptor gene polymorphism . . . . 1267 Calcitonin therapy does not prevent . . . 1282

Bone marrow t ransp lan ta t ion Transjugular intrahepatic portal-systemic... 591 0rthotopic liver transplantation... 1499

Brain The accumulation of glutamine in... 213 Portacaval anastomosis results in... 215 Extracellular brain amino acids. . . 216 Changes in evoked cerebral activity.. . 266 Removal of ~mmonia and nitrogenous... 432 Presence of liver necrosis is needed. . . 1097

Brain na t r iu re t ic pept ide Differential gene expression o f . . . 1596

Branched chain DNA assay Comparison of branched DNA probe. . . 286 Evaluation of two methods fo r . . . 1000 Comparison of two quantitative HCV. . . 1001 Quantification of hepatitis C v i rus . . . 1007 Comparison OfHCV RNA levels b y . . . 1453 Comparative evaluation of HCV viremia . . . 1456

Breast feeding Neonatal hepatitis of non-familial... 1566 Comparison of infectivity of breast . . . . 1603

Breath tests Oral lsc galactose breath tes t . . . 565 Quantitative liver function testing... 1616

Brucellosis Hepatic involvement in Brucellosis... 1320

Budd-Chiari syndrome Pathophysiology

Clinical and angiographic characteristics... 1325 Hepatic nodules in patients wi th . . . 1597 Hepatic and portal vein phlebitis... '1605

Prognosis Acute Budd-Chiari syndrome... 586 Poor prognosis and limited therapeutic... 1380

Therapy Does surgery influence the prognosis i . . 152 Liver transplantation for Budd-Chiari... 1247 Treatment of chroni c Budd-Chiari... 1397

Budesonide Treatment of autoimmune hepatitis.. . 1525

Buthionine sulfoximine Development of new therapy targeting... 1301

Butylated hydroxytoluene Effect of butylated hydrexytoluene... 781

Butyrates Sodium butyrate reversibly blocks... 507

C

C-type nat r iure t ic pept ide Differential gene expression of . . . 1596

Ca-ATPase Endothelin-1 enhances bile caualicniar... 841

Calcitonin Does long-term calcitonin, calcium... 77 Calcitenin therapy does not prevent... 1282

Calcitonin gene-related peptide Vasodilation to nerve stimulation... 603 Effect of adrenomedullin, a novel . . . 716

Calcium Admin i s t ra t ion a n d dosage

Does leng-tarm celcitonin, calcium... 77 Antagon i s t s a n d inhibi tors

Glycine blocks the increase in intracenular.. . 804 In t race l lu lar

[Ca2+] i responses during proliferation... 512 [Ca2+]i oscillations involve... 514 Coordinated calcium signals in r a t . . . 798 Calcium end IP s regulate the calcium... 800 Modulation of iniracellular calcium... 801 Endothelin-1 enhances bile canalicular... 841 Increases in intraceliular calcium... 1105

Pathophysiology Calcium and the anionic polypeptide... 23 The role of plasma in the disturbance... 802 Role of mitochendrial free calcium... 1083 Calcium-induced mltochondrial... 1087

Transpor t Glycine prevents elevation in intrace]inlar... 803 Effect of bile acids on hepatocellniar... 862

Calcium channels The calcium channel activator, Bay . . . 247 Effect of calcimn channel blockers... 446 The role of calcium channel inhibition... 608 Properties of hepatocollniar cation . . . 799

Calcium phosphate Oral calcium phosphate lowers serum. . . 1069

Calpain Enhanced liver calpain protease... 119

Canalieular membranes SEE ALSO Basolateral membranes Cloning of a liver-specific IVIRP... 753 Expression and localization of t h e . . . 754 The bile canalicular membrane contains... 755 Demonstration and part ial . . . 791 Acetaminoplien glucurenide transport. . . 817 Bile canalicular vesicles are markedly. . . 840 Daunorubicin protects against estradiol... 843 Selectively increased translocatien... 863

Carbon dioxide Cerebrevascular CO 2 reactivity... 574 Preservation of CO 2 -dependent... 613 Cerebrovascular CO 2 reactivity... 1352

Carbon monoxide Carbon monoxide as an endogenous... 838 Carbon monoxide generated by heme . . . 839

Carbonic anhydrase II Does antibody response to carbonic... 726 Immunization of mice with carbonic... 1261

Carboxylesterases Identification of h,~m,n l iver . . . 733

Cardiac function Left ventricular volumes in non-ascitic... 232 Cardiac contractility and muscurlnic... 243 Attenuation of cardiac ~-adrenargie... 244 Cardiac evaluation in adult l iver . . . 414

Cardiac surgery SEE Heart surgery, transplantation

Cardiotrophin-1 A new hepatecyte st~nulating factor. . . 1043

Carnit ine Plasma caruifine pool and carnitine.. . 1336

Carvedilol Actions of carvedilal, a vasodilafing... 598

Catalase Catalase inhibits collagen synthesis.. . 749 Effects of vitamin E, ascorbic acid . . . 1617

Cathepsins The effect of chronic ethanol. . . 541 Immunohistochemical localization... 1553

Caudate vein Treatment of chronic Budd-Chiari... 1397

CD antigens CD14

Human hepatocytes produce a form. . . 83 LPS-mediated NF-r~B activation... 1036 Different receptors for endotoxin... 1405

CD28 Human intrahepatic biliary epithelial... 435

CD30 CD30-inductien on T lymphocytes... 913 Immunodominant hepatitis C virus... 916 CD44 Expression of the cell adhesion... 1606

CD80 Expression of CD80 (B7/BB-1) i n . . . 922

Hepat i t i s C Lymphocyte surface antigen expression... 1373

CD4+ T cells SEE ALSO Lymphocytes

Cell pro l i f era t ion Effective antigen presentation a n d . . . 81 Human intrahepatic biliary epithelial... 435

Hepat i t i s C Lymphocyte phenotypes in chronic... 462 Viral clearance during acute hepatitis. . . 912 Chronic hepatitis C virus infection... 932

Liver transplantation, experimental Study of CD4 and CD8 level a n d . . . 1271

P r i m a r y bi l iary c irrhosis Cytokine responses to PPD in pr imary. . . 62

Thl /Th2 Predominance of IL-4 mRNA expression... 440 The role of TH1/TH2 lymphocytes... 1025 Requirement of Thl-like l iver . . . 1026

CD8+ T cells SEE ALSO Lymphocytes

Cell d i f f eren t ia t ion CD8au T lymphocytes... 80

I t B V vs. H C V infect ion Comparative analysis of the cytotoxic... 909

Hepat i t i s B The cytotoxic T lymphocyte response.. . 466

Hepat i t i s C Role of CD8 ÷ lymphocytes and natura l . . . 491 Defining the role ofintrahepatic... 724 Molecular mapping of an intrahepatic.. . 906 The peripheral blood cytotoxic T . . . 907 Viral escape from the HLA-A2 restricted... 908 Hepatitis C vlrus-specific cytotexic... 910

Cell adhesion SEEALSO Endothelial cells; ICAM-1;

Integrins; Lamim'ns; Seleetins; VCAM-1 Binding of livar-derived lymphocytos... 84 Twenty times less liver laminin. . . 767 Release of soluble intercellular... 1021 Liver endothelial cell dysfunction... 1022 Mechanism of the adhesion and nn'gration... 1023 Expression and function ofintegrin... 1047 Bile acid-induced increase in cell.., 1233 Expression of the cell adhesion... 1606

HEPATOLOGY Vol. 22 , N o . 4 , P t . 2, 1 9 9 5 S U B J E C T I N D E X 543A

C e l l c u l t u r e t e c h n i q u e s Establishment of 3-dimensional p r imary . . Extended primary culture of h u m a n . . .

C e l l c y c l e p53 status, pX induced cell cyc le . . . Transforming property of an HBV-cyclin.. Possible mechanism of cyclin A . . . Sodium butyrate reversibly blocks . . . Regulation of the p21/WAF1/CIP1/SDI1... HCV core protein subcellular localization... Changes in proliferative and cytotoxic... Effect of a high cholesterol d i e t . . .

C e l l p o l a r i t y Alterations of epithelial cell polar i ty . . . .120

C e l l v o l u m e Identification of cell-vohime-responsive... 771 cAMP and volume activated chloride. . . 805

C e n t r a l p o n t i n e m y e l i n o l y s i s Occurrence of central pontine.. . 1126 Recovery from central pontine.. . 1152

C e p h a l o s p o r i n s Spontaneous bacterial peri tonit is . . . 1396

C e r a m i d e s Reperfusion after liver t ransplantat ion. . . 442

C e r e b r a l b l o o d f l o w Single-photon emission computed... 381 Cerebrovascular CO~ react ivi ty . . . 574 Preservation of COs-dependent.. 613 Cerebrovascniar CO 2 reactivity.. 1352

C h e l a t i n g a g e n t s Biliary excretion of plasma non-transferr in. . . 811 Fructose and other iron-chelating... 1081 Inhibition of iron toxicity in h u m a n . . . 1088

Chemoembolization Prospective controlled trial of . . . . 357 Percutaneous ethanol injection o f . . . 1211 Treatment of hepatecellular carcinoma. . . 1237 Development of new therapy ta rge t ing . . . 1301 Changes in serum lipid peroxide. . . 1304

C h e m o k i n e s SEEALSO more specific entries Increased expression of ~ chemoklnes. . . 1030

C h e n o d e o x y c h o l a t e Generation of hydrogen peroxide. . . 1084 1~-, 4J3-, and 5~-hydroxychenodeoxycholic... 1272 Determinants of biliary bile a c id . . . 1274

C h i m p a n z e e s Prevention of HCV infection i n . . . 455

C h i n e s e H e r b a l m e d i c i n e Reduction of increased portal pressure... 1297

Chloride channels Glycine prevents elevation in intracellular... 803 cAMP and volume activated chloride. . . 805 Increases in intracellular ca lc ium. . . 1105

C h l o r i d e s Modulation by endothelin-1 of cyclic. . . 831

2 - C h l o r o d e o x y a d e n o s i n e The nucleoside analogues 2-chlorodeoxy.. 1263

C h o l a n g i o c a r e i n o m a SEEALSO Billary t ract neoplasms

Diagnosis A new use for an old drug: methylene. . . 14 Peripheral cholangiocardnoma: detection. 1193

Experimental models Does a pigment stone diet promote . . . 1420 The effect of 2,2'-dihydroxy-di-n-propyl... 1421

Genetics Genetic mechanisms of tumorigenesis... 13 Image analysis of lesions of the... 155 p53 and k-ras gene mutations i n . . . 156 ras-transduced diethylnitrosamine.. . 203

Pathophysiology Cellular distribution of t i s sue . . . 342 Expression of the cell adhes ion. . . 1606

Prevention Tamoxifen inhibits the growth o f . . . 1475

Surgery Major hepatic resection for extrahepatic. . 157

C h o l a n g i o c y t e s Apoptosis

Nuclear DNA fragmentation in b i l i a ry . . . 58 Apoptosis, electrolyte t ranspor t . . . 482

Cell proli feration Expression of c-met mRNA and TGF-~I... 504 Bile acids modulate proliferative... 865 Selective in vivo proliferation.. . 866 Compensatory cholangiocyto proliferation.. . 367 Insulin is a key regulator of cholangiocyte... 868

498 1332

202 204 337 507 519 901

1137 1393

C h o l a n g i o c y t e s (continued) Cytomegalovirus

CMV infection of hepatocytes a n d . . . 434 Immunology

Are bile duct epithelial cells capable . . . 10 Characterization of intrahepatic... 61 Human intrahepatic biliary epithelial . . . 435 Antlprcliferative effects ofT-interferon... 682 Does antibody response to carbonic. . . 726

Physiology Structural and functional s tudies . . . 436 Co-expression of cytokeratin 7 w i th . . . 765 Mechanism of extracellular ATP-induced.. • 830 Phenotypic characterization of h u m a n . . . 1230

C h o l a n g i o p a n c r e a t o g r a p h y Magnetic resonance cholangio... 1

C h o l a n g i o s c o p y Cirrhosis: a new, but expected cause . . . 7

C h o l a n g i t i s , autoimmune Does antibody response to carbonic... 726

Cholangitis, sclerosing Diagnosis

Detection of antineutrophil cytoplasmic,.. 1140 Immunology

Are bile duct epithelial cells capable. . . 10 Genetic predispositions for immunologic... 1193 Immunization of mice with carbonic. . . 1261 Analysis of the T cell antigen receptor . . . 1474

Liver transplantation Antineutrophil cytoplasmic antibodies.. . 1139 Choledochocholedechostomy bi l ia ry . . . 1243 Calcitonin therapy does not prevent . . . 1282 Prediction of acute rejection i n . . . 1493

Pathophysiology Hypercoagulability in patients with. ~. 78 Peroral cholangioscopy after operations. . . 1333 Interferon-gamma prsdustien in p r imary , . . 1391 Prevalence of primary sclerosing... 1480

Therapy Management of primary sclerosing.., 3 ERCP for primary sclerosing cholangitis. . . 9

C h o l e c y s t e c t o m y , l a p a r o s c o p i c Causes and risk factors for postoperative... 5 Trends in biliary tract injur ies . . . 158 Prediction for occurrence of hepatocellular.. . 1317 Laparoscepic cholecystoctomy injuries . . . 1374 Referral pattern and management . . . 1402

C h o l e d o c h o c h o l e d o c h o s t o m y Incidence of biliary complications... 398

Choledochostomy Choledechojejunostomy and pyogenic... 1392

Cholelithiasis SEEALSO Cholesterol gallstones;

Gallstone formation Diagnosis

Frequency and characteristics o f . . . 27 Laparoscopic cholecystectomy

Causes and risk factors for postoperative... 5 Parkinson disease

Parkinson's disease: a new r i s k . . . 1406 Pathophysiology

Fs-isoprostane excretion in h u m a n . . . 12 Portal hypertension and black gallstone. . . 1507

Recurrence Gallstone recurrence after successful.. . 25 Apciipoprotain E4 genotype is associated.. . 1484 Risk factors for gallstone recurrence. . . 1586

Risk factors Prevalence and risk factors f o r . . . 1362

Stents Endoscopic stenting of gallbladder. . . 1535

C h o l e s t a s i s SEE ALSO Bile duct obstruction; Jaundice

Cytohine effects Impaired IL-l~-induced hypothalamic. , . 1028 Hepatic interleukin-10 levels following... 1170 Increased IL-l~:IL-lra mRNA. . . 1562

Drug effects Daunorubicin protects against estradiol... 843 Colchiclne reverses a-naphthylisothio... 1089 Cholestasis associated with Turner's... 1369

Experimental models Further insights into the role o f . . . 842 Xanthine oxidase inhibition reduces . , . 844 Expression of the rat liver Na + . . . 850 Severely disturbed hepatic and skeletal . . , 1335 Biliary excretion of leukotrienes.. . 1449 Oncogenes expression after b i l e . . . 1482

Hepatitis C Pruritus in chronic hepatitis C . . . 975 Chronic cholestutic hepatitis C . . . 980

C h o l e s t a s i s ( c o n t i n u e d ) Pathophysiology

Role of endothelin.1 in hepat ic . . , 569 Bicarbonate biliary secretion i s . . . 832 Nitric oxlde-induced choleresis.. . 836 Liver cell dysplasia of large cel l . . . 1424 4-hydroxy-2,3-nonenal production. , . 1463

C h o l e s t a s i s , i n t r a h e p a t i c Case report: recurrence of progressive.. . 401 Urzedeoxychohc acid therapy i n . . . 845 Intrahepatic cholestasis of pregnancy. . . 1115 Prospective study of exogenous factors . . . 1138

C h o l e s t e r o l Biliary excretion

Hepatic transport of unesterified.. . 534 Preferential sterol transport f rom. . . 536

Blood Conversion to FKS06 immunosuppression... 146 Serum lipid levels in pediatr ic . . . 393 Increasing hepatic cholesterol 7a-hydroxy... 532

Dietary Hepatic and gallbladder acyl-CoA... 16 Regulation of sterol 27-hydroxylase... 857 Effect of a high cholesterol d i e t . . . 1393

Regulation Inhibiting Morris hepatoma growth . . . 366 Regulation of cholesterol and b i l e . . . 533 Bile salt toxicity is reduced b y . . . 1174

C h o l e s t e r o l g a l l s t o n e s Effect of dietary fat on hormone-induced... 18 Calcium and the anionic polypeptide.. . 23 Obesity and gallstones: is d ie ta ry . . . 26 Phenotypic characterization of Lith.., 732 Apolipoprotein E4 genotype is associated. . . 1484 The effect of gender on gallbladder. . . 1581 Ursodeoxycholic acid reduces protein. . 1592

C h o l e s t e r o l n u c l e a t i o n Antagonists and inhibitors

The effect of alteration of f a t t y . . . 17 Biliary apolipoprotein A-I p l a y s . . . 21 Isolation by immobilized art if icial . . . 22 Ursodeoxycholic acid reduces protein. . 1592

Pathophysiology Evidence that cholesterol antibodies.. 19 Promotion of cholesterol c rys ta l . . . 20 Calcium and the anionic polypeptide.. . 23 Trsnsferrin: a potent cholesterol... 24 The effect of alteration of leci thin. . . 1548 Risk factors for gallstone recurrence. . . 1586

C h o l e s t e r o l - 7 - h y d r o x y l a s e Protein kinase C activation/celhilar... 531 Increasing hepatic cholesterol 7 a . . , 532 Serum concentrations of 7a-hydroxy... 535 Coordinate regulation of s terol . . . 858 Hepatic cholesterol 7~-hydroxylase... 859

C h o l i c a c i d s Regulation of MDR2 P-glycoprotein... 864 Chelate handling by a bioartificial. . . 1467 Uptake of bile acids by isolated. . . 1511

C h r o m o s o m e s Physical mapping in the h e m s . . . 1658

Chronic active hepatitis Genetic predispositions for immtmologie... 1198 Expression of insulin like g rowth . . . 1423 Lideceine metabolite formation i n . . . 1568 Hepatic and portal vein phlebit is . . . 1605

C h r o n i c a c t i v e h e p a t i t i s , autoimmune

Autoantibodies Antineutrophil cytoplasmic ant ibody. . . 89 Precipitating antibodies to splenic... 1176 Cyclin A as molecular target o f . . . 1554

Drug therapy Treatment of autoimmune hepat i t i s . . . 1525

Genetic susceptibility Genetic susceptibility to autoimmune... 88

Hepatitis C Comparison of the prevalence o f , . . 1146 Autoimmune hepatitis: chnicopathologic... 1491

Immunology Cloning of the variable reg ions . . . 66 Analysis of the T cell antigen receptor . . . 1474

Liver transplantation Acute cellular rejection of l ive r . . . 143 Recurrent auteimmune hepatitis following... 433

Pediatric Validation of a scoring system f o r . . . 1470

Sclerosing cholangitis Overlap between type 1 autoimmtme. . . 90

C i m e t i d i n e Effects of cimetidine on blood e thanol . . . 1322

544A SUBJECT INDEX HEPATOLOGY October 1995

Ciprofloxacin Does ciprefloxacin alter survival . . .

Cirrhosis SEEALSO Collagen; Fibrosis

Aseites Effect of octreotide on endogenous... Sympathoadrenergic deactivation... CA-125 as a marker for detection... Dissecting the factors involved.. . Outcome alter transjugular intrahepatic.. . TIPSS for refractory ascites a n d . . . Comparison of albumin, dextran-70.,.

Cardiomyopathy Cardiac contractility and muscurinic... Attenuation of cardiac ~-adrenergic...

Cell physiology Immunolocalization ofbcl-2 a n d . . . Impaired endothelial function in... Altered intracellular signal transduction... Expression of metalloproteinases •. • Expression of metalloproteinase... Membrane potential of hepatocytes... Relationship between bepatecyte... Expression of heparin-binding EGP-like... Hyaluronic acid binding ability.. .

Cholelithiasis Portal hypertension and black gallstone... Endoscopic stenting of gallbladder...

Coagulation disorders Increased portal and systemic fibrinolysis... Recombinant VIIa (rFVIIa) in t h e . . .

Cytokine effects Antiproliferative effects of 7-interferen... Interferon increases extracellular... Transforming growth factor a lpha . . . Circulating interleukin-10 levels. . .

Diabetes mell i tus Changes in insulin secretory capacity... Glucagon secretion in diabetic and...

Diagnosis Diurnal variability of liver chemistries.. Oral IsC galaeteze breath test,.. Galactose elimination test versus... Diagnosis of cirrhosis in patients... ~Pseudo-ovarlan carcinoma"... Can cirrhosis be accurately diagnosed..

Drug effects The portal pressure-reducing effect.. . Actions of carvedilol, a vasedilating... Reduction of increased portal pressure. . . Phenprecoumon-induced cirrhosis . . . .

Drag metabolism Monoethylglycinexylidide and lldocaine.,. Lidocaine metabellte formation in...

Esophageal variees Propranolol does not decrease t h e . . . Reduction of esophageal variceal . . .

Etiology Left ventricular volumes in nen-ascitic... Prevalence of subclinical hepatic. . . Hepatic and portal vein phlebitis...

Experimental models Circulating endothalin (ET)-I a n d . . . Nitric oxide synthase activity is... Inhibition of hepatic nitric oxide... Effects of simvastatin, pentexyfylline... Terlipresein enhances free water...

Growth factors Serum hepatecyte growth factor levels. . . Decrease in fibrosis, and increase. . . Hepatic expression of hepatecyte. :. Increased intrahepatic mRNA expression... Blunt erythropoietin secretion i n . . .

Hepatit is B Transforming growth factor a lpha . . . Cirrhosis doesn't influence response.. .

Hepatitis C Hepatitis C virus genotypes and... A retrospective study of hepatitis. . .

Hepatocellular carcinoma MR[ reliably detects macroregeuerative... Liver transplantation for smal l . . . Serum y-gintamyl-transpeptidase... Surgical resection of hepatecellniar... Correlation between serum alpha-1. . . Percutaneous ethanol injection of . . . Prediction for occurrence of hepata . . . Axe acute phase proteins a n e w . . . Clinical features suggesting develop... Antibodies to mutant p53 in cirrhotic...

Infection Intestinal bacterial overgrowth... Characteristics of the infections... Selective intestinal decontamination...

1096

222 223 226 229 234 235 456

243 244

122 198 245

1054 1056 1166 1204 1328 1564

1507 1535

584 730

682 685

1360 1572

526 1340

91 565

1151 1209 1240 1278

197 596

1297 1549

660 1568

193 195

232 1117 1605

231 606

1329 1440 1591

327 1218 1404 1422 1536

1360 1466

945 1377

313 374

1148 1164 1185 1211 1317 1469 1527 1545

238 239

1268

Cirrhosis (continued) Liver transplantation

Absence of relationship between.. . 139 Poor outcome following orthotepic... 167 Liver transplantation for jejunoileai... 411

Pathophysiology Transcriptional activation of inducible... 196 Ambulatory monitoring of a diurnal. ;, 219 Effects of insulin on renal hemedynamics... 227 The effect of posture on central . . . 228 Daily profile of plasma concentrations... 230 Prolonged Q-T interval in drrhesis . . . 242 Perisinusoidal cell activation.,. 315 Variant liver estrogen receptor.. . 336 Endothelin homeostasis during l iver . . . 405 Insulin resistance in cirrhosis... 527 Circulating tumor necrosis factor-a.. . 599 Role of tumor necrosis fastor-alpha... 600 Resting vasodilatory capacity i n . . . 604 Effect of substance P and its receptor.. . 605 The role of calcium channel inhibition... 608 Plasma endethelin-1 levels in cirrhosis. 609 Influence of adrenergic nerves o n . . . 610 Upregulated expression of human . . . 683 The role of plasma in the disturbance.. 802 Systemic and regional hemedynamic.. 1155 Reduced filtration fraction a n d . . . 1163 Mediater production and phagocytic . . . . 1199 Aminoacids subtraction by paracentesis... 1217 The acid-labile subunit in acute . . . 1219 Serum level of thrombomedulin and . . . 1246 Changes in respiratory quotient.. . 1281 Hepatic extraction and systemic... 1298 Plasma carnitine pool and carnitine... 1336 Impaired baroreceptor sensitivity... 1337 CA 19-9 is not a reliable test i n . . . 1441 Prostaglandins and coagulation a n d . . . 1445 Improved liver function In cirrhotic... 1451 Elevated levels of natriuretie hormones... 1465 Pathogenesis of portal hypertensive... 1479 Hemodynamic effects of octreotide... 1501 Differential diagnosis ofischemie... 1538 Arterial plasma amino acid pat terns. , . 1570 Hasmedynamic measurements in t h e . . . 1594 Octreotide induces a negative Water.. . 1595

Prognosis Prognostic value of the perfused... 208 Mortality and morbidity in cryptegenic... 974 The prognostic value of serum laminin. . . 1338

Surgery Tolerance of nermothermic ischemia.. . 159

Therapy Conversion of failed transjugular.. . 160 Platelet concentrates have a ve ry , . . 1515

Thrombosis A classification of large vein thrombosis,.. 1145

TIPS Portal and systemic hemedynamie... 596 Portal vein thrombosis in cirrhosis... 1181 In vitro proton (IH) magnetic,.. 1310

Varieeal bleeding TIPSS versus variceal band ligatien... 578 Meta-analysis of endoscopic llgation... 580 Meta-analysis of propranalol p lus . . . 582 Daily modifications of splanchnic... 1541

Cirrhosis, alcoholic Liver transplantation

De nevo malignancy following orthotepic... 375 Recidivism following liver transplantation... 377 Is Mallory's body a prognostic factor. . . 1477 Liver transplantation for alcoholic.,. 1490

Pathophysiology Cirrhosis: a new, but expected cause. . . 7 Effects of dietary fat on ethanal-induced... 477 Estrogenicity of alcoholic beverages.. . 552 Prevalence of hepatitis C v i rus . . . 1186

Cisplatin Tolerance of the human liver t o . . . 358

Clavulanic acid Augmentin-induced hepate-renal failure. , , 1173

Clofibrate Clofibrate reduces bile acid synthesis... 860

Clostridium per~ ingens Mechanism of early biliary s tent . . . 1381

Coagulation Hypercoagulabillty in patients wi th . . . 78 Recombinant VIIa (rFVIIa) in t h e . . . 730 Effects of hepatecyte growth factor. . . 1103 Prostaglandins and coagulation a n d . . . 1445 Role of the template bleeding t ime . . . 1612

Cocaine Fructose and other icon-chalating... 1081 Cocaine-induced hepatic injury i n . . . 1085

C o e n z y m e QlO Estrogen and antioxidauts in hexaclfloco... 1086

C o l c h i c i n e Colchicine reverses a-napththylisothio... 1089 Stimulation of fibrolysiz by trlmethyl... 1416 Double-blind, randomized trial o f . . . 1578

C o l l a g e n SEEALSO Cirrhosis; Fibrosis; Procollagen

Antagonists and inhibitors Tranilast may inhibit collagen production.. 710

Cell physiology Effect of PDGF, pentexifylline a n d . . . 696 "Deactivation" of activated.. . 703 Collagen VI serves as potent growth. . . 709 Contraction of collagenous bands . . . . 1046 Expression and function of integrln. . . 1047

Cytokine effects Antipreliferative effects of y-interferon... 682 Reversion by interferon of l iver . . . 684 Interferon increases extracellular... 685

Gone expression Endothelin antagonism in experimental.. 460 Correlation between type I collagen... 673 Liver injury and fibrosis in interferon... 680 Mechanism of action of HOE077.. . 689 5 lipoxygenase inhibiter suppresses... 707 Catalase inhibits collagen synthesis.. . 749 Overexpressien ofl"m~nln and collagen... ~ 1048 Modulation of mucin and collagen.. : 1190 Influence of all-trans and 9-cis. . . 1264

Gene regulation Cell-specific transcription of t h e . . . 459 Transcriptional activation of u2(I) . . . 693 Recognition of two Spl binding si tes . . . 699 RAF and MAP kinase differentially.,. 748 Post-transcriptional regulation... 744

Pathophysiology Extracellular matrix proteins i n . . . 324 Serum undulln and collagen type . . . 720 Pyridlnollne collagen cross-links... 1283 Soluble collagens modulate t h e . . . 1524

C o l o r e c t a l c a n c e r Utility and cost effectiveness o f . . . 164 Hepatic metastasis of human colorectal... 373

C o m a Correlation of serial cytokine levels . . . 1038

C o m b i n a t i o n t h e r a p y A randomized controlled trial o f . . . 52 Interferon-alpha and tauroursodeoxy... 53 Combination treatment of a lpha . . . 182 Combination therapy for hepatitis. . . 1144 Combination therapy achieves.. . 1343 Combination therapy of interferon... 1419 Double-blind, randomized trial o f . . . 1578

C o m p l e m e n t Complement C1Q synthesis in r a t . . . 85 Complement activation in l iver . . . 137 Hyperacute rejection of discordant... 427 Complement C4 protein gone expression.. 713 Low expression of erythrocyte... 929

C o m p u t e d t o m o g r a p h y Clinical features suggesting develop... 1527 Hepatic cyst computed temography.. . 1619

C o n g e s t i v e h e a r t f a i l u r e Diagnosis of cirrhosis In patients. . . 1209

C o n n e x i n s Depression of gap junctional gene . . . 768 Gap junetion's role of differential... 1368

C o p p e r SEE ALSO Wflson's disease Conditionally immortalized hepatecytas.., 1065 Mitechendrial abnormalities in Long. . . 1066 Proliferation of hepatic lysosomes... 1067 Altered hepatecellular Cu transport... 1518

Cost analysis Hepatitis A vaccines

Declining prevalence of immunity. . . 311 Hepatitis C What serologic tests are necessary... 655 Screening strategies for hepatitis... 1113

Hepatotoxieity Incidence of acetaminopben overdose... 1091

Interferon a Efficacy and safety of leukocyte-derived,.. 34 Justification of single 6-month.. . 735 Strategies for prevention of dea th . . . 877

Liver transplantat ion Preoperative risk factors affecting... 389 ~Piggy-back" liver transplantation... 390 The impact of postoperative complications... 391 Maximal utilization of the "marginal"... 1299

HEPATOLOGY Vol . 22 , N o . 4, P t . 2 , 1 9 9 5 S U B J E C T I N D E X 5 4 5 A

Cost analys i s (continued) PET

Utility and cost effectiveness o f . . . 164 Spontaneous bacterial peritonitis

Is norfloxacin prophylaxis aga ins t . . . 240

C o u m a r i n Phenprocouman for prevention o f . . . 594 Phenprocoumon-inducod cirrhosis . . . 1549

C r i g l e r - N a j j a r s y n d r o m e Amelioration of bilirubin conjugation. . . 417 Primary hepatecytes t ransplanted. . . 419 Prolonged expression of bilirubin-UDP... 453 Oral calcium phosphate lowers s a r m n . . . 1069 Correction of biliruhin glururonidat ian. . . 1070 Long-term correction of b i l i rubin . . . 1071

C r y o g l o b u l i n e m i a Cryoglobulinemia in live r t r ansp lan t . . . 105 HCV infection of paripheral b lood. , . 925 HLA-B8 confers susceptibility t o . . . 985 Sequence analysis in hypervariable... 986 Mixed cryoglobulinemia and hepat i t i s . . . 988 Clinicopathological characteristics. . . 1249 Serum cryoglobulins and chronic.., 1316 Multivariate analysis of the potential... 1371 Anticardiotipin antibodies and mixed . , . 1417

C r y o p r e s e r v a t i o n Controlled rate freezing of hepatecytes. . . 420

C r y o s u r g e r y Technical failures of cryosurgically.. . 4 Cryosurgery for hepatic metas tases . . . 161

C y c l i c A M P cAMP and volume activated chloride. . , 805 Modulation by endothalin- 1 of cyclic. . . 831 Selectively increased translocation. . . 863 DE-cAMP treatment of experimental . . . 1626

C y c l i c G M P A novel mRNA cis-acting e lement . . . 788 Modulation of Kupffer cell funct ion. . . 807

Cycl in-dependent k inases Expression and regulation of p 5 3 . . . 334 Sodium butyrate reversibly blocks . . . 507 Cyciin-dependent kinase 4 inhihi ters . . . 1205

C y c l i n s Transforming property of an HBV-eyclln... 204 Possible mechanism of cyciin A . . . 337 Cyciin A as molecular target o f . . . 1554

C y c l o o x y g e n a s e s SEEALSO Prostaglandins Increased in vivo expression o f . . . 543 Effects oflipopolysaccharide tox in . . . 1041

C y c l o p h o s p h a m i d e Evaluation of hepatecellular defense. . . 1432

C y c l o s p o r i n e Tacrolimus (FK506) versus cyclosporine... 149 Effects of eyclosporine and tacrol imus. . . 430 Apoptesis induction in isolated. . . 489 Interactions of cyclosporine A a n d . . . 1104 Comparison of systemic and loca l . . . 1286 Cyclosporine A in the t r ea tment . . . 1315 Precise calculation of cyclosporine... 1319 Cyclosporine rechallenge after a . . . 1537

C y p e r m e t h r i n Cypermethrin induces subacute l ive r . . . 1124

C y s t i c f ibrosis Liver or combined lung and l ive r . . . 167

C y t o e h r o m e P450 Is oxygen tension a modulator o f . . . 458 Hmnan antibodies versus hydroxyethyl. . . 481 Decreased constitutive m u r i n s . . . 559 A novel cis-aeting element i n . . . 778 Intracellular cascade controlling.. . 779 Microsomal ethanol oxidizing sys tem. . . 1430 Expression of CYP1A1 and CYP1A2.. . 1471 Acotaminophen metabolism in pa t ien ts . . . 1585

C y t o k e r a t i u s Co-expression of cytokeratin 7 w i t h . . . 765 De nero expression of non-hepatacellular. . . 766

C y t o k i n e p r o f i l e s SEEALSO more specific entries

Alcohol liver disease Intrahepatie lymphocyte production. . . 1033

Hepatitis C Increased intrahepatic Thl cytokine. . , 461 Cytokine expression and T-cell subse t . . . 914 Thl cytokine pattaru and defective.. . 915 Immunodominant hepatitis C v i r u s . . . 916 Defective antiviral cytokines i n . . . 917 Transforming growth facter-J31... 920

C y t o k i n e p r o f i l e s ( c o n t i n u e d ) Interferon response

Plasma cytokines in patients w i th . , . 292 Liver transplantation, experimental

Predominance of IL-4 mRNA expression.. . 440 Primary biliary cirrhosis

Cytokine responses to PPD in p r imary . . , 62

C y t o m e g a l o v i r u s CMV infection of hepatecytes a n d , . . 434

C y t o s k e l e t o n De nero expression of non-hepatocollular... 766

D

Daunorubic ln Daunorubicin protects against estradiol . . . 843 Assessment of isolated rat hepatecyte. . . 1160

D e o x y c h o l a t e Gallstone recurrence after successful.. . 25

Desmin Co-expression of cytokeratin 7 w i th . . . 765 Desmin expressing cells du r ing . . . 1323

D e x a m e t h a s o n e Complement C1Q synthesis in r a t . . . 85 Inhibition of ra t Ite cell activation. . . 705 A novel cis-acting element i n . , , 778

D e x t r a n s Comparison of albumin, dextran-70. . . 456

D i a b e t e s m e l l i t u s Biliary excretion

The mystery of canalicular GSH t ranspor t . . . 816 Biliary excretion ofleukotrienes. . . 1449

Cell physiology Up-regulation of mitechondrial aspartate. 825 Increased hepatic NaK-ATPase act ivi ty. . . 828

Cirrhosis Changes in insulin secretory capacity. . . 526 Glucagon secretion in diabetic a n d . . . 1340

Hepatitis C Association of diabetes mell i tus . , . 977

Liver transplantation Association of HLA antigens w i th . . . 1311

D i a l y s i s SEE Hemodialysis

D i a p h r a g m Effect of abdominal paracentesis . , . 1543

D i c h l o r o e t h y l e n e s Rapid and sustained decrease i n . . . 1614

D i d e o x y n u c l e o s i d e s 2',3'-dideoxy-~-L-5'-fluorocytidine.., 888 Mechanisms of dideoxynurleoside... 1346

D i e t a r y f a t s Effect of dietary fat on hormone-induced.. 18 Effects of dietary fat on ethanol-induced.,, 477

D i e t a r y p r o t e i n s Does a pigment stone diet promote. . . 1420

D i f f e r e n t i a l f l o t a t i o n c e n t r i f u g a t i o n Differential flotation contrifugation... 289 Differential flotation centrifugation.. . 290 Hepatitis C virus density heterogeneity... 934 Dynamic changes of floating densi ty . . . 935

D i h y d r o d i o l d e h y d r o g e n a s e Induction of human hepatic b i l e . . . 777

D i m e t h y l s u l f o x i d e Late protection against chemical-induced... 1090

D i p e p t i d y l p e p t i d a s e I V Altered regulation and role of dipeptidyl.. . 1584

D i s e a s e transmiss ion Hepatitis B

Comparison of infectivity of b reas t . . . 1603 Hepatitis C

Hepatitis C viral genotypes, modes . . . 352 Intrafamilial spreading of HCV infection.. . 949 Different nucleotide diversity a n d . . . 955 Molecular evidence for nosocomial... 957 De novo hepatitis C virus infection.. . 959 Repeated transmission of HCV f rom. . . 962 Mode of transmission of hepat i t is . . . 965 Is the sexual transmission of HCV. . . 966 Mother-to-child transmission o f . . . 967 Mother to infant transmission o f . . . 968 Risk factors in chronic HCV carr iers . . . 970 Assessment and medical follow*up... 1114

Hepatitis G Prevalence of hepatitis G v i ru s . . . 303

D N A b i n d i n g p r o t e i n s Identification of proteins f rom. . . 330 Zf9, a novel zinc finger gene induced , . . 747 Expression of metallopanstimulin.. . 1248

DNA mismatch repair g e n e s Loss of the DNA mismatch r epa i r , , . 450

D N A s y n t h e s i s Iron induces beth DNA synthesis . . . 369 Middie-molecular-weight inhibi ter . . . 494 Mechanisms of dideoxynucleoside... 1346 Effect of a high cholesterol d i e t . . . 1393

D o p a m i n e The D2 dopamlne receptor A1 allele. 556

D o p p l e r u l t r a s o u n d i m a g i n g Use of color Doppler energy in t h e . . . 814 Alterations of blood supply to t h e , . . 316 Reproducibility of Doppler sonographic. . . 576 Doppler ultrasounds of the hepa t ic . , . 1192 Power Doppler examination f o r , . , 1302 Hepatic hemodynamics in living re la ted . . . 1395

D o x o r u b i c i n Multiple carriers involved in t h e . . . 812 Development of new therapy ta rge t ing . . . 1301

D r u g a b u s e Hepatitis B vaccination of methadone. . . 872 Chronic hepatitis C of drug u s e r s . , . 933 Molecular epidemialogy of hepat i t i s . . . 953 Distribution of hepatitis C v i ru s . . . 956 Assessment and medical fofiow-up... 1114 Hepatitis E virus surveillance i n . . . 1123 The prevalence of chronic hepat i t i s . . . 1280 Interrelation between HBV, HDV a n d . . . 1386 Accuracy of hepatitis C virus genotyping. . . 1574

D r u g d e l i v e r y s y s t e m s Adenovirus-associated, recepter-mediated.., 628 Pharmacokinetics of free and liposome.. . 889 Selective delivery of pr imaqulne. . . 1079

E

E251 g e n e Increased expression of E251 i n . , . 67

E i c o s a n o i d s Effects oflipopolysaccharide t ex in . . . 1041

E l d e r l y p a t i e n t s Hepatitis C virus infection a n d . . . 973 Analysis of the anti-HBs response. . . 1208

E m b r y o In vitro culture and differentiation... 497 Regulation of human heine oxygenase-1.. . 776

E m p e r i p o l e s i s Relevance of ultrastructural lymphocyte. . . 924

E n d - s t a g e l i v e r d i s e a s e SE~ ALSO Cirrhosis Preservation of CO s -dependent , . . 613 Hepatic iron concentration in e n d . . . 676

E n d o c y t o s i s Chronic ethanol administration increases. . . 797 Properties of hepatecellular cation.. . 799 Protein phosphatase 2A-mediated.. . 806 Modulation of Kupffer cell functiov . . . . 807 Chronic ethanol consumption impa i r s . . . 808 Endocytesis is an essential s t ep . . . 1365

E n d o p l a s m i c r e t i c u l u m Functional identification of ca r r i e r . . , 826

E n d o s c o p i c u l t r a s o u n d High resolution endoluminal sanography. . . 587

E n d o t h e l i a l c e l l s , s i n u s o i d a l Drug effects

Effect of calcium channel blockers . , . 446 Anticoagulant targeting endothelial . . . 575 Mannose-terminal glucocarebrosidase... 1074 Effects of long-term alcohol . . , 1412

Pathophysiology Loss of endothelial cell ecte-ATP... 437 Chronic ethanol consumption impai r s . . . 808 Liver endothelial cell dysfunction.. . 1022 Mechanism of the adhesion and migrat ion. . . 1023 Endotexemia induces E-selec~ mRNA. . , 1037

Physiology Effective antigen presentation a n d . . . 81 Differential expression of vascu la r . . . 511 Heterogeneity of procollagen types . . . 708 Modulation of intracellular ca lc ium. . . 801 Stimulation of nitric oxide production. . . 1018 Hyaluronic acid binding abi l i ty . . , 1564

5 4 6 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

E n d o t h e l i n s Blood

Daily profile of plasma concentrations... 230 Circulating endothelin (ET)-I a n d . . . 231 Endothelin-1 and F2-isoprostane... 406 Plasma endothelin-1 levels in cirrhosis... 609

Gene expression Altered pulmonary expression of . . . 457 Expression and potential role o f . . . 687

Pathophysiology Endothelin homeostasis during l iver . . . 405 Role of endothelin-1 in hepatic. . . 569 The role of calcium channel inhibition... 608 Hepatic extraction and systemic... 1298

Physiology Sympathoadrenargic deactivation... 223 Endothalin antagonism in experimental... 460 A critical balance between endothelins... 567 Endothelin-1 enhances bile canalicular... 841 Association between hyaluronic acid... 1483

Signal transduction Growth inhibition of myofibrchlastAike. •. 688 Nitric oxide preferentially upregulates.. . 793 Modulation by endothelin-1 of cyclic... 831

E n d o t h e l i u m - d e r i v e d h y p e r p o l a r i z i n g f a c t o r

Role of endothelium-derived... 568 Endothelium-derived hyperpolarizing... 570

E n d o t o x i n Blood

Peripheral endotoxemia and hyperdynamic... 601 Circulating interleukin-10 levels. . . 1572

Cell physiology Glycine prevents elevation in intracellular... 803 Antioxidants suppress endotexin-induced. . 1034 LPS-mediated NF-zB activation... 1036

In f lammat ion Stimulation of nitric oxide production... 1018 Kupffer cell derived IL-6 increases... 1031

Kupffer cells Effects of Hpopalysaccharide toxin. . . 1041 Endocytesis is an essential s tep . . . 1385

Nitric oxide Differential effects of nitric oxide,. . 1015 Role of nitric oxide in the hepatic. . . 1016 Metabolic effect of nitric oxide.. . 1017

Pathophysiology Human hepatecytes produce a form. . . 83 Endothelium-dependent vasorelaxation.. 246 The endotexin antagonist B-464 a n d . . . 550 A critical balance between endothelins... 567 Role of endothelin-1 in hepatic. . . 569 Nitric oxide-induced choleresie... 836 Release of soluble intercellular... 1021 Requirement of Thl-like l iver . . . 1026 Leucine metabolism in liver of endotoxin. 1294 Apoptesis and phagocytesis of circulating... 1532

Signal transduction Tyrosine phosphorylation is important. . . 796 Different receptors for endotexin... 1405

E n e r g y m e t a b o l i s m Extracellular brain amino acids. . . 216

E n h a n c e r s Phyllanthus amarus interferes.. . 647

E n t a m o e b a h i s t o l y t i c a Specific diagnosis of amebic l iver . . . 86

E n t e r a l f e e d i n g Does nasoenteral nutritional support . . . 135

E n t e r o t o x i n s Decreased constitutive routine. . . 559

E o s i n o p h i l - d e r i v e d n e u r o t o x i n Serum eosinophil granule-associated... 63

E p i d e r m a l g r o w t h f a c t o r Analysis of prolonged exposure t o . . . 795 Increased intrahepatic mRNA expression... 1422 Autophosphorylation of the epidermal.. . 1439

E p i m o r p h i n Epimorphin localizes in Ite cells . . . 513

E p i t h e l i a l c e l l s , b i l e d u c t SEE Cholangiocytes

E p i t h e l i a l c e l l s , s i n u s o i d a l Perisinusoidal cell activation... 315 Polypeptide growth factors participate... 367 Apoptesis and phagocytosis of circulating... 1532

E p s t e i n - B a r r v i r u s Epctein-Barr virus-related post-transplant... 416

e r b B g e n e s ErbB3, the major hepatic heregulin. . . 794 Oncegenes expression after b i le . . . 1482

E R C P , t h e r a p e u t i c Prospective long-term follow-up... ERCP for primary scierosing chalangitis... Mechanism of early biliary s tent . . . Endoscopic stenting of gallbladder...

E r y t h r o p o i e t i n Blunt erythropeietin secretion i n . . .

E s c h e r i c h i a c o i l Characteristics of the infections...

E s o p h a g e a l v a r i c e s SEE ALSO Sclerotherapy; Variceal bleeding

Drug effects Ursodeoxycholic acid delays t h e . . . Propranolol does not decrease t he . . . Hemodynamic effects of octreotide...

Diagnosis High resolution endoluminal sonography.

Prevention Reduction of esophageal variceal. . . Endoscopic sclerotherapy versus. . . Prophylactic endoscopic variceal. . .

TIPS Efficacy of TIPS in the prevention... TIPS versus sclerotherapy + propranolol..

E s t r o g e n s Antagonists and inhibitors

Paradoxical effects of tamoxifen... Treatment with tamoxifen in patients. . . Tamoxifen inhibits the growth of . . .

Pathophysiology Bicarbonate biliary secretion i s . . . Estrogen and antioxidants in hexachloro...

Physiology Variant liver estrogen receptor... Sex differences and hormonal regulation...

Transport Daunorubicin protects against estradiol... Multiple pathways for estrone sulfate.. .

E t h a n o l SEEALSO Acetaldehyde; Alcohol liver disease

Adverse effects Nimodipine, a dihydropyridine-type... Cellular fibrenectin and early markers . . . Autophosphorylation of the epidermal...

Cell physiology Alcohal-induced alterations in t he . . . Human antibodies versus hydroxyethyl.. The effect of chronic ethanol. . . The effect of acute ethanol exposure... Glutathione as an important antioxidant. Effects oflipopolysaccharide toxin.. . Effects of long-term alcohol...

Experimental models Polyenylphosphatidylcholine decreases... Treatment with dietary saturated. . . Increased in rive expression of . . . Effect of thromboxane inhibition...

Gamma glutamyltransferase Increased expression of gamma glutamyl..

Liver transplantation, experimental ICAM-1 is elevated dramatically... Inactivation of Kupffer cells minimizes...

Metabolism Acetaldehyde and mal]ondialdehyde... 4-hydroxynonenal (HNE) levels a r e . . . The endotoxin antagonist B-464 a n d . . . Increased susceptibility to alcoholic... Effects of cimetidine on blood ethanol. . . Microsomal ethanol oxidizing system.. .

Mitochondria Mechanism of defect in mitochondrial... Oxidation of DNA and proteins i n . . . Effects of ETOH on mitochondrial...

Pathophysiology Chronic alcohol consumption increases... The pancreas produces a-hydroxyethyl... Role of endothelium-derived... Lipid turnover in alcoholics before.. . The effect of alcohol on viral hepato. . .

Pharmacology Estrogenicity of alcoholic beverages.. .

Therapeutic use Pereutaneous ethanol injection of . . .

E t i d r o n a t e Cyclical etidronate versus sodium.,.

E t o p o s i d e Assessment of isolated rat hepatecyte...

E v o k e d p o t e n t i a l s Changes in evoked cerebral activity,..

Exercise Changes in respiratory quotient...

E x t r a c e l l u l a r m a t r i x 8 Extracellular matrix proteins i n . . . 324 9 Gone expression of matr ix . . . 517

1381 Reversal of activated lipocyte phenotype.. : 704 1 5 3 5 Heparitinase and heparinase induce.. . 1318

Soluble collagens modulate t h e . . . 1524

1536

239 F

F a c t o r V I I a Recombinaut VIIa (rFVIIa) in the . . . . 730

75 193 F a m c i c l o v i r

1 5 0 1 Famdclovir treatment of hepatit is. . . 449 Inhibitory effect of penciclovir... 890

587 F a m i l i a l a m y l o i d n e u r o p a t h y Portuguese national experience i n . . . 172

195 Liver transplantation in familial. . . 384 577 Orthotopic liver transplantation... 385 579 Farnesyltransferase

Inhibition of cell growth of human . . . 364 759 761 F a s antigen

SEE ALSO Apoptosis Antibody to

BCI-2 protects from lethal hepatic. . . 483 562 Fas-mediated intracellular inactivation... 629

1191 Drug effects 1475 .Apoptesis induction in isolated... 489

832 Hepatitis C Role of CD8 + lymphocytes and natura l . . . 491

1086 The localization of HCV and t h e . . . 672 Fas antigen expression in l ivers . . . 1446

336 Hepatitis, fu lminan t 824 Fas and Fas ligand strongly expressed... 493 843 Liver regeneration

1347 Apoptesis and cell proliferation... 1512 p53 tumor suppressor gene

p53 and Fas/APO-1 induction in hepatema. . . 200 Primary biliary cirrhosis

Immunohistochemical study of F a s . . . 1327 548 f a s - A P O - 1 g e n e

1257 1439 p53 and Fas/APO-linducti0n in hepatema. •. 200

Hepateprotective effect of anti-APO-1/Fas... 492

478 F a s c i o l a h e p a t i c a 481 Hepatic cyst computed temography... 1619 541 Fasting 542 Effects of fasting and glucose... 441 564

1 0 4 1 F a t t y a c i d b i n d i n g p r o t e i n s 1 4 1 2 Variations in L-FABP, flux and l ipid. . . 537

Up-regulation of mltechondrial aspartate . . . . 825 475 Mitochondrial aspartate amino. . . 1269

476 F a t t y a c i d s 543 The effect of alteration of fatsy. . . 17 545 Treatment with dietary saturated. . . 476

Effects of ETOH on mitochondrial... 540 547 Nonalcoholic steatohepatitis clinical... 1179

Correlation of plasma fatty ac id . . . 1221

438 F a t t y l i v e r 439 Use of donor livers with modarate-to... 395

Liver transplantation for jejunoileal... 411 479 Clinical significance of elevated. . . 1111 544 Galactsse elimination test versus . . . 1151 550 Genetic predispositions for immunologlc... 1198 555 F a t t y l i v e r , a l c o h o l i c

1322 1430 ICAM-1 is elevated dramatically... 438 Inactivation of Kupffer cells minimizes.. . 439 Overweight risk factor of alcoholic... 557

521 539 F e r r l t i n 54o Hepatitis C

Rod cell ferritin and serum ferri t in. . . 999 546 Iron hepatetexicity in post-menopausal... 1284 549 Interferon response 568 Serum ferritin levels, HCV vlremia . . . 297

1291 Response to a-IFN therapy : . . 1172 1 4 6 4 Pathophysiology

A novel three-step immunoscintigraphy... 318 552 al-antitrypsin reduces transferrin, . . 1044

Localisation of ferritin, transferrin. . . 1143

1 2 1 1 F e t a l l i v e r Propranolol elimination by r igh t . . . 1494

76 Fibrinolysis Increased portal and systemic fibrinolysis... 584

1 1 6 0 Prostaglandius and coagulation a n d . . . 1445

F i b r o b l a s t g r o w t h f a c t o r 266 Increased intrahepatic mRNA expression... 1422

F i b r o b l a s t s 1 2 8 1 correction of bilirubin glucuronidation... 1070

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 5 4 7 A

F i b r o n e c t i n Stimulation of c-inn kinase by fibronecl~n... 746 Fibroneetin isoform gene expression... 1049 Cellular fibrenectin and early markers . . . 1257

F i b r o s i s SEE ALSO Cirrhosis; Collagen;

Procollagen; Stellate cells Alpha fetoproteins

Heterogeneity in the induction o f . . . 1410 Anatomy and histology

Histological evaluation of l iver . . . 1476 Cell physiology

Apoptosis of hepatocytes highly. . . 644 Fibronectin isoform gene expression : . . 1049 Expression of metallopreteinases... 1054

Congenital Induction of transforming growth. . . 1226

Cytokine effects Liver injury and fibrosis in interferon... 680 Antlproliferative effects of ?-interferon... 682 Reversion by interferon of l iver . . . 684 Interferon increases extracellular... 685 Studies on the fibrogenic potential.. . 719 Plasma transforming growth facter-~. . . 721 Interferon gamma treatment inhibits. . . 1506

Diagnosis Tenassin is a serum marker of lobular. . . 1050

Drug effects Effect of pentoxifylline in a heteralogens... 1292 Stimulation of fibrelysis b y . . . 1416 Effects of simvastatin, pentoxyfylline... 1440 Fibroproliferation in swine a n d . . . 1472 Role of adenosine receptors in t h e . . . 1473

Endothelins Endothelin antagonism in experimental... 460 Expression and potential role o f . . . 687

Experimental models Regulation of TGF-beta expression... 717 Expression of CYPIA1 and CYP1A2... 1471

Genetics HGF transcription is under a cel l . . . 1279 Tissue transglutaminase gene expression... 702

Hemochromatosis Molecular and cellular aspects o f . . . 1057

Hepatitis B, chronic Serum transforming growth factor. . . 1359

Hepatit is C Correlation between type I collagen... 673 Hyaluronic acid: a useful marker . . . 998 Elevated pre~ollagen-III-peptide... 1433 Correlation between hepatic stellate. . . 1488 Evaluation of hepatic fibrogenesis... 1497

Hepatitis, viral Fyridinoline collagen cross-links... 1283

Hepatocyte growth factor Cellular localization of hepatocyte... 503

Integrins Contraction of eollagenous bands . . . 1046

Kupffer cells Destruction of Kupffer cells diminishes... 706

Pathophysiology Expression of c-met mRNA and TGF-131... 504 Expression of gelatinase A is increased... 1051 High TIMP-1 expression results i n . . . 1055 Cellular fibroneetin and early markers . . . 1257

Prevention New prolyl 4-hydroxylase inhibiter.. . 694

Prognosis No biological or histological data... 671

Retinoic acid Diminished retinoic acid signaling... 715

Sex differences Mechanism of action of HOE077. . . 689

Transforming growth factor Regulation of TGF-beta expression... 717 Identification of the antifibrogenic... 718 Characterization of TGF-~I . . . 1245 Destruction of Kupffer cells diminishes 706

Transgenic animals Role of platelet-derived growth. . . 697 Transcriptional activation of a2( I ) . . . 698

Zinc Effects of dietary zinc on vi tamin. . . 1462

F K - 5 0 6 Apoptosis

Apoptosis induction in isolated... 489 Food allergy

Life-threatening food allergy i n . . . 1345 Pharmacology

Conversion to FKS06 immunosuppression... 146 Comparative study of pharmacokinetic... 147 Effects of cyclosporine and tacrolimus... 430

F K - 5 0 6 ( c o n t i n u e d ) Therapeutic use

FK 506 is as effective as 0KT3 for . . . 148 Tacrelimns (FKS06) versus cyclesporine... 149 First year of tacrolimus: have w e . . . 150 Occurrence of central pontine.. . 1126 FK506 (tacrolimus, Prograf~), . , 1167 Primary liver transplantation i n . . . 1253 Chronic rejection following primary.. • 1309 Impact of positive crossmatch due . . . 1540

F l a v i v i r i d a e SEE Hepatitis G

f l k -1 g e n e Differential expression of vascular. . . 511

F l o w c y t o m e t r y Can flow cytometric DNA analysis.. . 317

F l u o r i d e s Cyclical etidronate versus sodium... 76

F o o d a l l e r g y Life-threatening food allergy i n . . . 1345

fos g e n e Impaired IL-l~-inducod hypothalamic... 1028

F r a c t u r e s Kupffer celt pro~inflammatory alterations... 1040 Femur fracture trauma to donors... 1468

F r e e r a d i c a l s S~EAL80 Oxidative injury Human antibodies versus hydroxyethyl... 481 Oxidation of DNA and proteins i n . . . 539 The pancreas produces a-hydroxyethyl . . . 549 Prolonged increase of portal pressure.. . 572 Fructose and other iron-chelating... 1081 Generation of hydrogen peroxide... 1084 Effects of vitamin E, ascorbie acid. . . 1617

F r u c t o s e Fructose and other iron-chelating... 1081

Furans Oncegenes expression after bile... 1482

Fusion proteins Transforming property of an HBV-cydin ~.. 204 Improved detection of anti-HCV antibody... 1129

G

G - C S F Combination therapy for hepatitis.. . 1144 Granulocyte colony stimulating factor... 1569

G proteins Regulation of Gict-protein... 368 Chronic ethanol administration increases... 797 Modulation of intracellular calcium... 801 Mechanism of extracellular ATP-induced... 830

G A B A The effect of acute ethanol exposure... 542

G a d o l i n i u m Gadolinium prevents hepatic granulomas... 1366

G a l a c t o s e Galaetose elimination test versus. . . 1151

G a l l b l a d d e r m o t i l i t y Gallstone recurrence after successful... 25 Ursodeoxycholic acid treatment. . . 1517 The effect of gender on gallbladder... 1581

G a l l b l a d d e r e p i t h e l i u m Prosteglandin E1 stimulates mucin. . . 15 Modulation by endothelin-1 of cyclic... 831 Modulation of musi n and collagen... 1190

G a l l s t o n e f o r m a t i o n SEEALSO Cholelithiasis; Cholesterol gallstones Cirrhosis: a new, but expected cause... 7 The effect of alteration of fa t ty . . . 17 Evidence that cholesterol antibodies... 19 Promotion of cholesterol crystal. . . 20 Biliary apolipoprotein A-I plays. . . 21 Isolation by immobilized artificial... 22 Transferrin: a potent cholesterol... 24 The effect of alteration of lecithin... 1548 Ursodeoxycholie acid reduces protein.. . 1592

G a l l s t o n e i l e u s One stage operative management o f . . . 1588

G a m m a - g l u t a m y l t r a n s f e r a s e Increased expression of gamma giutemyl , . . 547 Serum 7-glutamyl-transpeptidase... 1148

G a n c i c l o v i r Efficacy of ganciclovir in the treatment. . . 95 Combination therapy for hepatitis.. . 1144

G a p j u n c t i o n s Depression of gap junctional gene . . . 768 Gap junctlon's role of differential... 1308

G a r l i c Hepatopulmonary syndrome: open label . . . 241

G a s t r i c b l e e d i n g Transgastric collateral vessels. . . 583

G a s t r i c b l o o d f l o w The effects of somatostatin on gastric. . . 612 Evaluation of mucosal blood flow.. . 1259

G a s t r i c e m p t y i n g Ultrasonographic evaluation of gastric. ~. 1220

Gastric varlces Experiment of endoscopic variceal. . . 581 Efficacy of TIPS in the prevention... 759

G a u c h e r ' s d i s e a s e Uptake and metabolism in vice... 1073 Mannose-terminal giucocerchrosidase... 1074

Gc-globulin Early free serum Gc-globulin in... 1519

Gemeitabine The nucleoside analogues 2-chlorodeoxy... 1263

Gene expression SEEALSO Transcription factors

Actin Endethelin antagonism in experimental... 460 Inhibition of rat Ito cell activation... 705

Acute phase response factor APRF, increased nuclear binding... 515

Alpha fetoproteins Clinical implication of circulating... 1330 Heterogeneity in the induction o f . . . 1410 Characteristics of hepatocellular... 1431

Apolipoprotein(a) Viscosity but net colloidosmotic... 1435

Asialoglycoproteins Intrahepatic MDR3 P-glycoprotein... 1222

Aspartate aminotransferase Effects of ETOH on mitochondrial... 540 Up-regulation ofmitochondrial aspartate. . . 825

Atrial natriuretic factor Altered pulmonary expression o f . . . 457 Differential gene expression of . . . 1596

Cholesterol- 7-hydroxylase Protein kinase C activation/cellular... 531 Increasing hepatic cholesterol 7 a . . . 532

Collagen Endothelin antagonism in experimental... 460 Correlation between type I collagen... 673 Liver injury and fbrosis in interferon... 680 Mechanism of action of HOE077.. . 689 5 lipoxygenase inhibitor suppresses... 707 Catalase inhibits collagen synthesis... 749 Overexpression oflaminin and collagen... 1048 Modulation of mucin and collagen... 1190 Influence of all-trans and 9 -ds , , , 1264

Complement Complement C4 protein gene expression,.. 713

Connexins Depression of gap junctional gene . , , 768 Gap junction's role of differential.,. 1308

Cyclins Transforming property of an HBV-cyclin.., 204 Possible mechanism of cyclin A . . . 337

Cyclooxygenases increased in vice expression o f . . . 543

Cytochrome P45o Expression of CYP1A1 and CYPIA2.. . 1471

E251 gene Increased expression of E251 i n . . . 67

Endothelins Altered pulmonary expression o f . . . 457 Expression and potential role o f . . . 687

Epidermal growth factor increasedintrahepatlc mRNA expression... 1422

erb B2 gene Oncogenes expression after b i le . . . 1482

Estrogen receptor Variant liver estrogen receptor.. . 336

Ferritin Localisation of ferritin, transferrin.. . 1143

Fibroblast growth factor Increased intrahepatic mP~A expression... 1422

Fibronectin Fibronectin iseform gene expression... 1049

ilk-1 gene Differential expression of vascular... 511

Gamma glutamyltransferase Increased expression of gAmmA glutamyl. . . 547

5 4 8 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

G e n e e x p r e s s i o n ( c o n t i n u e d ) Glutathione-S-transferase

Selective zone 3 induction of gintathione... Expression of heparin-binding EGF-]ike...

Glyceraldehyde-3-phosphate deh ydrogenase

Comparison of glyceraldehyde-3.,. Heat-shock proteins

Heat-shock protein 70 gene expression... Effect of ischemisdreperfusion o n . . .

Heine oxygenase Gene expression of the antioxidants...

Heparin-binding EGF-like growth factor

Expression of heparin-binding EGF-like,.. Expression of heparin-binding EGF-like...

Hepatocyte growth factor Hepatic expression of hepatocyte...

HLA class I antigens Analysis of gene and protein expression...

ICAM-1 Intercellular adhesion molecule-1...

IGF binding proteins Differential gene expression of . . .

IGF-II receptor Distribution of insulin-like growth. . .

IGF-II Differential gene expression o f . . .

lntegrins Contraction of collagenous bands...

Interferon receptors Quantitative analysis of interferon,..

Interferon regulatory factor-1 Interferon regulatory facter-1 gene . . .

Interleukin-1 Increased IL-l~:IL-lra mRNA.. .

Interleukin-4 Predominance of IL-4 mRNA expression...

Interleukin-6 In vice suppression of Kupffer. . .

Interleuk in- l O Suppressor cytokine expression i n . . .

lnterleukin-13 Suppressor cytokine expression i n . . .

Laminins Overexpression of laminin and collagen...

Macrophage-stimulating protein Hepatic expression of hepatecyte.. .

Matrix metalloproteinases Gene expression of matr ix . . . Pentoxify]]ine inhibits the proliferation... Expression of gelatinase A is increased,.. Membrane-type matrix metallo. . . Expression of metalleproteinases...

MDR genes Intrahepatic MDR3 P-glycoprotein...

Mucin Prostaglandin E1 stimulates mucin . . . Modulation of mucin and collagen...

myb gene Activation of hepatic stellate cells. . .

No-bile acid cotransporter Sex differences and hormonal regulation... Expression of the rat liver Na ÷. ,. Increased Na*/taurocholate... Inflammatery cytckine regulation...

Na-K-ATPase Increased hepatic NaK-ATPase activity.. .

Nitric oxide synthase The role of inducible NO synthase. . . Altered pulmonary expression o f . . .

Organic anion transporter Sex differences and hormonal regulation...

P-glycoprotein Regulation of MDR2 P-glycoprotein...

p15 tumor suppressor gene Expression and regulation of p53 . . . Regulation oft~e p21/WAF1/CIP1/SDI1... Cyclin-dependent kinase 4 inhibitors...

Peroxisome-proliferator-activated receptor

Hepatic arinar expression of t h e . . . ProcoUagen

How are capsule and sepmm formed.. . New prolyl 4-hydroxylase inhibiter.. . Pentoxifynine inhibits the proliferation... TNF-c~ stimulates a l ( I ) . , . "Deactivation" of activated... Inhibition of rat Ite cell activation... Heterogeneity of procellagen types...

Prostaglandin F z receptor Molecular cloning, expression a n d . . .

G e n e e x p r e s s i o n ( c o n t i n u e d ) Purinergic receptors

1100 Cloning, functional characterization... 790 1323 RAG genes

RAG1, RAG2 and TdT expression i n . . . 79 Retinoic acid receptors

344 Diminished retinoic acid signaling... 715 S.adenosylmethionine synthetase

445 Molecular characterization of . . . 343 1 1 0 1 Selectins

Endotoxemia induces E-selectin mRNA.. . 1037 1 0 8 2 Stromelysin

Stimulation of c-jun kinase by fibronectin.., 746 Terminal deoxynucleotidyltransferase

5Ol RAG1, RAG2 and TdT expression i n . . . 79 1 3 2 8 Thrombin receptor

Upregnlated expression of human . . . 683 1404 Tissue inhibitors o f metalloproteinases

Expression of metalloproteinases... 1054 372 High TIMP-1 expression results i n . . . 1055

Expression of metalloproteinase... 1056 1045 Transforming growth factor

Regulation of TGF-beta expression... 717 340 Identification of the antifibrogenic... 718

Increased intrahepatic mRNA expression.., 1422 712 Acetaldehyde increases transforming.., 1461

Oncogenes expression after b i le . , . 1482 340 Cytokine mediated regulation of . . . 1607

Transglutaminase lO46 Tissue transglutaminase gene . . . 702

TAP genes 918 Analysis of gene and protein.. . 372

Tumor necrosis factor a 363 Treatment with dietary saturated.. . 476

In vice suppression of Kupffer.. . 1635 1 5 6 2 UDP-glucuronosyltransferase

Identification of bfiirubin UDP-GT.., 819 440 Vascular endothelial growth factor

Expression of vascular endothelial... 339

1035 G e n e r e g u l a t i o n Albumin

lO39 Control of albumin gene expression... 784 Recombinant adenovirus-mediated... 785

1 0 3 9 Aldehyde dehydrogenase Functional analysis of 5' regulatory... 775

1048 Aldolase A Oxygen regulates the expression... 774

1404 Alpha globulins Age-dependent repression of a lpha . . . 422

517 APRF, increased nuclear binding.. . 515 095 Apolipoprotein(a)

1 0 5 1 Apolipeprotein A-I gene expression... 1434 1052 Asialoglycoprotein receptor 1054 A novel mRNA cis-asting element. . . 788

Collagen 1 2 2 2 Cell-specific transcription of t h e . . . 459

Transcriptional activation of a2(I ) . . . 698 15 Recognition of two Spl binding si tes . . . 699

1190 RAF and MAP kinase differentially.,. 743 Post-transcrlptional regulation... 744

743 Cytochrome P 4ao A novel cis-asting element i n . . . 778

824 Intracellular cascade controlling... 779 350 Glyceraldehyde-3-phosphate 852 dehydrogenase 854 Oxygen regulates the expression... 774

Heine oxygenasc 828 Regulation of human heme oxygenase-1,.. 776

Induction of heine oxygenase-1 mRNA.. . 1350 199 Hepatic bile acid binder 457 Induction of human hepatic bi le . . . 777

Hepatocyte growth factor 824 HGF transcription is under a cel l . . . 1279

I CAM-1 864 Activation of nuclear facter-xB... 1098

Laminins 334 A silencer element in the LAMC1... 782 519 MAP kinase

1205 RAF and MAP kinase differentially... 743 Metallothionein

Induction of metallothionein mRNA.. . 780 786 Nitric oxide synthase

Regulation of inducible nitric oxide... 571 370 Phosphoenolpyruvate carboxykinases 694 Identification of cell-volume-responsive... 771 695 Oxygen modulates the glucagon... 772 701 Oxygen regulates the expression... 774 703 r a f genes 705 RAF and MAP kinase differentially... 743 708 Ribonucleoproteins 789 Post-transcrlptional regulation... 744

G e n e e x p r e s s i o n ( c o n t i n u e d ) Transforming growth factor

Towards to in vice gene knock. . . 1132 Tumor necrosis factor a

TNF-a stimulates a l ( I ) . . . 701 UDP.glueuronosyltransferase

Effect ofbutylated hydroxyteluene.,. 781 X protein

Tetracycline-regulated expression... 625

G e n e t h e r a p y SEE ALSO Antisense oligonueleotides;

Transfection Crigler-Najjar syndrome

Prolonged expression of biliruhin-UDP... 453 Correction of biliruhin glucuronidation... 1070 Long-term correction of bfiirubin... 1071

Hepatocellular carcinoma Gene therapy ofhepatecellular carcinoma... 206 Adenovirally directed enzyme prodrug.. , 328 Recenstitution of wild-type p53 . . . 331

Methods Cell ploidy-based frastionation.,. 452 Gene therapy studies in non-human.. . 1080 Study on the cDNA synthesis a n d . . . 1602

Wilson's disease Conditionally immortalized hepatecytes... 1065

G e n i s t e i n The isoflavone genistein undergoes... 563

G i l b e r t ' s d i s e a s e Persistent unconjugated hyperbilirubin... 397 Gilbert syndrome is associated wi th . . . 1072

G l u c a g o n Oxygen modulates the glucagon... 772 Oxygen regulates the expression... 774 Glucagon secretion in diabetic a n d . . . 1340 Study of "hepatetrophie" substances... 1363

G l u c o c e r e b r o s i d a s e Uptake and metabolism in v i ce . . . 1073 Mannose-terminal glucocerebrosidase... 1074

G l u c o c o r t i c o i d s SEE ALSO other more specific entries A novel c/s-acting element i n . . . 778 Increased IL-l~:IL-lra mRNA.. . 1562

G l u c o s e Effects of fasting and glucose... 441 Increase in hepatic glucose uptake . . . 528 Stimulation of liver regeneration... 1260

G l u c o s e - 6 - p h o s p h a t a s e Exon redefinition by a point mutation. . . 1077

G l u c o s i d a s e s Purification and characterization... 538

G l u t a m i n e The accumulation of glutamine i n . . . 213 Increase in hepatic glucose uptake . . . 528

G l u t a t h i o n e Biliary excretion

The mystery of canalicular GSH transport . , . 816 Nitric oxide stimulates bile f low.. . 834 Role of nitric oxide in the hepatic. . . 1016

Cell physiology Glutathione suppression of endotexin... 522 Glutathione as an important antioxidant. 564 Altered hepatoceUular Cu transport . . . 1518

Pathophysiology Hepatic reperfusion damage ~ t e r . . . 444 Alteration of GSH homeostasis i n . . . 524 Vitamin B deficiency results i n . . . 525

Transport Mechanism of defect in mitechondrial... 521 Maturational increase in canalicular... 814 High affinity transporter of reduced.. . 815

G l u t a t h i o n e - S - t r a n s f e r a s e Selective zone 3 induction o f . . . 1100 Improved detection of anti-HCV... 1129 Minimal preservation-reperfuslon... 1225 Expression of heparln-binding EGF-like.. 1328 The interest of measuring p lasma. . . 1458

G l y b u r i d e Choleretic action of glibenclamide... 837

G l y c e r a l d e h y d e - 3 - p h o s p h a t e d e h y d r o g e n a s e

Comparison of glyceraldehyde-3... 344 Multiple enzyme activities of h u m a n . . . 651 Oxygen regulates the expression... 774

G l y c i n e Glycine prevents elevation in . . . 803 Glycine blocks the increase i n . . . 804 Increases in intraeellular calcium... 1105

HEPATOLOGY Vol. 22, No. 4, Pt. 2, 1995 SUBJECT INDEX 549A

Glycogen Severely disturbed hepatic and skeletal. . . 1335 Exen redefinition by a poInt mutat ion. . . 1077

Glycosaminoglycans Characterization ofheparan sulfate... 1575

Glycosylphosphatidylinositol The glycosyl-phosphatidylinositel-linked... 764

Glycyrrhlzin Combination therapy of interferon... 1419

Golgi apparatus Hydrophobic and hydrophilic b i le . . . 1485

GOR epitope Anti-GOR in patients with chronic... 118

Graft function Hepatocyte transplantation

Increased liver engraftment o f . . . 418 Primary hepatecytes transplanted.. . 419

In pregnancy Pregnancy and liver graft survival . . . 136 OutcOmes of multiple pregnancies... 171

Ischemia-reperfusion injury Graft function following l iver . . , 127 Improvement of liver graft viability... 1182

Liver transplantation, experimental Femur fracture trauma to donors. . . 1468

Markers Hyaluronic acid in clinical l iver . . . 124 The value of caval effluent in predicting... 125

Organ preservation Effects ofintracellular pH a n d . . . 1428

Graft rejection SEE ALso Liver transplantation;

Organ preservation Autoimmune chronic active hepatit is

Acute cellular rejection of l iver . . . 143 Hepatocyte transplantation

Aliogeneic Kupffer cell is important. . . 426 Immunology

Significance of immune activation.., 189 Precipitation of fatal rejection... 190 Changes in the activation s ta tus . . . 1197

Markers Can soluble adhesion molecules be,.. 126 Assessment of histologic examination... 141 The early diagnosis of chronic ductopenie... 1168 Prediction of acute rejection in... 1493

Pathophysiology Hemodynamlc and oxygen variable. . . 121 Immunolecalization of bcl-2 a n d . . . 122 Microcirculatery impairment during. . . 192 Distribution of inducible nitr ic. . . 1019 Allograft rejection and lack o f . . . 1502

Prevention and treatment FK 506 is as effective as OKT3 fo r . . . 148 Ursodeexysholic acid reduces hepatic. . . 170 FKS06 (tacrolimus, PrografrM)... 1167 Chronic rejection following pr imary. . . 1309 Incidence and outcome of OKT3 therapy. . . 1496

Risk factors Risk factors for chronic rejection... 144

Xenotransplantation Hyperacute rejection of discordant... 427 Histopathology of l iver . . . 428

Graft vs hos t disease Binding of liver-derived lymphecytes... 84 Effects of in vice menoclonal... 429 Study of CD4 and CD8 level a n d . . . 1271 Antibodies against adhesion molecules... 1326

Granulocyte-colony s t imu la t ing factor

Combination therapy for hepatitis. . . 1144 Granulocyte colony stimulating factor. . . 1569

Grb2 pro te in Cellular transformation induced.. . 509

Growth hormone Synthesis of insulin-like growth. . . 510 Sex differences and hormonal regulation.., 824

Gut decon t amina t i on Antibiotic therapy for bacterial. . . 1130

H

Health care workers Seroprevalence of hepatitis A i n . . . 1427

Heart su rge ry Repeated transmission of HCV f rom. . . 962

Heart diseases Cardiac evaluation in adult l iver . . , 414

Heart t r a n sp l a n t a t i on Liver or combIned lung and l iver . . . 167 Clinical experience with hepatitis.. . 963 Outcomes of heart transplant recipients... 064

Heat-shock proteins Autoantibody against a heat shock... 64 Heat-shock protein 70 gene expression... 445 Effect of ischemia/reparfusion on... 1101 Reduced expression of heat shock... 1508

Helicobacter pylori The role of Helicobacterpylori... 218 Pathogenesis of portal hypertensive... 1479

Hemaccel Comparison of albumin, dextran-7O ~.. 456

Hematin Hematin therapy In cbJldren wi th . . . 1075

Hematocr i t Effects of protein binding and hematocrit... 813

Hem~topoiesis Desmin expressing cells during. . . 1323

Heme Biochemical events following part ial . . . 516 Induction of metallothienein mRNA.. . 780

Heme oxygenase Regulation of human heine oxygenase-1... 776 Carbon monoxide as an endogenous... 838 Carbon monoxide generated by heine. . . 839 Gene expression of the antiexidants... 1082 Induction of heine oxygenase-1 mRNA.. . 1350

Heme proteins Oxygen modulates the glucagon... 772 Oxygen regulates the expression... 774 Metabolic effect of nitric oxide... 1017 Gene expression of the antioxidants... 1082

Hemochromatosis SEE ALSO Iron overload

Diagnosis Hepatic iron in hereditary.. . 1059 Hereditary hemechromatssis: diagnosis... 1064

Genetics Molecular and cellular aspects of,,. 1057 Physical mapping in the heine... 1058 Phenotype and genotype variability.,. 1060

Hepatocellular carcinoma Which factors determine the development... 1063

Pathophysiology Hepatic stellate cell activation.,. 691 Hepatic lipid peroxidation in patients.., 1062

Hemodiabsorption The Biologic TM serbent- and cell-based,.. 1133 Hemediabsorption in treatment of... 1134

Hemodialysis Acute hepatic failure

Removal of ammonia and nitrogenous... 432 Continuous veno-venous heine... 1227

Hepatitis C A double-blind controlled trial... 37 Molecular evidence for nosecomial... 957 Prospective virologic follow-up... 958 De novo hepatitis C virus infection... : 959 A study of tmexplained aminotransferases... 989 Hepatitis C in hemodialysis patients. . . 1128 Chronic HCV infection in HE}... 1175 The effect of ursedeoxychelic acid. . . 1457 The interest of measuring plasma. . . 1458 Evaluation of the Amplicer TM HCV.. . 1625

Hepatitis E Hepatitis E virus surveillance i n . . . 1123 Hepatitis E in dialysis: fact o r . . . 1372

Hemolysis Does TIPS induce mechanical... 1442

Hemophil ia Chronic hepatitis C virus infection... 264 Safety and utility of percutaneous.,. 679 Liver biopsy in hemephilic patients. . . 1201 Quantitative detection of hepatitis.. . 1202

Hemosider in Neonatal hepatitis of non-familial... 1566

Hep3B cells Recenstitution of wild-type p63 . . . 331

Heparan sulfate Characterization of heparan sulfate.. . 1575

Hepar in TIPS: thrombogenicity and early... 592 Continuous veno-venous heine... 1227

Heparin-binding EGF-like growth factor

Expression of heparin-binding EGF-like... 501 Expression of heparin-binding EGF-like... 1328

Hepar inase Heparitinase and heparinase induce. . . 1313

Hepatic ar ter ies Hepatic artery resistance index. . . 11 A new look at the "hepatic".,. 209 Alterations of blood supply to the... 316 Clinical significance of the... 1178 Thrombectemy and intraoperative... 1195

Hepatic bile acid binder Induction of human hepatic bile,., 777

Hepatic blood flow Improving hepatic hemodynamic a n d . . . 431 Hepatic haemodynamic changes induced.. . 566

Hepatic cyst Hepatic cyst computed temography.,. 1619

Hepatic encepha lopa thy Epidemiology Prevalence of subclinicel hepatic,.. 1117

Liver transplantation Hepatic encephalopathy in patients. . . 378 Effect of liver transplantation... 379 Changes in blood explain increased... 380

Pathophysiology Characterization of early signs... 214 Extracenular brain amino acids. . . 216 The role of manganese in chronic... 217 The role of Helicobactcrpylori... 218 MRI findings in chronic hepatic. . . 1289

Portasystemic shunt Portacaval anastomosis results i n . . . 215

TIPS Quantification of the extent o f . . . 757 The influence of TIPS on portal . . . 760 Latent hepatic encephalopathy i n . . . 1478

Tumor necrosis factor a Correlation of serial cytokine levels... 1038

Hepatic granuloma In vice IL-10 treatment suppresses... 1029 Gadolinium prevents hepatic granulomas.,. 1366

Hepatic iron index Hepatic iron in hereditary... 1069 Intra-organ variability in hepatic... 1061

Hepatic necrosis Anticoagulant targeting endothelial... 575 TNFa-induced apoptesis o f . . . 1093 Presence of liver necrosis is needed. . . 1097 Sermn isocltrate dehydrogenase a s . . . 1107

Hepatic veins Doppler ultrasounds of the hepatic. . . 1192

Hepatic veno-occlnsive disease Transjugular intrahepatic portal-systemic... 591

Hepatitis A Epidemiology

Hepatitis A,B,C and E seroprevalence... 1120 Hepatitis A virus infection: i s . . . 1121 Hepatitis A virus seroprevalence... 1122 Seroprevalence of hepatitis A infection... 1231 Acute hepatitis in western Amazon,. . 1252 Seroopidemiologic study of hepatitis. . . 1546

Immunization Immunogenicity and reactogenicity... 871

Vaccines Declining prevalence of immunity. . , 311 Imm~unogenicity and reactegenicity... 871 HeI~titis A virus infection: i s . . . 1121

Hepatitis, alcoholic Nimodipine, a dihydropyridine-type... 548 Overweight risk factor of alcoholic... 557 Amlodipine therapy in acute alcoholic... 558 Liver endothelial cell dysfunction... 1022 Usefulness of technetium-99m GSA. . . 1305 Bacterial infections as bad prognostic... 1555 HMG-CoA reductase inhibitor... 1623

Hepatitis B Blood donors

Viral hepatitis markers and evaluation... 990 Detection of HBV-DNA by PCR in serum. . . 1242

Core antigen Hepatitis B virus core promoter.. . 616 Serial analysis of hepatitis B v i rus . . . 621 HBV core proteins with central deletions... 643 The use of hepatitis B core antibody... 1530 Subcellular localization of hepatitis. . . 1642

Core heterogeneity Core gene heterogeneity in HBV-DNA... 640

5 5 0 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

H e p a t i t i s B ( c o n t i n u e d ) Drug therapy

Efficacy of ganciclovir in the t reatment . . . I-IBV marker kinetics during therapy. . . Reduction in hepatitis B virus quasispecies.. Histological improvement in patients. . . Inhibitory effect of pensiclovir...

Envelope proteins Altered regulatory mechanisms which. . . Expression of the interfaron-induced...

Epidemiology An epidemioleglcal survey for hepatitis. . . Hepatitis A,B,C and E seroprevalence... Acute hepatitis in western Amazen... Comparison of infectivity of breast...

Experimental models Tupaia belangeri: a novel smal l . . . Pharmacekinetics of free and liposome...

Gene therapy Pharmarokinetics of free and lipesome... Study on the cDNA synthesis a n d . . .

Genetics Absence of unique HBV mutation i n . . . The complete nucleotide sequence... Mutagenesis and expression of I-1BsA~... Presence of hepatitis B virus precore.. . Phyllanthus amarus interferes... Replication-defective HBV mutants . . . The relationship between hepatit is. . . Can hepatitis B virus precere mutan t . . .

HBIG (Hepatitis B immunoglobulin) Predictors of hepatitis B v i rus . . .

HBV DNA Quantitative hepatitis B virus DNA. . . Specific detection ofHBV DNA i n . . .

Hepatitis C co.infection Effect of chronic HCV infection... Alpha interferon therapy in HBsAg.. . Viral interference in double infection... Rare coexpressien of tissue HBV. . . Quantitative hepatitis B virus DNA. . .

Hepatitis, fulminant Fulminant hepatitis associated wi th . . .

Hepatocellular carcinoma Transforming property of an HBV-cyclin... The effect of alcohol on viral hepate...

H1V co.infection Hepatitis C and Hepatitis B in H1V..

Immunization Effect of a nationwide hepatitis. . . Vaccine therapy for hepatitis B . . . Immunogenicity and reactogenicity. Hepatitis B vaccination of methadone.. . Long-term immunity to hepatitis. . . Efficacy of vaccination against . . . Immunogenicity of alternative hepatit is. . . Analysis of the anti-HBs response•..

Immunocompromised host Fibrosing chelestatic and steateviral. . .

Immunology The cytotexie T lymphocyte response.. . Hyperimmune response in mice t o . . . Pelynucleotide-based immunization... Serum intercellular adhesion molecule-1... Apoptesis and clonal growth inhibition...

Interferon therapy Long-term follow-up of HBe-Ag positive... Targeted treatment of hepatitis... Effects of recombinant interferon... Interrelation between HBV, HDV and...

Liver transplantation Survival after liver transplantation... Strategies for prevention of dea th . . .

Mutants Use of dominant negative mutants . . . Absence of unique HBV mutation i n . . . Fulminant hepatitis associated wi th . . . Inhibition ef viral replication... Replication-defective HBV mutants . . . Immunolegically negative hepatitis. . . Hepatitis B virus mutations associated... Natural occurring escape mu tan t . . .

Pre-core mutants Mutations in the precero/eere a n d . . . Presence of hepatitis B virus precere. . . High incidence ofHBV pre-cere gene . . . Method for detection of epsilen-secendary... Survival after liver transplantation... Hepatitis B virus variants wi th . . . Hepatitis B virus pre-cere mutat ion. . . Detectien of hepatitis B virus precore.. . The relationship between hepatit is. . . Can hepatitis B virus precere mu tan t . . . Quantitative analysis of wild-type... The relationship between pre-core~cere...

Hepatitis B ( c o n t i n u e d ) Pre-S protein

95 A binding protein for curboxyl terminal. . . 649 884 Interaction between a curboxypeptidase... 650

• 685 Promoters 887 HBV core prometer mutations cause. . . 614 890 Absence of unique HBV mutatien i n . . . 615

Hepatitis B virus core promoter.. . 616 96 Renal transplantation

883 Immunologically negative hepatitis.. . 1523 Ribozymes

622 Multimeric self-cleaving rlbozyme... 474 1 1 2 0 Sequence analysis 1252 The complete nucleotide sequence... 618 1603 Serial analysis of hepatitis B v i rus . . . 621

Sequencing analysis of the terminal. . . 642 646 Surface antigens 889 S gene escape mutants as a cause. . . 174

Mutagenesis and expression of HBsAg.. . 620 889 An epidemiolegicel survey for hepatitis. . . 622

1602 Unravelling of the binding mechanism... 630 Production ef antibody to hepatitis.. . 631

615 Transcription factors 618 Generation of tetracyclin-inducible... 653 620 Transfeetion 645 Adenovirus-associated, recepter-mediated... 628 647 Vaccines

1290 Effect of a nationwide hepatitis.. . 468 1567 Vaccine therapy for hepatitis B . . . 469 1573 Safety and CTL determinatiens f rom. . . 870

Immunogenicity and reactogenicity... 871 97 Hepatitis B vaccination of methadone... 872

Long-term immunity to hepatitis. . . 873 638 Efficacy ef vaccination against . . . 875 641 Immunogenicity of alternative hepatitis.. . 1177

Analysis of the anti-HBs response... 1208 637 Viral replication

38 Liver transplantation for patients. . . 94 634 Routine evaluation of hepatitis. . . 471 636 Use of deminant negative mutants . . . 472 638 Inhibition ef hepatitis B v i rus . . . 473

HBV core promoter mutations cause. . . 614 619 Fas-mediated intracellular inactlvatien... 629

Inhibition of viral replication... 648 204 Multiple enzyme activities of human . . . 651

1 4 6 4 Lamivudine results in a complete... 886 2',3'-dideoxy-~-L-5'-fluorocytidine... 888

1443 Inhibition of hepatitis B v i ra l . . . 891 The effectiveness of antisense... 1285

468 The mitechondrion is the key organelle... 1459 469 The acute phase protein alpha-1.. . 1487 871 The relationship between hepatitis. . . 1567 872 X gene/protein 873 p53 status, pX induced cell cycle... 202 875 Genemie variations in the hepatitis. . . 345

1 1 7 7 Mutations in the precoreJcere a n d . . . 346 1208 Detection of hepatitis B virus X . . . 347

In,eased 8-hydroxy-2'-deoxyguanosine... 348 Cancer formation in WAP-HBV-X... 349

1 2 4 1 Characterization of a liver-specific .... 623 466 Use of the yeast twe-hybrid system.. . 624

Tetracycline-regulated expression... 625 617 Effect ef hepatitis B virus X gene . . . 626 869 Subcellular localization ef hepatitis. . . 1542

1119 1 4 2 5 H e p a t i t i s B , c h r o n i c

Autologous lymphocyte therapy 880 Autelogous lymphocyte therapy for . . . 892 882 Diagnosis

1189 Histological diagnosis of chronic... 1379 1386 Comparative study of chronic hepatitis.. . 1627

Drag therapy 1255 HBV marker kinetics during therapy. . . 884 877 Histological improvement in patients... 887

Combination therapy for hepatitis... 1144 472 Outeeme of prolonged Arabinoside... 1559 615 Genetics 619 Chronic hepatitis B virus infection... 627 648 Core gene heterogeneity in HBV-DNA... 640

1290 Sequencing analysis of the terminal. . . 642 1523 HBV core proteins with central deletions... 643 1529 Hepatitis B virus pre-core mutation.. . 1413 1604 The relationship between pre-coce/coce... 1628

Growth factors 346 Serum transforming growth factor. . . 1359 645 Transforming growth factor a lpha . . . 1360 652 Hepatitis C co-infection 654 What are epidemiological, biochemical... 635

1 2 5 5 Immunization 1265 Safety and CTL determinations f rom. . . 870 1413 Immunology 1429 Antigen independent activation of . . . 632 1567 Restriction of V beta gene usage. . . 633 1 5 7 3 Comparative analysis of the cytotexic... 909 1583 Clinical, biological and histolegical... 1131 1628

H e p a t i t i s B , c h r o n i c ( c o n t i n u e d ) Interferon therapy

Long-term treatment with recombinant... 874 Long-term follow-up of patients. . . 876 Randomized study comparing a fixed.. . 878 Lymphoblasteid interferon-a... 879 Long-term follow-up of HBe-Ag positive... 880 Retreatment of chronic hepatitis. . . 881 Long-term monthly follow-up of patients. . . 1448 Cirrhosis doesn't influence response.. . 1466 Quantitative analysis of wild-type... 1583

Pathophysiology Apoptesis of hepatecytes highly. . . 644 Tenazcin is a serum marker oflchular . . . 1050 Lipid- and lipoprotein changes i n . . . 1522

Hepatitis B , p o s t - t r A n ~ p l a n t a t i o n Drug therapy

Efficacy of ganciclovlr in the t reatment . . . 95 Famciclovir treatment of hepatitis. . . 449 Lamivudine therapy of fibrosing... 1615

Genetics Altered regulatory mechanisms which. . . 96 S gene escape mutants as a cause. . . 174 Replication-defective HBV mutants . . . 1290

Hepatitis D Liver transplantation for patients. . . 94

Immunology Immune mechanisms in liver g ra f t . . . 93

Pathology Histepathelogical a n d . . . 1357

Prevention Lamivudine prophylaxis: a new strategy. . . 470 Lamivudine results in a complete... 886

Risk factors Predictors of hepatitis B v i rus . . . 97

H e p a t i t i s C sEE ALSO more specific entries (following)

Alcohol liver disease Hepatitis C virus infection enhances. . . 465 Prevalence ef HCV infection among. . . 972 Prevalence ef hepatitis C v i rus . . . 1186

Anti.core antibody Changes in HCV antl-cere and anti-E2.. . 258 Determination of serum anti-core... 259 IgM anti-HCV testing in chronic... 293 The significance of IgM antibody... 991 Diagnostic significance of IgM anti-HCV... 992 Improved detection of anti-HCV antibedy.. . 1129 Anti-HCV core antibody levels correspond... 1370 Significance of anti-HCV-cere IgM. . . 1498 Hepatitis C virus anti-cere IgM. . . 1577 Quantitation of anti-core HCV antibodies. 1624

Anti-E1 antibody E1 antibody level monitoring predicts.. . 740 Prognosis oflong-tarm resolvemcnt... 994

Anti-E2 antibody Changes in HCV anti-cere and anti-E2.. . 258

Anti-envelope peptides Significance of antibody to anti-envelepe.. 1613

Antisense oligonucleotides Specific inhibition of hepatitis. . . 893 Specific inhibition of hepatit is. . . 894 Targeted inhibition of HCV promoter. . . 895

Autoimmunity Auteimmune hepatitis: clinicopathologlc... 1491

Blood donors Hepatitis C virus genotypce, RNA. . . 662 Viral hepatitis markers and evaluation... 990 Significance of anti-HCV in blood... 1509 Analysis ofHCV genotype in blood... 1556

Cellular immunology Lymphocyte phenotypes in chronic... 462 Hepatitis C virus-specific cytotoxic... 910 Accumulation of HCV-core specific... 911 CD30-induction on T lymphocytes... 913 Cytokine expression and T-cell subset . . . 914 Immunodeminant hepatitis C v i rus . . . 916 Lymphocyte surface antigen expression... 1373

Cirrhosis No biological or histological d a t a . . . 671 Correlation between type I collagen... 673 Mortality and merbidity in cryptegenic. 974 al-antichymotrypsin deficiency... 979 Hyalnronic acid: a useful marker . . . 998 Correlation between hepatic stellate.. . 1488

Chronic active hepati t is Female predominance in chronic . . . 1256 Mild or aggressive chronic active. . . 1266

Classification Hepatitis C virus genotypes 7, 8 . . . 951 Comparative study of chronic hepatitis. 1627

Co-infection Co-infection with several HCV genotypes... 668

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 551A

Hepatitis C (continued) Core antigen

Expression and immune response to. •. 454 Efficient production of a portion.. . 900 HCV core protein subcellular localization... 901 Maturation and biological importance... 902 Clinical application of a fluorescence... 995 Significance of serum hepatitis... 1452

Cryoglobulinemia HCV infection of peripheral blood... 925 HLA-B8 confers susceptibility t o , . . 985 Sequence analysis in hypervariable... 986 Mixed cryoglchulinemia and hepatitis.. • 988 Clinicopathalogical characteristics... 1249 Serum cryoglobulins and chronic•.. 1316 Multivariate analysis of the potential.. . 1371 Anticardiolipin antibodies and mixed. . . 1417

Dialysis Molecular evidence for nosocomial... 957 Prospective virologic fallow-up... 958 De nero hepatitis C virus infection,.. 959 A study of unexplained aminotransfarases... 989 Hepatitis C in hemodialysis patients. . . 1128

Drug abuse Assessment and medical follow-up,.. 1114 The prevalence of chronic hepatitis. . . 1280

Epidemiology Hepatitis C virus genotypes a n d . . . 945 Intrafamilial spreading of HCV infection... 949 Are hepatitis C virus genotypes... 950 Clinical and epidemiological backgrounds... 952 Molecular epidemialogy of hepatitis. , . 953 Hepatitis C virus genotypes in se rum. . . 954 Distribution of hepatitis C v i rus . . . 956 Prevalence of HCV infection among. . . 961 Repeated transmission of HCV from. . . 962 Clinical experience with hepatitis. . . 963 Outcomes of heart transplant recipients... 964 Mode of transmission of hepatit is. . . 965 Is the sexual transmission of HCV. . . 965 Mother-to-child transmission o f . . . 967 Mother to infant transmission of . . . 968 Prevalence of HCV infection among. . . 972 Hepatitis C virus infection a n d . . . 973 Hepatitis A,B,C and E seroprevalence... 1120 Level ofHCV RNA is related to genotype... 1188 Hepatitis C virus genotype prevalence... 1355 Unusually high prevalence of HCV. . . 1384

Epitope mapping Identification of cross-subtype... 467 Molecular mapping of an intrahepatic.. . 906

Floating density Differential flotation centrifugation... 289 Differential flotation centrifugation... 290 Hepatitis C virus density heterogeneity... 934 Dynamic changes of floating density. . . 935

Hepatit is B co-infection Viral interference in double infection... 634 What are epidemiological, biochemical... 635 Rare coexpression of tissue t tBV. . . 636 Effect of chronic HCV infection... 637 Quantitative hepatitis B virus DNA. . . 638

Hepatitis E Hepatitis E virus surveillance i n . . . 1123

Hepatocellular carcinoma Hepatitis C-related hepato-Ca (HCC)... 321 HCV proteins do not bind p53 o r . . . 350 Changing prevalence of hepatit is. . . 351 Hepatitis C viral genotypes, modes. . . 352 Follow-up of French patients wi th . . . 353 HCV genotypes and hepatecollular... 354 Genotypes/amount of HCV, background.. 355 Expression of insulin like growth. . . 1423

HIP" co-infection Increased variability in the HCV. . . 904 Chronic hepatitis C virus infection... 932 Enhancement of HCV replication i n . . . 1251 Human immunodeflciency virus/hepatitis. . 1353 Hepatitis C and Hepatitis B in HIV. . . 1443

HLA typing Differential prevalence of HLA class. . . 971 Liver inflammatory activity in chronic... 1206

Hyperimmune serum Prevention of HCV infection i n . . . 455

Hypervariable region The mutual effect of genetic heterogeneity. . 253 Changes in genetic variability o f . . . 255 Antibody response to hypervariable... 898 Single-strand conformation polymorphism... 903 Increased variability in the HCV. . . 904 Sequence analysis in hypervariable... 985

Immune response Viral escape from the HLA-A2 restricted... 908 Patterns of immune responses t o . . . 921 Immunological events during t h e . . . 928

Hepatitis C ( c o n t i n u e d ) Immunodeflciency

Immunological events during t h e . . . 928 Hepatitis C virus density heterogeneity... 934

Immunologic cytoxicity Role of CD8 ÷ lymphocytes and natura l . . . 491 Defining the role ofintrahepatic... 724 Viral escape from the HLA-A2 restricted... 908 Comparative analysis of the cytotoxic... 909 Expression of CD80 (B7/BB-1) i n . . . 922

Immunology Anti-GOR in patients with chronic... 118 Dose-dependent acute reduction of . . . 261 Restriction of V beta gone usage. . . 633 Thl cytokine pattern and defective... 915 Defective antiviral cytokines i n . . . 917 Transforming growth factor-~l... 920 Relevance of ultrastructural lymphocyte... 924 Low expression oferythrocyts complement... 929 Elevated serum levels of IL-10 i n . . . 997 intsrleukin 6 and chronic hepatitis... 1382

Interferon receptors Quantitative analysis of interferon... 918

Interferon response Baseline level and kinetics of HCV.. . 260 Does hepatitis C viral genotype... 278 Prognostic markers for the response... 1154 Chronic HCV infection in H D . , . 1175 HCV genotypes: correlation wi th , . , 1213 HCV genotype in interferon... 1236

Iron overload Hepatic iron concentration in end . . . 676 Red cell ferritin and serum ferritin.. . 999 Reduction of liver iron content... 1162 Iron hepatotexicity in post-menopausal... 1284

Iron reduction Phlebotomy followed by a-intsrferon... 51 Randomized controlled trial of t he . . . 295 Phlebotomy reduces transaminase... 1207

Iron stores Iron stores and virus genotypes... 294 Intra-organ variability of hepatic.. . 677 Response to a-IFN therapy. , , 1172 Iron and response to intsrferon-a... 1234

Killer cells, natural Phenotypic and functional characterization... 923

Non-structural proteins Changes of variabilities in t h e . . . 257 Expression of enzymatical]y active.. . 897 Expression and characterization... 899 Viral clearance during acute hepatitis... 912

Pathology OV-6 positive, HepParl negative.. . 496 Histepathologic heterogeneity in... 656 Liver histology in patients wi th . . . 660 The localization of HCV and t h e . . . 672 Safety and utility of percutaneous... 679 Liver biopsy in hemophilic patients. . . 1201 Histological diagnosis of chronic... 1379 Preliminary study on infection of . . . 1601 Comparative study of chronic hepatitis.. 1627

Quasispecies Changes in genetic variability of... 255 Different quasi-species of hepatitis.. . 463 Modulation of hepatitis C v i rus . . . 738 Different quasispecies of hepatitis .... 927 Rapid quasispecies analysis of t h e . . . 941 Quasispecies of hepatitis C v i rus . . . 942 Quasispecies of the hepatitis C . . . 943 Different nncleotide diversity and . . . 955

Ribozyme inhibition Inhibition of hepatitis C virns-clirected,, 896

Risk factors The D2 dopamine receptor A1 allele.. . 556 Risk factors in chronic HCV carriers. . . 970

Screening Histological progression of chronic... Liver biopsy discloses occult chronic... Liver biopsy in anti-HCV(+) blood... Hepatitis C virus genotypes, RNA... Prevalence of HCV infection among... Viral hepatitis markers and evaluation.. Screening strategies for hepatitis. •. Detection of HBV-DNA by PCR in serum... Significance of anti-HCV in blood... Analysis ofHCV genotype in blood...

Sequence analysis Different nucleotide diversity and . . . 955 Molecular evidence for nosocomial... 957 DNA sequencing of 5'-UTR to determine... 1011 Molecular analysis of the HCV 5'UR/cere... 1557

Sexual transmission Intrafamllial spreading of HCV infection... 949 Is the sexual transmission of HCV.. , 966 Absence of detectable HCV RNA i n . , . 1013

657 658 659 662 961 990

1113 1242 1509 1556

Hepatitis C ( c o n t i n u e d ) Single s trand conformation

polymorphism Rapid quasispecies analysis of t h e . . . 941 Quasispecies of the hepatitis C . . . 943

Tissue culture Low production of HBV and HCV i n . . . 639

Vaccines Expression and immune response t o . . . 454 Efficient production of a portion.. ~ 900

Viral load HCV viremia in serum and liver t issue. . . 663 The spontaneous fluctuation of viremia. . . 937 Spontaneous fluctuations of v i ra l . . . 938 HCV viraemia and presence o f , . . 1141 Comparative evaluation of HCV viremia. . . 1456

Viral replication Genotypes/amount of HCV, background... 355 Dynamics of hepatitis C virus turnover. . . 723 In vitro effects ofintorfaran... 905 The %ake-over ~ phenomenon... 936 The spontaneous fluctuation ofviremia. . . 937 Quantitation ofintra-hepatic HCV-RNA... 1216 Enhancement of HCV replication i n . . . 1251 Detection of hepatitis C virus replication... 1426 Cell to cell HCV transmission b y . . . 1590

H e p a t i t i s C, c h r o n i c a c t i v e Combination therapy

Double-blind, randomized trial o f . . . 1578 Drug metabolism

Assessment of liver function before.. . 1367 Fibrosis

Hepatic expression of a-smooth., . 686 Tenascin is a serum marker of lobular. . . 1050 Elevated proceflagen-HI-peptide... 1433

Interferon therapy Randomized trial of effects of 1FN-a.. . 43 Side effects of high dose interferon,.. 45 Can prolonged alpha-IFN administration... 50 CAH HCV related: evaluation of five... 1150 Alpha-IFN treatment in HCV CAH, . . 1157 Lipid- and lipoprotein changes i n . . . 1522

Pathophysiology al-antichymo~ypsin deficiency... 979 Mild or aggressive chronic active. . . 1266

Hepatitis C, complications Autoimmune manifestations Chronic HCV hepatitis is associated... 982 Rheumatologic and immunologic... 983 Prospective study of primary Sj0gren... 984 Comparison of the prevalence of . . . 1146 Lacrimal dysfunction in patients. . . 1200 Myasthenia gravis and hepatitis. , , 1275 Peripheral neuropathy related t o . . , 1495 Prevalence of auteantibodies i n , , . 1547

Cryoglobulinemia HCV infection of peripheral blood... 925 HLA.B8 confers susceptibility t o . . . 985 Sequence analysis in hypervarlable... 986 Hepatitis C virus infection a n d . . . 987 Mixed cryogiobulinemia and hepatitis. . . 988 Clinicopathological characteristics... 1249 Serum cryogiobulins and chronic... 1316 Multivariate analysis of the potential... 1371 Relevance of hepatitis C virus infection... 1385 Anticardiolipin antibodies and mixed. . . 1417

Diabetes melli tus Association of diabetes mellitus. . . 977

Epidemiology A retrospective study ofliepatitis... 1377

Hepatocellular carcinoma Hepatitis C-related hepato-Ca (HCC)... 321 HCV proteins do not bind p53 o r . . . 350 Changing prevalence of hepatitis. . . 351 Hepatitis C viral genotypes, modes. . . 352 Follow-up of French patients wi th . . . 353 HCV genotypes and hepateceflular ~., 354 Genotypes/amount of HCV, background... 355 Expression of insulin like growth. . . 1423

Iron overload Hepatic iron concentration in end... 676 Red cell ferritin and serum ferritin... 999 Iron hepatotoxicity in post-menopausal... 1284

Lichen p lanus Lichen planus and hepatitis C v i rus . . . 948

Lymphoma Infection by HCV and other lymphotropic... 981 Analysis of HCV infection in patients... 1629

Porphyria cutanea turda HCV type lb in patients with chronic... 976

Pruritus Pruritus in chronic hepatitis C . . . 975 Chronic cholestatic hepatitis C . . . 980

5 5 2 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

H e p a t i t i s C , d i a g n o s i s Age factors

Age and platolets: a simple index. . . 1486 Algorithm

Virologic diagnosis of HCV infection... 1276 Antibody levels

E1 antibody level monitoring predicts.. . 740 The significance of IgM antibody... 991 Diagnostic significance of IgM anti-HCV... 992 Poor correlation of hepatitis activity.. . 993 Prognosis of long-term resolvement... 994 Significance of anti-HCV-eore IgM. . . 1498

Classification Comparative study of chronic hepatitis .... 1627

Dialysis A study of unexplained aminotransferases... 989 Hepatitis C in hemodialysis patients... 1128

Genotyping Hepatitis C virus diversity a n d . . . 108 Nucleotide variability in the 5'nonceding... 256 DNA sequencing of 5'-UTR to determine.. . 1011 Application of a simple serology... 1258 Molecular analysis of the HCV 5'UPJcere... 1557 A second generation line probe assay . . . 1558 Variations of hepatitis C v i rus . . . 1561 Accuracy of hepatitis C virus genetyping... 1574

Genotyping vs. serotyping Serological assay to determine HCV. . . 1008 Hepatitis C virus genotype determination... 1009 Virus hepatitis C typing: comparison... 1158

Glutathione-S-transferase Impreved detectlan of anti-HCV antibody... 1129 The interest of measuring p lasma. . . 1458

HCV RNA detection Quantitative detection of HCV RNA.. . 1002 Comparison of three PCR-based... 1003 Analytical evaluation of the Amplicor TM . . . 1004 Detection of cemplete genomie a n d . . . 1012 Frognostic value of hepatitis C . . . 1014 HCV-RNA detection in paraffin... 1156 Evaluation of Roche Amplicer HCV. . . 1235 Stability and detection ofHCV RNA.. . 1437 Conditions for quantitatien ofHCV.. . 1403 Detection of hepatitis C virus replication... 1426 HCV RNA quantitatien: is p lasma. . . 1436 Variability in HCV RNA quantitation... 1438 Comparison of two quantitative.. . 1500 Evaluation of the Amplicor HCV RNA.. . 1576 Interest of the in situ hybridization... 1600 Detection of hepatitis C virus us ing . . . 1622 Evaluation of the Amplicer TM HCV. . . 1625

Liver biopsy What serologic tests are necessary... 655 Histepathologic heterogeneity i n . . . 656

Methods comparisons Evaluation of two methods for . . . 1000 Comparison of two quantitative HCV. . . 1001 RIBA-3 or PCR as a complementary... 1005 Quantification of hepatitis C v i rus . . . 1007 Comparison of HCV RNA levels b y . . . 1453 Comparative evaluation of HCV viremia.. 1456

Pathology Liver histology and serum HCV-RNA... 1409 A comparative assessment of histological. 1609

Serotyping What serologic tests are necessary... 655 HCV serotype and pathogenesis o f . . . 666 Lack of association between type . . . 939 Clinical application of a fluorescence... 995 Simple fluorescent EIA for detection... 996 Evaluation of a novel serotyping... 1006 Serological assay to determine HCV... 1008 Hepatitis C virus genotype determination:... 1009 Prevalence of anti-HCV antibodies... 1142 Virus hepatitis C typinw, comparison... 1158 Third generation hepatitis C v i rus . . . 1277 Identification of an endemic a r e a . . . 1387 Significance of serum hepatit is. . . 1452 Hepatitis C virus anti-cere IgM. . . 1577

H e p a t i t i s C , d i s e a s e s e v e r i t y Alcohol drinking

Does excessive alcohol consumption... 1544 Anti-HCV core antibodies

Anti-HCV core antibody levels correspond... 1370 Autoimmunity

Association of anti-Fab auteantibodies... 263 Blood transfusion

Mode of transmission of hepatit is. . . 965 HCV genotypes

Co-infection with several HCV genotypes... 668 Hepatitis C virus genotypes a n d . . . 945 Quantitative HCV RNA levels by PCR. . . 1571

Hepatitis C serotypes HCV seretype and pathogenesis o f . . . 666

H e p a t i t i s C, d i s e a s e s e v e r i t y ( c o n t i n u e d )

HIV co-infection Chronic hepatitis C of drug users . . .

HLA antigens D-related human leukocyte antigens.. .

Immunology The peripheral blood eytotexic T . . . Patterns of immune responses t o . . . HCV viraemia and presence of anti-HCV : . . Enlargement of lymph nodes within. . .

Interferon response Decreased prevalence of hepatecellnlar...

Iron overload Iron overload in chronic hepatitis. . .

Pathology Increased intrahepatie Thl cytokine... Histological progression of chronic... Clinical and histological features... Hepatitis C virus genotypes, RNA... Relationship between the severity... Liver biopsy in patients with chronic... Histological consequences of chronic...

Prognosis Serum aspartate aminotransfarase...

Viral load Dynamic changes of floating density.. . Lack of association between type . . .

Viral replication The severity of liver disease influences...

Hepatitis C, h e a l t h y c a r r i e r s Disease transmission

Mother-to-child transmission of . . . HCV genotypes Virological characterization of... Genomic characterization of HCV...

Interferon therapy Randomized controlled trial of HCV.. . Hepatitis C virus carriers wi th . . .

Outcome Histological progression of chronic... Natural course of "healthy carriers"...

Pathology Liver biopsy discloses occult chronic... Liver biopsy in anti-HCV(+) blood... Virelogical and histological characteristics...

H e p a t i t i s C , o u t c o m e Alcohol abstinence

Amelioration of liver damage aRer . . . Cellular immunology

Accumulation of HCV-core specific... Viral clearance during acute hepatitis...

Dialysis Prospective virologic follow-up...

Genotypes Prognostic value of hepatitis C . . . Relations among HCV genotypo a n d . . . HCV genotypes: relevance in lent- term.. .

Hepatitis B co-infection Alpha interferon therapy in HBsAg.. .

HepatoceUular carcinoma Follow-up of French patients wi th . . .

HIV co-infection Hepatitis C and Hepatitis B in HIV. . .

Interferon therapy Lent-term treatment of cirrhosis... Changes of variabilities in the... Changes in evoked cerebral activity... Four years of follow-up of patients... Long-term biochemical, virological... Long-term follow-up of 364 patients... Analysis of prognosis in patients... Serum ferritin levels, HCV viremia... Interrelation between HBV, HDV and... Long-term follow-up of patients...

Leukemia Prevalence and natural history of . . .

Hepatitis C, p o s t - t r a n s p l a n t a t i o n Cryoglobulinemia Cryoglobulinemia in liver transplant...

Drug therapy Effect of interferon and ribavirin.. .

Epidemiology Hepatitis C virus infection is no t . . .

Genetics HCV-RNA titers in the early course.. . Early reinfection of and late HCV. . .

Heart transplantation Clinical experience with hepatitis.. . Outcomes of heart transplant recipients...

HCV+ donors Effect of donor hepatitis C seropositivity...

47 257 266 268 269 270 284 297

1386 1510

Hepatitis C, p o s t - t r a n s p l a n t a t i o n ( c o n t i n u e d )

HCV genotypes 933 HCV genotypes and quantitatlon o f . . . 109

Hepatitis C viral genotypes: association... 110 930 HCV genotypos and outcome in HCV. . . 177

Hepatitis G 907 Hepatitis G virus in hepatitis C . . . 178 921 Immunology

1141 Hepatitis C virus infection recurrence... 99 1232 Specific humeral immune response.. . 106

HCV reinfection in liver transplanted.. . 175 267 Immunotherapy

OKT3 use associated with d~m~n~abed... 104 675 Infection

Increased infections in liver transplant... 116 461 Interferon therapy 657 Treatment of HCV after solid organ. . . 102 661 Interferen-alpha therapy for hepatitis. . . 103 662 O u t c o m e 667 Recurrence and outcome of hepatitis. . . 98

1238 Long-term outcome of hepatitis C . . . 112 1314 Hepatitis C virus reinfection after... 115

Hepatitis C viral infection and... 1361 664 Pathology

Long-term histelogie foliow-up after... 100 935 Severe recurrent HCV ~ l iver . . . 101 939 Serum HCV RNA levels and histological... 669

Pathophysiology 944 Serum cytokine levels in patients... 107

Renal transplantation Chronic HCV infection in H D . . . 1175

967 In kidney graft recipients ribavirin e . . . 1187 Retransplantation

931 Poor prognosis of patients retransplantod... 113 947 Outcome of liver retransplantatien... 188

H e p a t i t i s C , r e c u r r e n t 734 Genetics 946 Long-term histelogic follow-up a f te r . . . 100

Interferon dosing 657 Retreatment followed by long-term... 42 969 Retreatment and intermittent. . . 1215

Interferon therapy 658 Interferon retreatment of relapsing.. . 40 659 Interferen-alpha therapy for hepatit is. . . 103 665 Features of relapse after alpha... 1149

Chronic hepatitis C and interferon... 1296 Risk factors

265 Recurrence and outcome of hepatit is. . . 98

H e p a t i t i s C , t h e r a p y 911 Antisense oligonucleotides 912 Specific inhibition of hepatitis. . . 893

Specific inhibition of hepatitis. . . 894 958 Targeted inhibition of HCV promoter. . . 895

Chinese herbal medicines 1014 Efficacy of Jigreen: an herbal d rug . . . 1270 1 5 0 3 Chronic active hepatitis 1 5 5 2 Randomized trial of effects of IFN-a . . . 43

Side effects of higli dose interferon... 45 38 Can prolonged alptm-IFN administration... 50

CAH HCV related: evaluation of f ive . . . 1150 353 Alpha-IFN treatment in HCV CAH. . . 1157

Lipid- and lipoptutein changes i n . . . 1522 1 4 4 3 Combination therapy

A randomized controlled trial o f . . . 52 Interferon-alpha and taurourcedeexycholic... 53 Combination treatment of alpha interferen.. . 182 Effect of interferon and ribavirin. . . 722 Combination therapy achieves.. . 1343 Combination therapy of interferon... 1419 Double-blind, randomized trial o f . . . 1578

Complications Auteimmunity and thyroid dysfunction .... 978

Cyclosporine Cyclosporine A in the t reatment . . . 1315

Dialysis 960 A double-blind controlled t r ia l . . . 37

The effect of ursodeoxycholic ac id . . . 1457 Fas antigen

Fas antigen expression in livers . . . . 1446 105 HCV genotypes 722 The effect of antiviral therapy. . . 254

Genotype-dependent response t o . . . 277 HCV RNA quantitation using RT-PCR... 287

117 Activation of interferon system.. . 464 Sustained response after alpha interferon... 739

111 Serial quantitative analysis o f . . . 1228 114 Response to interferon of anti-HCV... 1239

Quantitation of HCV RNA in p lasma. . . 1580 963 Healthy carriers 964 Randomized controlled trial of HCV. . . 734

Hepatitis C virus carriers w i th . . . 946 176 Genomic characterization of HCV. . . 947

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 5 5 3 A

H e p a t i t i s C, t h e r a p y ( c o n t i n u e d )

Hemophilia Chronic hepatitis C virus infection... 264 Quantitative detection of hepatitis.., 1202

H1V co-infection Interferon-a 2b t reatment . . . 36

Interferon dosing Breakthrough and interferon dose. . . 29 Comparative efficacy of high a n d . . . 32 Low dose of interferon can induce. . . 33 Three versus five million un i t s . . . 35 Natural alfa interferon (Alferon@... 41 Retreatment followed by long-term... 42 Tapering dose of interferon therapy. . . 44 Intensive 6 month course of interferon... 46 Long-term treatment with different.. . 55 Lymphoblastoid interferon improves.. . 181 Comparison between fixed and escalating... 183 Justification of single 6-month.. . 735 Retreatment and intermittent. . . 1215 A therapeutic trial of higher dosing.. . 1321 A randomized study comparing a fixed.. . 1621

Interferon response Breakthrough during therapy wi th . . . 30 Efficacy and safety of leukocyte-derived... 34 interferon therapy induces superoxide... 56 Long-term lymphoblastoid interferon... 179 Natural alfa interferon (Alferon®... 180 Treatment of chronic hepatitis C . . . 184 Interferon reduces tissuiar expression... 249 Effect ofintefferen alpha on TNF-a . . . 250 Changes in HCV anti-core and anti-E2.. . 258 Determination of serum anti-core... 259 Baseline level and kinetics ofHCV. . . 260 Dose-dependent acute reduction o f . . . 261 Does hepatitis C viral genotype... 278 Number of HCV-infectod hepatocytos... 280 Analysis of the early phase response.. . 281 Number of HCV-infected hepatocytes... 282 Prognostic value of immunologic... 291 Plasma cytokines in patients wi th . . . 292 IgM anti-HCV testing in chronic... 293 The role ofiren indices in predicting... 296 Hepatitis C virus replication i n . . . 926 Wide fluctuation of plasmatic HCV. . . 940 Prognostic markers for the response.. . 1154 Chronic HCV infection in H D . . . 1175 HCV genotypes: correlation wi th . . . 1213 HCV genotype in interferon... 1236 Comparison of biochemical and virological... 1254 Changes of liver function tes ts . . . 1303 Influence of serum zinc level t o . . . 1341 Influence of hepatitis C virus genotype... 1447 Significance of in vitro immunogiobuiin... 1505 Variations of hepatitis C v i rus . . . 1561 Quantitation of anti-core HCV antibodies... 1624

Interferon Recombinant interferon beta fo r . . . 49

Interferon, lymphoblastoid Long-term lymphoblastoid interferon... 179 Lymphoblastoid interferon improves.. . 181 Lymphoblastoid interferen-a.. . 879 Long-term treatment of chronic hepatitis. . . 1161

Iron reduction Phlebotomy followed by a-interferon... 51 Randomized controlled trial of t h e . . . 295 Phlebotomy reduces transaminase. . . 1207

Iron stores Iron stores and virus genstypes.. . 294 Intra-organ variability of hepatic. . . 677 Response to a-IFN therapy. . . 1172 Iron and response to interferemc~... 1234

Meta-analysis Mete-analysis of interferon randomized... 28 Treatment of chrenic NANB and C . . . 185

Outcome Long-term treatment of cirrhosis... 47 Can prolonged alplia-IFN administration... 50 Changes of variabilities in t h e . . . 257 The development of autoantibodies... 262 Changes in evoked cerebral activity.. . 266 Four years of fallow-up of patients. . . 268 Long-term biochemical, virological... 269 Lang-term follow-up of 364 patients. . . 270 Analysis of prognosis in pat ients . . . 284 Serum ferritin levels, HCV viremia. . . 297 Is interferon alpha atherogenie?... 1342 Interrelation between HBV, HDV a n d . . . 1386 Long-term follow-up of patients. . . 1510

Pediatric Intorferon-alfa therapy of chronic... 39

Post-transplantation Treatment of HCV after solid organ. . . 102 Interferon-alpha therapy for hepatitis. . . 103

H e p a t i t i s C, t h e r a p y ( c o n t i n u e d )

Predictors of response Serum levels of soluble vascular. . . Temporal changes in the distribution... The mutual effect of genetic heterogeneity.. The effect of antiviral therapy. . . Predictors of response to a lpha. . . Predictive factors of response t o . . . Identification of factors predicting... Predictors of sustained response... Predictors of sustained biochemical... HCV genotype and serum 90K levels. . . Does hepatitis C viral genotype... Correlation of hepatitis C v i rus . . . Loss ofHCV RNA at week 2 interferon... Early loss of minus HCV RNA strand. . . Comparison of branched DNA probe.. . Hepatic HCV-RNA does predict long-term... Pretreatment histology in 288 patients. . . Histology and hepatic iron content... Modulation of hepatitis C v i rus . . . Serum levels of IL-10 and s-ICAM-1... Resistance to interferon treatment. . . Changes in serum soluble interleukin-2... Wide fluctuation of plasmatic HCV.. . Clinical application of a fluorescence... Simple fluorescent EIA for detection... Disproportional secretion of IL- 1 . . . Prognostic markers for the response... Quantitative detection of hepatitis.. . HCV genotypes and viremia in predicting... HCV RNA levels measured with a n . . . Evaluation of hepatic fibrogenesis... Predictive value of the detection...

Recurrence Interferon retreatment of relapsing... Retreatment followed by long-term... Interferon-alpha therapy for hepatitis.. . Features of relapse after a lpha. . . Retreatment and intermittent,.. Chronic hepatitis C and interferon...

Ribavirin Two year course of ribavirin for... Hepatic iron deposition during ribavirin...

Tauroursodeoxycholate Tauroursodeoxycholic acid for t he . . .

Viral replication "Breakthrough ~ during interferon...

H e p a t i t i s , c h r o n i c a c t i v e Randomized trial of effects of IFN-a . . . Side effects of high dose interferon... Can prolonged alpha-IFN administration... Hepatic expression of a-smooth... al-antichymotrypsin deficiency... Tenascin is a serum marker oflobulsr. . . CAH HCV related', evaluation of f ive. . . Alpha-IFN treatment in HCV CAH.. . Genetic predispositions for immunologic.. Mild or aggressive chronic active. . . Assessment of liver function before... Expression of insulin llke growth. . . Elevated procollagan-III-peptide... Lipid- and lipopretoin changes i n . . . Lidocaine metabolite formation i n . . . Double-blind, randomized trial o f . . . Hepatic and portal vein phlebitis...

H e p a t i t i s D Interferon therapy

Nucleotide variability in the 5'noncoding... Long-term course ofIFN 2b treatment. . . Long-term treatment of chronic hepatitis.. . Interrelation between HBV, HDV and . . .

Liver transplantation Liver transplantation for patients... Strategies for prevention of death,..

Outcome Natural history of chronic hepatitis...

Virology Genotypic analysis and variability. Three-dimensional models reveal. . Hepatitis delta virus replication...

H e p a t i t i s E Diagnosis

Acute hepatitis E acquired in the . . Acute HEV infection in Egyptian..

Epidemiology Hepatitis A,B,C and E seroprevalance... Hepatitis E virus surveillance i n . . . Hepatitis E in dialysis: fact o r . . . Do sporadic and asymptomatic cases. . . Seroprevalance of hepatitis A i n . . . Etiology of acute sporadic v i ra l . . . Prevalence of anti-HEV IgG in Buenos...

251 252

• 253 254 271 272 273 274 275 276 278 279 283 285 286 288 674 737 738 741 742 919 940 995 996

1118 1154 1202 1288 1454 1497 1528

40 42

103 1149 1215 1296

48 736

54

31

43 45 50

686 979

1050 1150 1157 1198 1266 1367 1423 1433 1522 1568 1578 1605

256 306

1161 1386

94 877

307

308 309 310

304 305

1120 1123 1372 1390 1427 1460 1492

H e p a t i t i s , f a l m i n a n t Hepatitis B

HBV core promoter mutations cause. . . 614 Absence of unique HBV mutation i n . . . 615 Hyperimmune response in mice t o . . . 617 The complete nucleotide sequence... 618 Fulminant hepatitis associated wi th . . . 619 Mutagenesis and expression of HBsAg.. . 620 Hepatitis B virus pre-core mutation. . . 1413 Can hepatitis B virus precore mutan t . . . 1573

Liver transplantation Severe neurologice] sequelae a f a r . . . 383

Pathophysiology Fas and Fas ligand strongly expressed... 493 Upregulated expression of human . . . 683 Significance of autoantibodies i n . . . 1579

H e p a t i t i s G Epidemiology

Hepatitis G virus in hepatitis C . . . 178 Hepatitis G virus infection in patients. . . 302 Prevalence of hepatitis G v i rus . . . 303

Genetics Sequence analysis of a new RNA vi rus . . . 298 Genetic organization and sequence... 299 Model of translocation and cleavage.. . 301

Virology Pretealytic processing of the polyprotein... 300 Identification of a new hepatitis. . . 447

H e p a t i t i s , n e o n a t a l Neonatal hepatitis of non-familial... 1566

H e p a t i t i s , s a l m o n e l l a Salmonella hepatitis: analysis o f . . . 312

H e p a t i t i s , t o x i c Hepatic changes in workers f rom. . . 1196 Mechanisms of dideoxynucleoside... 1346 Minocycline-induced liver injury. . . 1383 Apoptosis in experimental hepatitis. . . 1415 Biliary excretion of leukotrienes... 1449

H e p a t i t i s , v i r a l ( u n s p e c i f i e d ) Prevalence and acquisition of v i ra l . . . 92 Treatment of chronic NANB and C . . . 185 Monoethylglycinexylidide and lidoeaine... 560 Clinical significance of elevated.. . 1111 Serum level of thrombomodulin a n d . . . 1246 Efficacy of Jigreen: an herbal d rug . . . 1270 Hepatitis-associated aplastic anemia . . . 1418 Etiology of acute sporadic v i ra l . . . 1460

H e p a t i t i s v i r u s , r o u t i n e Resistance to murine hepatitis v i rus . . . 1024 The role of THlfPH2 lymphocytes... 1025

H e p a t i t i s , w o o d c h u c k The effect of alcohol on v i ra l . . . 1464

H e p a t o b l a s t o m a Expression and regulation of p53 . . . 334 Altered hepatocellular Cu transport. . . 1518

H e p a t o c e l l u l a r c a r c i n o m a Angiogenesis

Perisinussidal cell activation... 315 Expression of vascular endothelial... 339

Cell physiology p53 and Fas/APO-1 induction in liepatoma... 200 Topoisomerase I inhihitors induce. . . 365 Regulation of Gia-protein... 368 c-myc induction of hepatoma cel l . . . 485 Nitric oxide and tumor necrosis... 486 Cellular transformation induced.. . 509 NF-r~B binding is elevated.. . 783 Bile acid-induced increase in cel l . . . 1233 Difference in activation of Raf/MEK.,, 1295 Activation of phosphatidylinositol... 1513 Tumor necrosis factor alpha increases... 1514 Soluble collagens modulate t h e . . . 1524 Lewis Y antigen expression i n . . . 1599

Cells, cultured A silencer element in the LAMC1... 782 Characterization of TGF-~I . . . 1245

Chemoembotization Prospective controlled trial o f . . . 357 Percataneous ethanol injection of . . . 1211

Diagnosis Staging laparescopy with laparescopic... 2 Use of color Doppler energy in t h e . . . 314 Can flow cytometric DNA analysis.. . 317 Albumin-mRNA positive circulating... 325 Comparison of giyceraldehyde-3-phosphato... 344 Serum y-glutamyl-transpoptidase... 1148 Correlation between serum alpha-1.. . 1185 Power Doppler examination for . . . 1302 Clinical implication of circulating... 1330 Are acute phase proteins a new biological... 1469 Clinical features suggesting development... 1527

5 5 4 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

H e p a t o c e l l u l a r c a r c i n o m a ( c o n t i n u e d )

Drug therapy Tolerance of the human liver to... Effect of antiandrogen t reatment . . . Treatment with tamoxifen in patients. . . Meta-analysis of medical treatments...

Experimental therapy Gone therapy of hepatocellular carcinoma... AdenoviraUy directed enzyme prodrug.. . Inhibiting Morris hepatema growth... The nucleoside analogues... Development of new therapy targeting...

Genetics ras-transduced diethylnitrosRmlne . . . A novel abl-like gene associated... Identification of proteins from... Rocenstitution of wild-type p53... p53 abnormalities in hepatecenular... Sequence-specific transcriptional... Expression and regulation of p53... Development of a novel retroviral... Inhibition of cell growth of human... Role of signal transduction pathways... Cyclin-dependent kinase 4 inhlbitere... The clinicepathological study~of... Antibodies to mutant p53 In cirrhotic...

Growth factors Prognostic significance of p lasma. . . Serum hepatecyte growth factor levels. . . Expression of HGF and c-MET protein. . . Differential gene expression o f , . . Inhibition of neoplastic development... Possible involvement of transforming...

HBV X protein p53 status, pX induced cell cycle.,. Genornic variations in the hepatitis... Mutations in the preccre/core and... Detection of hepatitis B virus X... Cancer formation in WAP-HBV-X...

Hepatitis C/D Long-term treatment of cirrhosis.., Hepatitis delta virus replication... Hepatitis C-related hepate-Ca (HCC).. Changing prevalence of hepatit is. . . Hepatitis C viral genotypes, modes. . . Follow-up of French patients w i th . . . HCV genotypes and hepatecellular... A retrospective study of hepatitis. . . Expression of Insulin like growth. . .

Laparoscopic cholecystectomy Prediction for occurrence of hepate . . .

Liver function tests Long-term study on the hepatic. . .

Liver transplantation Liver transplantation for smal l . , . Liver transplantation for hepatecellalar...

Magnetic resonance imaging MRI reliably detects macroregenerative..,

Multidrug resistance Immunohistechemical study o n . . . Mechanisms whereby a Synthetic...

Pathogenesis Cellular distribution of t issue. . , Polypeptide growth factors participate... Iron Induces both DNA synthesis.. , How are capsule and septum formed.. . Loss of the DNA mismatch repa i r , , . Which factors determine the development... Heterogeneity in the induction o f . . . Liver cell dysplasia of large cel l . . . The effect of alcohol on viral hepato... Abnormalities in tyrosine degradation.., Immunohlstechemical localization.,,

Pathology A novel three-step immunoscintigraphy... Expression of metallopanstimulin... Expression of the cell adhesion...

Pathophysiology Transforming property of an HBV-cyclin.., Alterations of blood supply to t h e . . . Cliulcepathological significance... Extracellular matrix proteins i n . . . Variant liver estrogen receptor.. . Possible mechanism of cyclin A . . . Localization of 92kD gelat£uase... Molecular characterization of S-adenosyl... Interferon regulatory factor-1 gene . . . Analysis of gene and protein expression... Overexpression of laminin and collagen... Serum level of thrombomodulin and . . . Changes in serum lipid peroxide... Characteristics of hepatecellular... Biological significance of P-glyroprotein... Novel ornithine decarboxylase protein. . .

H e p a t o c e l l u l a r c a r c i n o m a ( c o n t i n u e d )

Prevalence 358 Decreased prevalence of hepatecel]ular... 267 359 Prevention

1 1 9 1 Randomized trial of effects of IFN-a . . . 43 1394 Prognosis

Prognostic value of the lens calinaris-A... 320 206 Predictive value of liver iron for .... 1183 328 Radiotherapy 366 Percutaneous intratumoral injection... 356

1263 Recurrence 1301 Ki-67 and p53 immuncetaining methods,. . 323

203 Genotypes/amount of HCV, background... 355 329 Surgery 330 Surgical resection of hepatecellular... 1164 331 Survival 332 Treatment of hepatecellular carcinoma... 1237

333 H e p a t o c e l l u l a r i n j u r y 334 8EEALSO Hepatotoxicity 360 Cell physiology 364 Hepatoprotective effect of anti-APO-1/Fas... 492 371 Suppressor cytckine expression in . . ~ 1039

1205 Gens expression of the antioxidants... 1082 1 3 0 7 Activation of nuclear facter-xB... 1098 1545 Increases in intracellular calcium... 1105

Apoptesis of rat hepatecyte af ter , . . 1533 326 Drug effects 327 Fructose and other iron-chelating... 1081 338 Estrogen and antioxidants in hexachloro... 1086 340 Colchicine reverses a-naphthylisothio... 1089 451 Graft survival

1306 Increased liver engraftment o f , . . 418 Cold preservation sensitizes hepatecytes,.. 1598

202 lschemia-reperfusion injury 345 L-arginine minimizes reperfusion... 1099 346 Effect ofischemia/reperfusion o n . . . 1101 347 Lysosomal enzymes as early a n d . . . 1102 349 Liver regeneration

Role of liver stem cells in t h e . . . 500 47 Expression of heparin-bindlng EGF-like,.. 501

310 Mitochondria 321 Role of mitechondrial free calcium... 1083 351 Generation of hydrogen peroxide... 1084 352 353 Mechanisms of dideoxynucleoside... 1346 354 Pathology

1377 Recovery of rate with D-galactosamine... 502 1423 Serum isocitrate dehydregenase a s . . . 1107

Prevention 1 3 1 7 Polyenylphosphatidylcholine decreases.,. 475

Inhibition of iron toxicity in human . . . 1088 1378 Does ciprofloxacin alter survival. . . 1096

Effects of hepatocyte growth factor. . . 1103 S-adenssylmethlonine versus . . . 1153

374 Hypothyroidism inhibits experimentally... 1450 1414 Effects of vitamin E, ascerbic acid. . . 1617

313 H e p a t o c y t e g r o w t h f a c t o r Gone expression

1279 335 HGF transcription is under a cel l . . . 361 Hepatic expression of hepatecyte... 1404

Hepatocellular carcinoma 342 Serum hepatocyte growth factor levels. . . 327 367 A novel abl.like gone associated... 329 369 Expression of HGF and c-MET protein.. . 338 370 Polypeptide growth factere participate... 367 450 Inhibition of neoplastic development... 451

1 0 6 3 Hepatocellular injury 1410 Effects of hepatecyte growth factor. . . 1103 1424 Hepatocyte transplantation 1464 Increased liver engraftment o f . . . 418 1534 Inflammation 1553 Hepatecyte growth factors-scatter... 1027

Liver regeneration 318 Apoptosis in the liver after discontinuation ..... 490

1248 Are transforming growth factor a . . , 505 1606 Interaction of hepatecyte growth. . . 1348

Localization 204 Immunolocaiization of bcl-2 a n d . . . 122 316 Cellular localization of hepatocyte... 503 322 H e p a t o c y t e g r o w t h i n h i b i t o r y 324 336 f a c t o r 337 A new model for liver regeneration,.. 1610

341 H e p a t o c y t e t r a n s p l a n t a t i o n 343 Acute hepatic failure 363 Critical analysis of intra-spleulc... 387 372 Rapid integration and proliferation... 499

1048 Crigler-Najjar syndrome 1246 Amelioration ofbflirubin conjugation... 417 1304 Primary hepatecytes transplanted. 419 1431 " " 1563 Graft function 1565 Increased liver engrvftment o f . . . 418

H e p a t o c y t e t r a n s p l a n t a t i o n ( c o n t i n u e d )

Immunologic cytoxicity Hepatecyte transplant combined wi th . . . 424 The role of MHC antigens and adhesion... 1364

Methods Controlled rate freezing of hepatocytes... 420 Preliminary evaluation of a n e w . . . 423 Isolated fetal porcine hepatocytes... 425 Study of CD4 and CD8 level a n d . . . 1271

Radionuclide imaging Transplantation of hepatecytes marked . . . 1078

Rejection Allogeneic Kupffer cell is important. ~, 426

Safety 99m-Tc-labeled human serum albumin... 421

H e p a t o c y t e s Apoptosis/cell cycle

Knpffar cell induces hepatocyte... 484 Apoptesis induction in isolated.. . 489 Hepatoprotective effect of anti-APO-1/Fas... 492 Fas and Fas ligand strongly expressed... 493 DNA strand break and fragmentation... 495 Sodium butyrate reversibly blocks... 507 Regulation of the p21/WAF1/CtP1/SDI1... 519 Apoptesis of hepatecytes highly,... 644 Control of albumin gone expression... 784 TNFa-induced apoptesis of... 1093

Carcinogenesis p53 status, pXinduced cell cycle.. . 202 ras-transduced diethylnitrosamine. :. 203 Increased 8-hydroxy-2'-deoXyguanosine... 348 Cellular transformation induced.. . 509

Cell culture techniques Hepatecyte cell lines are derived.. . 201 Establishment of 3-dimensional primary.. 498 Conditionally immortalized hepatocytas... 1065 Long-term correction of bilirubin... 1071 Extended primary culture of h u m a n . , . 1332

Cell physiology Differential gene expression o f . . . 340 Structural and functional studies. . . 436 Alcohol-induced alterations in t h e . . . 478 Synthesis of insulin-like growth. . . 510 Role of apolipopr0tein E in intracenular. . . 529 The glycesyl-phcephatidylinositol-linked.,. 764 Twenty times less liver laminin. . , 767 Experimental colitis increases hepatecyte.,. 769 Methimazole slows hepatecyte streaming.. . 770 Molecular cloning, expression a n d . . . 789 Properties of hepatocellular cation. . . 799 Glycine blocks the increase in intracellular... 804 Hepatecyte differentiation en masse . , . 1125 Assessment of isolated rat hepatocyte... 1160 Heparitinase and heparinase induce. . . 1318 Expression of heparin-binding EGF-like... 1328

Cell proliferation Hepatitis delta virus replication... 310 Antibodies to tumor necrosis factor-a. . . 362 TGF-~I induction of apoptesis... 488 Apoptesis in the liver a f te r . . . 490 Rapid integration and proliferation... 499 Are transforming growth factor a . . . 505 Impaired liver regeneration in transgeulc.. , 506 Kupffer cell depletion shifts t h e . . . 508 [Ca2+]i oscillations involve.. . 514 Gene expression of matr ix . . . 517 Co-mitogenic effect of vasoacfive.. 518 Activation of cultured hepatic steUate.. . 692 Induction of retinoic acid receptor.. . 792 Relationship between hepatecyte.. . 1204 Granulocyte colony stimulating factor. . . 1569

Cytohine effects Bifunctional effect of tumor necrosis... 523 Kupffcr cell derived IL-6 increases.. . 1031 A new hepatocyta stimulating factor. . . 1043

Cytology Cell ploldy-based fractionation... 452

Cytomegalovirus CMV infection of hepatecytes a n d . . . 434

DNA synthesis Iron induces both DNA synthesis.. . 369 Middle-molecalar-weight ~nhibiter... 494

Drug effects Intracellular cascade controlling... 779 2',3'-dideoxy-[3-L-5':fluorecytidine... 888 Selective delivery of primaqnine.. . 1079 Interactions of cyclosporine A a n d . . . 1104

Ethanol Human antibodies versus hydroxyethyl... 481 The effect of chronic ethanol. . . 541 The effect of acute ethanol exposure... 542 Increased expression ofg~mm, glutamyl. . , 547 Glutathione as an important antioxidant... 564

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 555A

H e p a t o c y t e s ( c o n t i n u e d ) Genetics

Protein klnase C activation/cellular... 531 Induction of metallothionein mRNA.. . 780 Recombinant adenovirus-mediated... 785 Bile acids suppress the rat l iver . . . 847 Induction of hems oxygenase-1 mRNA.. . 1350 Apolipoprotein A-I gene expression... 1434

Growth and development Age-dependent repression of a lpha . . . 422 0V-6 positive, HepParl negative. . . 496 In vitro culture and differentiation... 497 Role of fver stem cells in t h e . . . 500 Regulation of human hems oxygenase-1... 776 The Darwinian basis of cellular.. . 1399

Hepatitis C Number of HCV-infected hepatocytes... 280 Number of HCV-infected hepatocytes... 282 Different quasi-species of hepatitis. . . 463 HCV core protein subcellular localization.,. 901 Relevance of ultraetructural lymphocyte... 924

Membrane potentials Changes in liver membrane potentials... 1165 Membrane potential of hepatocytes... 1166

Pathology Liver cell dysplasia eflarge cel l . . . 1424

Pathophysiology ' Human hepatecytes produce a form. . . 83 Identification of human l iver . . . 733 The acid-labile subunit in acute . . . 1219 Gene expression of the antioxidants... 1082 Apoptesis of rat hepatecyte af ter . . . 1533 Cold preservation sensitizes hepatocytes... 1598

Signal transduction ErbB3, the major hepatic heregulin.. . 794 Coordinated calcium signals in rat .... 798 Calcium and IP s regulate the calcium... 800 Effect of bile acids on hepatocefular. . . 862 Difference in activation ofRaf. . 1295 Activation of phosphatidylinositel... 1513

Transfection Prolonged expression of bilirubin-U-DP... 453 Adenovirus-associated, receptor-mediated... 628 High efficiency transfection o f . . . 787

Transforming growth factor [~ Transgenic mice expressing a Z n . . . 205

Transport Hepatocellular thyroid hormone efflux... 728 Chronic ethanol administration increases.. . 797 cAMP and volume activated chloride . . . . 805 Protein phosphatase 2A-mediated... 806 Carrler-mediated uptake of lucifer. . . 810 Effects of protein binding and hematecrit . . . 813 Hepatecytes express an array o f . . . 821 Metabolism and enterohepatic circulation... 655 Tauroursodeoxychofe acid activates.. . 861 Altered hepatecyte transport i n . . . 1159 Microtubule-dependent bile acid . . . 1620 Desmin expressing cells during embryonic... 1323 Multiple pathways for estrone sulfate. . . 1347

H e p a t o m e g a l y Hepatic involvement in Brucellosis... 1320

H e p a t o p u l m o n a r y s y n d r o m e Hepatepulmonary syndrome: open label . . . 241 Altered pulmonary expression o f . . . 457 Response to 100% inspired oxygen... 1339

H e p a t o r e n a l s y n d r o m e Terlipressin in the treatment o f . . . 236

H e p a t o t o x i c i t y SEE ALSO Hepatoceilular injury

Acetaminophen Incidence of acetaminophen overdose... 1091

Alcohol liver disease S=adenosyImethionine deficiency... 1092

Apoptosis Apoptosis in experimental hepatitis. . . 1415

Calcium Calcium.induced mitechondrial... 1087

Clavulanic a c i d Augmentin-induced hepato-renal failure.. : 1173

Cocaine Cocalne-induced hepatic injury i n . . . 1085

Copper Altered hepatocellular Cu transport . . . 1513

Coumarin Phenproceumon-induced cirrhosis... 1549

Cyclosporine Interactions of cyclosporlne A a n d . . . 1104

Drug interactions Evaluation of hepatocellular defense.. . 1432

Fibrogenesis Distribution of insulinolike growth. . . 712

H e p a t o t o x i c i t y ( c o n t i n u e d ) Hepatic blood flow

Hepatic haemodynamic changes induced... 566 Methotrexate

Medium term treatment of PBC wi th . . . 71 Minocycline

Minocycline-induced liver injury. . . 1383 Outcome

Improved outcome from severe.. . 1110 Pathology

OV-6 positive, HepParl negative.. . 496 Hepatic changes in workers from.. . 1196

Prevention Late protection against chemical.,. 1090 The effect of augmenter of l iver . . . 1094 Bile salt toxicity is reduced b y . . . 1174

Pyrethrins Cypermethrin induces subacute l iver . . . 1124

Reye's syndrome Induction of the permeability transition.,. 1106

H e p G 2 ( h e p a t o m a ) c e l l s Cell physiology

p53 and Fas/APO. 1induction in hepatoma.. . 200 Regulation of cholesterol and bi le . . . 533 High TIMP-I expression results in... 1055

Cytokine effects Bifunctional effect of tmnor necrosis... 523 Tumor necrosis factor alpha increases... 1514

Drug effects The nucieoside analogues... 1263 Mechanisms of dideoxynucleoside... 1346 Acetaldehyde increases transforming... 1461

Genetics Inhibition of cell growth of human. . . 364 Induction of human hepatic bi le . . . 777

Hepatocellular injury Effects of vitamln E, ascorbic acid. . . 1617

Hepatotoxicity Bile salt toxicity is reduced b y . . . 1174

Physiology Molecular characterization of S-adenosyl... 343 Effects of ETOH on mitochondrial... 540 Activation of cultured hepatic s te fa te . . . 692 The mechanism of serum amyloid A . . . 1042

Transport Bile acid uptake in human hepatoblast... 750 Localization of the multidrug resistance... 822

H e r e g u l i n ErbB3, the major hepatic heregulin... 794

H I V i n f e c t i o n Hepatitis B and C

Immune complexes in AIDS with chronic... 1356 Hepatitis C and Hepatitis B in HIV. . . 1443

Hepatitis C Interferon-a 2b treatment. . . 36 Increased variability in the HCV.. . 904 Chronic hepatitis C virus infection... 932 Chronic hepatitis C of drug users... 933 Chronic cholestatic hepatitis C . . . 980 Enhancement of HCV replication i n . . . 1251 Human immunodeficiency v i rus . . . 1353

H L A a n t i g e n s Class I

Number of HCV-infected hepatecytes... 282 Analysis of gene and protein expression... 372 The role of MHC antigens and adhesion... 1364

Class H Hmnan intrabepatic blliary epithelial... 435

Hepatitis C D-related human leukocyte antigens.. . 930 Liver in0ammatory activity in chronic... 1206

HLA-A Physical mappIng in the hemochromatesis... 1058

HLA-A2 Viral escape from the HLA-A2 restricted... 908

HLA-B8 HLA-B8 confers susceptibility t o . . . 985

HLA.DQBI Differential prevalence of HLA class. . . 971

HLA-DR3 Genetic predispositions for immunologic... 1198

HLA-DRB4 Genetic susceptibility to auteimmune... 88

Liver transplantation Favourable clinical and HLA. . . 145 Precipitation of fatal rejection... 190 Association of HLA antigens wi th . . . 1311

H M G C o A r e d u c t a s e Coordinate regulation of sterol.. . 858 HMG-CoA reductase inhibitor... 1623

H T L V - I v i r u s Level of HCV RNAis related to genotype... 1188

H y a l u r o n i c a c i d Hyaluronic acid in clinical l iver . . . 124 Hyaluronic acid: a useful marker . . . 998 Histological evaluation of f v e r . . . 1476 Association between hyaluronic acid . . . 1483 Hyaluronic acid binding ability.. . 1564 Clinical significance of se rum. . . 1589 Expression of the cell adhesion... 1606

H y d r o x y a p a t i t e s Development of new therapy targeting. , . 1301

8 - h y d r o x y - 2 ' - d e o x y g u a n o s i n e Increased 8-hydroxy-2'-deoxyguanosine... 348

H y d r o x y n o n e n a l 4-hydroxynonenal (HNE) levels a r e . . . 544 4-hydroxy-2,3-nonenal production... 1463

H y d r o x y p y r i d o n e s Biliary excretion of p lasma. , . 811

H y p e r b i l i r u b i n e m i a SEEALSO Crigler-Najjar syndrome,

Gilbert syndrome, Jaundice Persistent tmcenjugated... 397

H y p e r g a m m a g l o b u l i n e m i a Immunoglobulin A antibody to a 140kDa... 82

H y p e r i n s u l i n i s m Insulin resistance in cirrhosis... 527

H y p e r l i p i d e m i a Hyperfpidemia following l iver . . . 392 Serum lipid levels in pediatric.. . 393 Increasing hepatic cholesterol 7 u . . . 532 Viscosity but not colloidosmotic... 1435

H y p e r o s m o t i c s t r e s s In vitro performance of l ivers . . . 1481

H y p o t h a l a m i c - p i t u i t a r y - a d r e n a l a x i s

Impaired IL-l~-induced hypothalamic... 1028 Increased IL-l~:IL-lra mRNA.. . 1562

H y p o t h y r o i d i s m Methimazole slows hepatocyte streaming.. . 770 Hypothyroidism inhibits experimentally... 1450 Improved liver function in cirrhotic,.. 1451

I

I C A M - 1 Pathogenetic origin of soluble ICAM-1... 60 Soluble intercellular adhesion molecule.., 72 Can soluble adhesion molecules b e . . . 126 Effects of in vivo monodonal,. . 429 ICAM-1 is elevated dramatically.., 438 Serum levels of IL-10 and s-ICAM-1... 741 Release of soluble intercellular... 1021 Mechanism of the adhesion and migration... 1023 Intercellular adhesion moleoale-1... 1045 Activation of nuclear factor-xB... 1098 Serum intercellular adhesion molecule-1,.. 1119

IgA, IgE SEE Immunoglobulin A, E

I G F . I Differential gene expression o f . . . 340 Synthesis of insulin-like growth. . . 510 Activation of cultured hepatic stellate.. . 692 Insulin is a key regulater of cholangiocyte... 968 The acid-labile subunit in acute . . . 1219

I G F - I I Differential gone expression of . . . 340 Polypeptide growth factors participate... 367 Activation of cultured hepatic stellate.. . 692 Distribution of insulin-fke growth. . . 712 Insulin is a key regulator of cholangiocyte... 863 The acid-labile subunit in acute . . . 1219 Expression of insulin like growth. . . 1423

I G F b i n d i n g p r o t e i n s Differential gene expression of . . . 340 Synthesis of insulin-fke growth. . . 510 Novel expression of a unique I t s . . . 711 The acid-labile subunit in acute . . . 1219

I g G , I g M SEE Immunoglobulin G, M

I l e u m Identification of a dysfunctional... 727 Correct targeting of rat liver a n d . . . 846 Characterization of the human i leal . . . 848

H e n s , g a l l s t o n e One stage operative management o f . . . 1588

5 5 6 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

I m m u n e c o m p l e x e s Low expression of erythrocyte complement.., 929 Quasispocies of hepatitis C virus . . . . 942 Immune complexes in AIDS with chronic... 1356

I m m u n e t o l e r a n c e Precipitation of fatal rejection... 190 Predominance of IL-4 mRNA expression... 440 Rapid formation of donor cell,.. 1136

Immunization Hepatitis A and B

Immunogenicity and reactogenicity... 871 Hepatitis B

Effect of a nationwide hepatitis. . . 468 Vaccine therapy for hepatitis B . . . 469 Polynucleotide-based immunization... 869 Safety and CTL determinations f rom. . . 870 Long-term immunity to hepatitis. . . 873 Efficacy of vaccination against . . . 875 Immunogenicity of alternative hepatitis. . . 1177 Analysis of the anti-HBs response.. . 1208

I m m u n o g l o b u l i n A Immunoglobulin A antibody to a 140kDa... 82

I m m u n o g i o b u l i n E Effects of in vivo monoclonal... 429

I m m u n o g i o b u l i n G Declining prevalence of immunity... 311 Do sporadic and asymptematie cases. . . 1390 Prevalence of anti-HEV IgG in Buenos.. . 1492

I m m u n o g l o b u l i n M Evidence that cholesterol antibodies.., 19 Promotion of cholesterol crystal . . . 20 Bfliary atresia - an autoimmune.. . 87 IgM anti-HeY testing in chronic,.. 293 The significance of IgM antibody... 991 Poor correlation of hepatitis activity.. . 993 HCV viraemia and presence o f . . . 1141 Significance of anti-HCV-core IgM. . . 1498 Hepatitis C virus anti-core IgM. . . 1577

I m m u n o l o g i c c y t o x i c i t y SEEALSO CD8+ T cells; Lymphocytes, NKC;

Lymphocytes, LAK cells Hepatecyte transplant combined wi th . . . 424 The cytotexic T lymphocyte response.. . 466 Role of CD8 + lymphocytes and natura l . . . 491 Defining the role of intrahepatic.. . 724 Viral escape from the HLA-A2 restricted... 908 Comparative analysis of the cytotoxie... 909 Expression ofCD80 (B7/BB-1) i n . . . 922

I m m u n o s c i n t i g r a p h y A novel three-step immunoscintigraphy.,. 318

I m m u n o s u p p r e s s i o n Tacrelimus (FKSO6) versus eyclosporine... 149 First year of tarrolimus: have w e , . . 150 Is Neoral® a viable a l ternat ive , . . 151 Primary liver transplantation i n . . . 1253 Precise calculation of cyclosperine... 1319

I n d o c y a n i n e g r e e n Effects of protein binding and bematecrit . . . 813 Long-term study on the hepatic . . . . 1378 Sex differences in membrane binding.. . 1455

I n d o m e t h a c i n Role of interferon alpha on arachidonic... 248

I n f l a m m a t i o n Alcohol liver disease

Liver endothelial cell dysfunction... 1022 Increased expression of [~ chemokines... 1030 Intrahepatic lymphocyte production... 1033 Effects of long-term alcohol... 1412

Anemia al-antitrypsin reduces transferrin... 1044

Bile duct obstruction Hepatic interleukln-10 levels following... 1170

Cell physiology NF-xB binding is elevated.., 783 Release of soluble intercellular... 1021 Mechanism of the adhesion and migration... 1023 Kupffer cell derived IL-6 increases... 1031 LPS-mediated NF-xB activation... 1036

Cytokine effects The soluble IL-6 receptor amplifies... 1032 Suppressor cytokine expression i n . . . 1039 A new hepatecyte stimulating factor. . . 1043

Drug effects Antioxidante suppress endotexin-induced... 1034 Gadolinium prevents hepatic granulomas.. . 1366

Hepatic encephalopathy Correlation of serial cytokine levels . . . 1038

Hepatocyte transplantation Hepatecyte transplant combined wi th . . . 424

Hyperbaric oxygen Activation of Kupffer cells by a. ,. 1631

I n f l a m m a t i o n ( c o n t i n u e d ) Kupffer cells

Kupffer cell pro-inflammatory alterations... 1040 Endocytesis is an essential s tep. . . 1365

Liver regeneration Hepatecyte growth factors-scatter... 1027

Metabolism Altered hepatocyte transport i n . . . 1159

Nitric oxide Differential effects of nitric oxide... 1015 Role of nitric oxide in the hepatic. . . 1016 Metabolic effect of nitric oxide... 1017

Prevention Glydne prevents elevation in intracellular... 803 In vivo IL-10 treatment suppresses... 1029

Selectins Expression of E-selectin and E-selectln... 59

Signal transduction The mechanism of serum amyloid A . . . 1042

Thl cells Requirement of Thl-like liver... 1026

Transplant rejection Distribution of inducible nitr ic. , . 1019

Ursodeoxycholate Ursodeoxycholic acid inhibits induction... 1020

I n f l a m m a t o r y b o w e l d i s e a s e Prevalence of primary sclerosing... 1480

I n o s i t o l t r i p h o s p h a t e Calcium and 1P s regulate the calcium... 800

I n s u l i n Effects of insulin on renal hemodynamies... 227 Changes in insulin secretory capacity... 526 Insulin resistance in cirrhosis... 527 Insulin is a key regulater of cholangiocyte... 868 Study of '~epatetcephic" substances... 1363

I n s u l i n - l i k e g r o w t h f a c t o r - I Differential gene expression of . . . 340 Synthesis of insulin-like growth. . . 510

I n s u l i n - l i k e g r o w t h f a c t o r - I I Differential gene expression of , . . 340 Palypeptide growth factors participate.., 367 Distribution of insulin-like growth. . . 712 Expression of insulin like growth. . . 1423

I n s u l i n - l i k e g r o w t h f a c t o r s SEEALSO IGF binding proteins Activation of cultured hepatic stellate.. . 692 Insulin is a key regulator of cholangiocyte... 868 The acid-labile subunit in acute . . . 1219

I n s u l i n r e c e p t o r s u b s t r a t e - 1 Role of signal transduction pathways.. ~ 371 Cellular transformation induced.. . 509

I n s u r a n c e Carbehydrate-deficient transferrin... 1147

I n t e g r i n s Contraction of collagenous bands . . . 1046 Expression and function ofintegrin.. . 1047

I n t e r f e r o n a l p h a SEEALSO Interferon dosing;

Interferon response; other related entries Apolipoproteins

Is interferon alpha atherogenic?... 1342 Cell physiology

Role of interferon alpha on arachidonic... 248 Interferon reduces tissular expression... 249 Correlation of hepatitis C v i rus . . . 279 Expression of the interferon-induced... 883 Apoptosis and clonal growth inhibition... 1425

Drug metabolism Assessment of liver function before.. . 1367

Hepatocellular carcinoma Randomized trial of effects of IFN-a , , . 43 Interferon regulatory factor-1 gene... 363

Therapeutic use Intensive 6 month course of interferon... 46 Treatment of HCV after solid organ. . . 102 Interferon-alpha therapy for hepatitis.. . 103 Reversion by interferon of l iver . . . 684 Interferon increases extracellular... 685 Effect of in~rferon and ribavirin.. . 722 Long-term treatment with recombinant... 874 Long-term follow-up of patients. . . 876 Lymphoblastoid interferon-u... 879 Long-term follow-up of HBe-Ag positive... 880 Retreatment of chronic hepatitis. . . 881 HBV marker kinetics during therapy... 884 Combination therapy for hepatitis.,. 1144 Effects of recombinant interferon.,. 1189 Cirrhosis doesn't influence response... 1466

Viral replication In vitro effects of interferon... 905

I n t e r f e r o n b e t a Recombinant interferon beta fo r . . . 49 Targeted treatinent of hepatitis. . . 882

I n t e r f e r o n d o s i n g Dose reduction

A randomized study comparing a fixed.. . 1621 Economics

Justification of single 6-month.. . 735 Hepatitis C, recurrent

Retreatment and intermittent. . . 1215 Hepatitis D

Long-term treatment of chrenlc hepatitis. . . 1161 Interferon response

Breakthrough and interferon dose. . . 29 Comparative efficacy of high a n d . . . 32 Low dose of interferon can induce. . . 33 Long-term treatment with different... 55 Comparison between fixed and escalating... 183 Treatment of chronic hepatitis C . . , 184 A therapeutic trial of higher dosing.. . 1321

Outcome Three versus five million uni te . . . 35 Randomized study comparing a fixed.. . 878 Long-term monthly follow-up of patients. . . 1448

Tapering Tapering dose of interferon therapy. . . 44

I n t e r f e r o n g a m m a Cell physiology

Interferon-~-mediated activation... 681 Hepatic fibrosis

Liver injury and fibrosis in interferon... 680 Antipreliferative effects ofy-in~rferon... 682 Interferon g~mma treatment iuldbits. . . 1506

Secretion Resistance to murine hepatitis v i rus . . . 1024 Interferon-gamma production in pr lmary . . . 1391

I n t e r f e r o n r e g u l a t o r y factor-1 Interferon regulatory facter-1 gene. •. 363

I n t e r f e r o n r e s p o n s e Analysis

Predictors of response to a lpha . . . 271 Predictive factors of response t o . . . 272 Does hepatitis C viral genotype... 278

Anti-HCV antibodies IgM anti-HCV testing in chronic... 293 Chau~es in HCV anti-care and anti-E2.. . 258 Determination of serum anti-cere... 259 Anti-HCV core antibody levels correspond... 1370 Significance of anti-HCV-cere IgM. . . 1498 Significance of in vitro immunoglobulin... 1505

Autoantibodies The development of auteantibedies... 262 Alpha-IFN treatment in HCV CAH. . . 1157

Cytokine profiles Plasma cytokines in patients wi th . . . 292

Differential flotation centrifugation Differential flotation contrifugation... 289 Differential flotation centrifugation... 290

Drug abuse Interrelation between I-IBV, HDV a n d . . . 1386

Ferritin Serum fercitin levels, HCV viremia. . . 297

HBV-HCV co-infection Alpha interferon therapy in HBsAg.. . 38

HCV genotypes The mutual effect af genetic heterogeneity... 253 Nudeotide variability in the 5'noncoding.., 256 Dose-dependent acute reduction o f . . . 261 Predictors of sustained response.. . 274 Predictors of sustained biochemical... 275 HCV genotype and serum 90K levels. . . 276 Genotype-dependent response t o . . . 277 Analysis of the early phase response.. . 281 Activation of interferon system.. . 464 Modulation of hepatitis C v i rus . . . 738 Sustained response after alpha interferon... 739 Antibody response to hypervariable... 898 Genomic characterization of HCV. . . 947 Chronic HCV infection in H D . . . 1175 HCV genotypes: correlation wi th . . . 1213 Variations of hepatitis C v i rus . . . 1561

HCV RNA Temporal changes in the distribution... 252 Number of HCV-infected hepatecytes... 280 Loss of HCV RNA at week 2 interferon... 283 Early loss of minus HCV RNA s t rand. . . 285 HCV RNA quantitation using RT-PCR... 287 Hepatic HCV-RNA does predict long-term... 288 Serial quantitative analysis o f . . . 1228 HCV genotypos and viremin in predicting... 1288 Influence of hepatitis C virus genotype... 1447 HCV RNA levels measured with a n . . . 1454 Predictive value of the detection... 1528

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 5 5 7 A

I n t e r f e r o n r e s p o n s e ( c o n t i n u e d ) Hepatocellular carcinoma

Decreased prevalence of hepatecelinlar . . . . 267 HLA typing

Number of HCV-infected hepatocytes. 282 Immunology Pregnostic value of immunologic... 291 Hepatitis C virus-specific cytotexic... 910

Interferon dosing Breakthrough during therapy wi th . . . 30 LOw dose of interferon can induce. . . 33 Long-term lymphoblasteid interferon... 179 Lymphoblasteid in~rferon improves.. . 181 Treatment of chronic hepatitis C . . . 184

Iron reduction Phlebotomy followed by a-interferon.. 51 Iron stores and virus genotypes... 294 Randomized controlled trial of t h e . . . 295 The role ofiren indices in predicting.. 296 Histology end hepatic iron content. . . 737 Response to a-IFN therapy. . . 1172 Phlebotomy reduces transaminase. . . 1207 Iron and response to interferon-a... 1234

Liver function tests Changes of liver function tes ts . . . 1303

Meta-analysis Comparison of biochemical and virological.,. 1254

Outcome Prognostic markers for the response... 1154

Pathology Pretreatment histology in 288 patients... 674

Relapse Features of relapse after a lpha . . . 1149

V CAM-1 Serum levels of soluble vascular . . . 251

Viral replication Dynamics of hepatitis C virus turnover. . . 723 Hepatitis C virus replication i n . . . 926

Zinc Influence of serum zinc level t o . . . 1341

I n t e r f e r o n t h e r a p y Adhesion molecules

Interferon reduces tissular expression... 249 Adverse effects

Side effects of high dose Interferon... 45 Colchicine

Double-blind, randomized trial o f . . . 1578 Combination therapy

A randomized controlled trial o f . . . 52 Interferon-alpha and taureursodeoxycholic... 53 Combination treatment of alpha interferon... 182

Complications Can prolonged alpha-IFN administration. 50 Autoimmunity and thyroid dysfunction.. 978

Cytokine profile s Effect of interferon alpha on TNF-a . . . 250

Dialysis A double-blind controlled t r ia l . . . 37

Drug metabolism Assessment of liver function before... 1367

Economics Efficacy and safety of leukocyte-derived... 34 Strategies for prevention of dea th . . . 877

Fas antigen Fas antigen expression in l ivers . . . 1446

Fibrosis Hepatic expression of a-smooth.. . 686 Tenascin is a serum marker of lobular. . . 1050 Correlation between hepatic stellate.. . 1488

Healthy carriers Randomized controlled trial of I ICV. . . 734 Hepatitis C virus carriers w i th . . . 946

Hepatic iron Intra-organ variability of hepatic. . . 677 Reduction of liver iron content... 1162

Hepatitis B Targeted treatment of hepatitis... 882 Effects of recombinant interferon... 1189

Hepatitis B, chronic Long-term treatment with recombinant.. 874 Long.term follow-up of patients. . . 876 Randomized study comparing a f x e d . . . 878 Lymphoblasteid interferon-a... 879 Long-term follow-up of HBe-Ag positive... 880 Retreatment of chronic hepatitis. . . 881 HBV marker kinetics during therapy. . . 884 Combination therapy for hepatitis. . . 1144 Long-term monthly follow-up of patients. . . 1448 Quantitative analysis of wild-type... 1583

HCV genotypes The effect of antiviral therapy. . . 254 Changes in genetic variability o f . . . 255 Quantitative detection of hepatitis. . . 1202

I n t e r f e r o n t h e r a p y ( c o n t i n u e d ) HCV RNA

Baseline level end kinetics of HCV.. . 260 Comparison of HCV RNA levels b y . . . 1453 Evaluation of the Amplicor HCV RNA.. . 1576 Quantitatien of HCV RNA in plasma. . . 1580 Interest of the in situ hybridization... 1600

Hepatitis C, post-transplantation Treatment of HCV after solid organ. . . 102 Interferon-alpha therapy for hepatitis.. . 103 Effect of interferon end ribavirin.. . 722

HIP" co-infection Interferen-<z 2b treatment. . . 36

Maintenance therapy Retreatment followed by leng-term... 42 Retreatment end intermittent... 1215

Meta-analysis Meta-analysis of interferon randomized... 28 Treatment of chronic NANB end C . . . 185

Monitoring Determination of serum anti-core... 259 E1 antibody level monitoring predicts... 740 Poor correlation of hepatitis activity... 993 Prognosis of long-term resolvement... 994 Response to interferon of anti-HCV... 1239 Quantitatien of anti-core HCV antibodies... 1624

Outcome Long-term treatment of cirrhosis... 47 Natural alfa interferon (Alferen®... 180 Changes of variabilities In t h e . . . 257 Changes in evoked cerebral activity... 266 Four years of follow-up of patients.. . 268 Long-term biochemical, virological... 269 Long-term follow-up of 364 patients. . . 270 Identification of factors predicting... 273 Analysis of prognosis in patients. . . 284 Long-term course of IFN 2b treatment. . , 306 Disproportional secretion of IL-1. . . 1118 CAH HCV related: evaluation of f ive . . . 1150 Long-term fellow-up of patients. . . 1510 HCV genotypes: relevance in long-term... 1552

Pediatric Interferen-alfa therapy of chronic... 39

Physiology Interferon therapy Induces superoxide... 56 Changes in serum soluble interleukin-2... 919

Relapse Interferon retreatment of relapsing... 40 Chronic hepatitis C and interferon... 1296

Resistance "Breakthreugh ~ during interferon... 31 Natural alfa interferon (Alferen®... 41 Serumlevels of IL-10 and s-ICAM-1... 741 Resistance to interferon treatment. . . 742 HCV genotype in Interferon... 1236 Cyclosporlne A in the treatment. . . 1315 CombInation therapy achieves... 1343

Transplantation for hepatitis C Hepatitis C virus diversity end . . . 108

I n t e r f e r o n , l y m p h o b l a s t o i d Long-term lymphoblastoid interferon... 179 Lymphoblastoid interferen improves... 181 Lymphoblastoid interferon-a... 879 Long-term treatment of chronic hepatitis.. . 1161

I n t e r l e u k i n - 1 Effective antigen presentation and . . . 81 Stimulation of c-jun kinase by fibronectln... 746 Inflammatory cytokine regulation... 854 Impaired IL-l~-induced hypothalamic... 1028 Intrahepatic lymphocyte production... 1033 The mechanism of serum amylsid A... 1042 Disproportional secretion of IL-1,.. 1118 Increased IL-l~:IL-lra mRNA.. . 1562

I n t e r l e u k i n - 1 c o n v e r t i n g p r o t e a s e Apoptesis, electrolyte transport. . . 482

I n t e r l e u k l n - 1 r e c e p t o r a n t a g o n i s t Disproportional secretion of IL-I... 1118 Increased IL-l~:IL-lra mRNA.. . 1562

I n t e r l e u k i n - 2 Precipitation of fatal rejection... 190 Changes in serum soluble interleukin-2... 919

I n t e r l e u k i n - 4 Predominance of IL-4 mRNA expression... 440

I n t e r l e u k i n - 6 APRF, Increased nuclear binding.. . 515 Circulating tumor necrosis factor-u... 599 Int],mm~tery cytokine regulation... 854 Kupffer cell derived IL-6 increases... 1031 The soinble IL-6 receptor amplifies... 1032 Intrahepatic lymphocyte production... 1033 In vivo suppression of Kupffer. . . 1035 Mediator production and phagocy~c... 1199 Interleukin 6 end chronic hepatitis.. . 1382

I n t e r l e u k i n - 8 Adenovirus-mediated expression of . . . 725

I n t e r l e u l d n - 1 0 Serum levels of IL-10 and s-ICAM-1... 741 Thl cytokine pattern and defective.,. 915 Elevated serum levels of IL-1O i n . . . 997 In vivo IL-10 treatment suppresses... 1029 Suppressor cytokine expression i n . . . 1039 Hepatic interleukin-10 levels following.. 1170 Circulating interleukin-10 levels. . . 1572

I n t e r l e u k i n - 1 3 Suppressor cytokine expression i n . . . 1039

I n t e s t i n a l a b s o r p t i o n The isofiavone genistein undergoes.., 563

I n t e s t i n a l e p i t h e l i a l c e l l s Ureedeoxycholic acid inhibits induction. 1020

I n t e s t i n a l f l o r a Antibiotic therapy for bacterial. . . 1130

I n t e s t i n e s The Darwinian basis of cellular.. . 1399

I n t r a c e l l n i a r p H Activation of fat-storing cells. . . 829 Effects ofintracsllular pH a n d . . . 1428

I n t r a c r a n i a l p r e s s u r e Inability efintracranial pressure. . . 408 Stability of cerebral perfusion.,, 1560

I r o n Antagonists and inhibitors

Phlebotomy followed by a-interferon... 51 Iron steres and virus genotypes... 294 Randomized controlled trial of t h e . . . 295 Phlebotomy reduces transaminase.. . 1207

Biliary excretion Blliary excretion of plasma nen-transferrin... 811

Cell physiology Iron induces both DNA synthesis.. . 369 Hepatic stellate cell activation... 691 In rive suppression of Kupffer. , . 1035

Diagnostic use Histology and hepatic iron content. . . 737 Predictive value of liver iron for . . . 1183

Drug effects Hepatic iron deposition during ribavirin. . . 736 Effect of UDCA on liver iron s tore . . . 1368

Genetics Induction ofmetallothioneIn mRNA.. . 780

Interferon response The role ofiren indices In predicting... 296 Response to u-IFN therapy. . . 1172 Iron and response to Intei'feron-a... 1234

Localization Intra-organ variability In hepatic. . . 1061

Pathophysiology Vitamin E suppresses lipocyte activation... 690 Molecular and cellular aspects o f . . . 1057 Hepatic iron in hereditary.. . 1059

Toxicity Inhibition of iron toxicity in human . . . 1088

Transport al-antitrypsin reduces transferrin... 1044 Role of transferrin In the t issue. . . 1214

I r o n o v e r l o a d SEEALSO Hemochromatosis

Etiology Hepatic iron concentration in end . . . 676

Hepatitis C Iron overload in chronic hepatitis. . . 675 Intra-organ variability of hepatic. . . 677 Red cell fecritin and serum ferrit in. . . 999 Reduction of liver iron content. . . 1162 Response to cL-IFN therapy. . . 1172 Iron hepatoto:dcity in post-menopausal... 1284

Hepatocellular carcinoma Iron induces both DNA synthesis.. . 369 Predictive value of liver iron for , . . 1183

Pathology Localisatien of ferritin, transferrin.. . 1143

I s c h e m i a - r e p e r f u s i o n i n j u r y sr~ ALSO Organ preservation

Bile acid transport Impairment of taurecholate-dependent.., 443

Cell physiology Alterations of epithelial cell polarity... 120 The role of apoptosis In the init ial . . . 128 Reperfusion after liver transplantation... 442 Depression of gap junctional gone. . . 768 Activation of nuclear facter-r~B... 1098 Selective zone 3 Induction of giutathiene... 1100

Cold storage organ preservation Cold preservation sensitizes hepatocytes... 15~}8

5 5 8 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1 9 9 5

I s c h e m i a - r e p e r f u s i o n i n j u r y ( c o n t i n u e d )

Diagnosis Hyaluronic acid in clinical l ive r . . . 124 The value of caval effluent in predict ing. . . 125 Association between hyaluronic a c id . . . 1483 Differential diagnosis ofischemic... 1538

Drug effects Improving hepatic hemodynamic a n d . . . 431

Liver transplantation Graft function following liver... 127 Impact of preservation injury o n . . . 402 Inactivation of Kupffer cells minimizes. . . 439 Minimal preservation-reperfusion... 1225

Nutritional status Effect of ischemia/reperfusion o n . . . 1101

Pathology Post-revascularization biopsy i n . . . 1358

Pathophysiology Actin-containing complexes in liver... 168 Less of endothelial cell ecto-ATP... 437 Heat-shock protein 70 gene expression.. . 445 Lysosomal enzymes as early and . . . . 1102

Prevention Effects of cyclosporine and tacral imus. . . 430 Hepatic reperfusion damage a f t e r . . . 444 Effect of calcium channel blockers . . . 446 L-arginine minimizes reperfusion. . . 1099 Improvement of liver graft viabi l i ty . . . 1182 Effect of ischemi 9 preconditioning.. . 1203 Beneficial effects ofpentexlfynine. . . 1334 Protective effect of lidocaine aga ins t . . . 1344

Risk factors Enhanced liver calpain protease . . . 119

I s o c i t r a t e d e h y d r o g e n a s e Serum isocitrate dehydrogenase a s . . . 1107

I s o p r o s t a n e Endothelin-1 and F2-isoprostane.. . 406

I t o c e l l s SEE Stellate cells

J K

J a u n d i c e SEEALSO Bile duct obstruction; Cho]estasis Gilbert syndrome is associated w i t h . . . 1072 Ultrasonographic evaluation of gas t r i c . . . 1220 Hepatic involvement in Brucellosis.. . 1320

J e j u n o i l e a l b y p a s s Liver transplantation for jejunoileal. . . 411

j u n g e n e Reperfusion after liver t ransplantat ion. . . 442 Growth inhibition of myofibroblast-like... 688 Stimulation of e-jun kinase by fihronectin. . . 746 Heparitinase and heparinase induce... 1318

Ketoprofen A randomized controlled trial of... 52

Ki antigen Ki.67 and p53 immunostaining methods... 323

Kidney SEE ALSO Renal function, transplantation Differential processing of an organic . . . 823

K i l l e r c e l l s , n a t u r a l Role of CD8 + lymphocytes and n a t u r a l . . . 491 Phenotypic and functional characterization.. . 923 Possible involvement of t ransforming. . . 1306

K n o c k o u t m i c e Liver injury and fhrosis in interferon. . . 680 Bile canalicular vesicles are markedly . . . 840

K u p f f e r c e l l s Activation

Femur fracture trauma to donors . . . 1468 Activation of Kupffer cells by a . . . 1631

Apoptosis Kupffer cell induces hepatecyte . . . 484 Nitric oxide and tumor necrosis . . . 486

Cell adhesion Stimulation of nitric oxide production. . . 1018

Drug effects Complement CIQ synthesis in rat... 85 Effects of cyclosporine and tacrol imus. . . 430 Anticoagulant targeting endothelial . . , 575 Antioxidants suppress endote~dn-induced... 1034 In vivo suppression of Kupffer , . . 1035 Gadolinium prevents hepatic granulomas . , . 1366 Effects of long-term alcohol . . . 1412

K u p f f e r c e l l s ( c o n t i n u e d ) Endetoxin

The endotoxin antagonist B-464 a n d . . . 550 Endotexemia induces E-selecfiu mRNA. . . 1037 Kupffer cell pro-inflammatory al terat ions. . . 1040 Effects of lipopolysaccharide tox in . . . 1041 Endocytesis is an essential step... 1365

Fibrosis Destruction of Kupffer cells diminishes . . . . 706 Hepatic expression ef hepatocyte. . . 1404

Genetics Towards to in vivo gene knock . . , 1132

Hemochromatosis Molecular and cellular aspects of... 1057

Inactivation Inactivation of Kupffer cells minimizes. . . 439 Effects of fasting and glucose. . . 441 Heat-shock protein 70 gene expression.. . 445

Liver regeneration Allogeneic Kupffer cell is impor tan t . . . 426 Kupffer cell depletion shifts t h e . . . 508 Kupffer cell depletion and the in tensi ty . . . 1349

Liver transplantation, experimental Antibiotic therapy for bacter ia l . . . 1130

Physiology Synthesis of insulin-like g rowth . . . 510 Glntathione suppression of endotexin. . . 522 Prolonged increase of portal pressure . . . 572 Glycine prevents elevation in intracollular. . . 803 Suppressor cytokine expression i n . . . 1039 Mannose-terminal glucocerehrosidase... 1074

Signal transduction Thiol regulation of endotoxin-induced... 520 Tyrosine phosphorylation is important. :. 796 Modulation of Kupffer cell funct ion. . . 807 Kupffer cell derived IL-6 increases. . . 1031 LPS-mediated NF-r.B activation. . . 1036

L

L a c r i m a l a p p a r a t u s Lacrimal dysfunction in pa t ien ts . . . 1200

L A K c e l l s Possible involvement of transforming... 1306

Laminins Twenty times less liver laminin... 767 A silencer element in the LAMC1.. . 782 Expression and function of in tegr in . . . 1047 Overexpression of laminin and collagen.. 1048 The prognostic value of serum lamin in . . . 1338

L a m i v u d i n e Lamivudine prophylaxis: a new strategy. . 470 HBV marker kinetics during the rapy . . . 884 Reduction in hepatitis B virus quasispecies.. . 885 Lamivudine results in a complete. . . 886 Histological improvement in pa t ients . . . 887 Lamivudine therapy of f ibrosing.. . 16'15

L a p a r o s c o p i c c h o l e c y s t e c t o m y Causes and risk factors for postoperative... 5 Trends in biliary tract in jur ies . . . 158 Prediction for occurrence of hepatocsllular. . . 1317 Laparoscspic cholecystectomy injur ies . . . 1374 Referral pattern and management . . . 1402

L a p a r o s c o p y Staging laparoscopy with laparoscopic... 2

Laser-doppler flowmetry Evaluation of mucosal blood flow... 1259

L a s e r s In situ detection of marker proteins. . . 57 Calcium-induced mitechondrial. . . 1087

L e u c i n e Leucine metabolism in liver of endotoxin.. . 1294

L e u k e m i a Prevalence and natural history o f . . . 960

L e u k o t r i e n e s Biliary excretion ofleukotrienes. . . 1449

L e w i s Y a n t i g e n Lewis Y antigen expression i n . . . 1599

L F A - 1 Pathogenetic origin of soluble ICAM-1.. . 60 Antibodies against adhesion molecules.. . 1326

L i c h e n p l a n u s Lichen planus and hepatitis C v i ru s . . . 948

L i d o c a i n e Manoethylglycinexylidide and lidoceine.. . 560 Protective effect of lidocaine aga ins t . . . 1344 Lidocaine metabolite formation i n . . . 1568

L i g a s e c h a i n r e a c t i o n Detection of hepatitis B virus precere . . . 1429

Lipid p e r o x i d a t i o n SEE ALSO Free radicals; Oxidative injury

Antagonists and inhibitors Colchicine reverses a-naphthyllsethio.. . 1089

Chemoembolization Changes in serum lipid peroxide. . . 1304

Cholestasis 4-hydroxy-2,3-nonenal production. . . 1463

Hemochromatosis Hepatic lipid peroxidation in pa t ien ts . . . 1062

Hepatitis C Hepatic lipid peroxidatian in chronic . . . 678

Iron overload Vitamin E suppresses lipocyte activation. . . 690

Liver transplantation, experimental Inactivation of Kupffer cells minimizes. . . 439

Pathophysiology 4-hydroxynonenal (HNE) levels a r e . . . 544 Xanthine oxidase inhibition reduces... 844

Lipocytes SEE SteUate cells

L i p o p r o t e i n s Role of apolipoprotoin E in intracellular . . . 529 Increasing hepatic cholesterol 7 a . . . 532 Preferential sterol transport f r om. . . 536 Apolipoprotein E4 genotype is associated. . . 1484 Lipid- and lipoprotein changes i n . . . 1522

L i p o x y g e n a s e 5 lipoxygenase inhibiter suppresses . . . 707

L i t h g e n e s Phenotypic characterization of Lith... 732

L i v e r SEEALSO more specific entries

Anatomy and histology The liver edge and the subcapsular . . . 207 Portal lobules in the ra t f ibrotic . . . 210 The geometry of the liver lobule . . . 1400 Hydrophohic and hydrophilic b i l e . . . 1485

Blood supply A new look at the "hepatic". . . 209 Portal ~watershed" at t h e . . . 1630

Growth and development In vitro culture and differentiation... 497 Gap junction's role of differential. . . 1308

Innervation Increase in hepatic glucose up t ake . . . 528

Radionuelide imaging Portal flow after orthotopic l ive r . . . 132 Prognostic value of the perfused. . . 208 A novel three-stop immunoscintigraphy.. . 318 Radioisotope scanning of AFP producing. . . 319 Bile physiology studies in pa t ien ts . . . 400 99m-Tc-labeled human serum a lbumin . . . 421 Transplantation of hepatecytes marked . . . 1078 The impact of spleen volume on su l fu r . . . 1293 Usefulness of technetium-99m G S A . . . 1305

L i v e r a b s c e s s Specific diagnosis of amebic l ive r . . . 86 Choledochojejunostemy and pyogenic . . . . 1392

L i v e r b i o p s y SEE ALSO specific diseases

Complications Role of the template bleeding t i m e . . . 1612

Diagnostic use Safety and utility of percutaneous... 679 Transvenous liver biopsy in fulminant... 1108 Diagnosis of cirrhosis in patients... 1209

Donor sereening Liver biopsy for t ransplantat ion. . . 138

Hepatitis B and C Histological diagnosis of chronic . . . 1379

Hepatitis C What serologic tests are necessary . . . 655 Histepathalogic heterogeneity i n . . . 656 Histological consequences of chronic . . . 1314

Hepatocellular carcinoma Ki-67 and p53 immunostaining methods . . . 323

Instrumentation Increasing size of true cut needle . . . 1551

Liver transplantation Assessment of histologic examination... 141 Post-revascularization biopsy in... 1358

Ultrasound imaging The effect of ultrasonography o n . . . 1112

L i v e r d i s e a s e , n o n - B , n o n - C , n o n - a l c o h o l i c

Clinical features of symptomatic. . . 1444

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 559A

L i v e r f u n c t i o n t e s t s SEE ALSO Aminotransferases

Cirrhosis Correlation of plasma fatty acid . . . 1221

Diurnal variations Diurnal variability of liver chemistries... 91

Drug effects The effect of ursodeoxycholic acid . . . 1457

Galactose breath test Oral lsC galactose breath t e s t . . . 565

Hepatocellular carcinoma Long-term study on the hepatic functional... 1378

Interferon response Changes of liver function tes ts . . . 1303

Liver transplantat ion Quantitative liver function test ing. . . 1616

L i v e r g r o w t h f a c t o r Recovery of rate with D-galastesamine... 502 Variations in L-FABP, flux and l ipid. . . 537 Decrease in fibrosis, and increase.. . 1218

L i v e r i m a g i n g ( r a d i o n u c l i d e ) Hepatitis, alcoholic

Usefulness of technetinm-99m GSA. . . 1305 Hepatobiliary physiology

Bile physiology studies in pat ients . . . 400 Hepatocyte transplantat ion

Transplantation of hepatooytes marked . . . 1078 Liver cancer

Radioisotope scanning of AFP producing... 319 Methods A novel three-step immunoscintigraphy... 318

Perfused hepatic mass Prognostic value of the perfused.. . 208 The impact of spleen volume on sulfur . . . 1293

Portal circulation Portal flow after orthotepic l iver . . . 132

Serum albumin microspheres 99m-Tc-labeled human serum albumin. . . 421

L i v e r m e t a s t a s i s Technical failures of cryosurgically... 4 Cryosurgery for hepatic metastases. . . 161 Utility and cost effectiveness o f . . . 164 Can flow cytometric DNA analysis. . . 317 Hepatic metastasis of human colorectal... 373 Overexpression of Inminin and collagen... 1048 Expression and activity o f . . . 1053 Calcified liver metastases of Vipoma.. . 1526

L i v e r n e c r o s i s Anticoagulant targeting endothelial... 575 TNFa-induced apoptesis o f . . . 1093 Presence of liver necrosis is needed. . . 1097 Serum isocitrate dehydrogenase a s , . . 1107

L i v e r r e g e n e r a t i o n Acute hepatic fai lure

Emergency amdliary liver transplantation... 165 Does ciprofioxacin alter survival. . . 1096

Apoptosis Modulation of apoptesis-associated... 487 TGF-~I induction of apoptesis... 488 Apoptesis and cell proliferation... 1512

Bile acid transport Microtubule-dependent bile ac id . . . 1620

Cell physiology Middie-malecular-weight inhibiter.. . 494 Role of liver stem cells in t h e . . . 500 Differential expression of vascular . . . 511

2+ [Ca ]i responses during proliferation... 512 Epimorphin localizes in Ite cells... 513 APRF, increased nuclear binding.. . 515 Gene expression of matr ix . . . 517 Regulation of the p21/WAF1]CIP1/SDI1... 519 Control of albumin gene expression... 784 Hepatocyte differentiation en masse . . . 1125 Changes in liver membrane potentials... 1165

Dietary cholesterol Effect of a high cholesterol d ie t . . . 1393

Hepatocellular injury Expression of hepurin-binding EGF-like... 501

Hepatocyte growth factor Apoptosis in the liver after discontinuation... 490 Cellular localization ofhepatecyte... 503 Interaction of hepatecyte growth. . . 1348

Hepatocyte transplantat ion Rapid integration and proliferation... 499

Immunology Hepatecyte growth factors-scatter... 1027 Changes in proliferative and cytotexic... 1137

Kupffer cells Kupffer cell depletion and the intensity.. . 1349

Liver growth factor Recovery of rats with D-galactasamine... 502

L i v e r r e g e n e r a t i o n ( c o n t i n u e d ) Pathology

OV.6 positive, HepParl negative.. . 496 Physiology

Are transforming growth factor a . . . 505 Kupffer cell depletion shifts t h e . . . 508 Biochemical events following part ial . . . 516 Co-mitegenic effect of vasoactive... 518 A novel experimental Animal model. . . 1095 Stimulation of liver regeneration... 1260 Study of '~epatetrophic ~ substances... 1363 Viscosity but not colloidosmotic... 1435 Vascular and distribution changes.. . 1504 Granulocyte colony stimulating factor.. . 1569 Characterization of heparan sulfate.. . 1575 Altered regulation and role of dipeptidyl... 1584 A new model for liver regeneration... 1610

Signal transduction ErbB3, the major hepatic heregulin.. . 794 Activation ofphosphatidylinositol... 1513

Transgenie animals Impaired liver regeneration in transgeuic... 506

L i v e r r e s e c t i o n Cholangiocareinoma

Major hepatic resection for extrahepatic... 157 Cirrhosis Tolerance of normothermic ischemia... 159

Hepatocellular carcinoma Surgical resection of hepatocellular... 1164

Liver metastasis Utility and cost effectiveness of . . . 164

Methods Liver resection utilizing total . . . 162

Sarcoma Liver resection for metastatic sarcomas.,. 1375 Liver resection for primary sarcomas:... 1376

L i v e r t r a n s p l a n t a t i o n SEE ALSO Graft function; Graft rejection;

Hepatocyte transplantation; Organ preservation

Acute hepatic failure Outcome of liver transplantation... 407 Inability of intracranial pressure.. . 408 Liver transplantation for F H : a .... 410

Age factors Fate of transplanted hepatic allografts... 1539

Alcoholic cirrhosis De novo malignancy following orthotepic... 375 In spite of an increased frequency... 376 Recidivism foll0wing liver transplantation... 377 Liver transplantation for alcoholic... 1490

Autoimmunity Acute cellular rejection of l iver . . . 143 Significance of immune activation... 189 Recurrent auteimmune hepatitis following... 433 Does autoimmuulty affect the outcome... 1262

Bile composition Bile physiology studies in patients. . . 400

Biliary stricture A positive lymphocytotexic crossmatch... 169

Bone marrow transplantation Orthotepic liver transplantation... 1499

Bone resorption Mechanisms of bone loss following... 404 Vitamin D receptor gene polymorphism... 1267 Calcitenin therapy does not prevent. . . 1282

Cardiac evaluation Assessment of QT interval prolongation... 382 Cardiac evaluation in adult l iver . . . 414

Central pontine myelinolysis Occurrence of central pontine . . . . 1126 Recovery from central pontine.. . 1152

Cirrhosis Poor outcome following orthotopic... 187

Cold storage organ preservation Extended cold ischaemia is not associated.,. 129 Donor organ cold ischemia time a n d . . . 191

Complement Complement activation in l iver . . . 137

Complications The effects of postoperative complications... 140 The impact of postoperative complications... 391 Incidence of biliary complications... 398 Staphylococcus epidermidis is a n . . . 399 Epstein-Barr virus-related post-transplant... 416 Thrombectomy and intraoperative... 1195 Biliary complications in 150 living.. . 1224 Transient myocardial dysfunction... 1324 Choledochojejunostemy and pyogenic... 1392

Cystic fibrosis Liver or combined lung and liver... 167

Diabetes mellitus Association of HLA antigens wi th . . . 1311

L i v e r t r a n s p l a n t a t i o n ( c o n t i n u e d ) Donor evaluation

Liver biopsy for transplantation... 138 Effect of donor hepatitis C seropozitivity... 176 Maximal utilization of the "marginal".. . 1299 The use of hepatitis B core antibody... 1530

Drug metabolism Comparative study of pharmacekinetic... 147

Drug therapy/immunosuppression Tasrolimns (FK506) versus cydosporine... 149 First year of tasralimns: have w e . . . 150 Is Neoral@ a viable alternative.. . 151 Primary liver transplantation i n . . . 1253 Precise calculation of cyclosporine... 1319 Prostaglandin E a for severe, ear ly . . , 1331

Economics Preoperative risk factors affecting... 389 Strategies for prevention of death... 877

Enteral feeding Does nasoenteral nutritional support. . . 135

Famil ial amyloid neuropathy Portuguese national experience i n . . . 172 Liver transplantation in familial. . . 384 Orthotepie liver transplantation... 385

Fat content The outcome of liver allografts... 394

Fatty liver Use of donor livers with moderate-tc... 395 Liver transplantation for jejunoileal... 411

Genetics Assessment of microchimerism following... 412

Graft function Hyaluronie acid in clinical l iver . . . 124 The value of caval effluent in predicting... 125 Predictors and outcome of ear ly , . . 130

Hemodynamies Hepatic hemodynamice in living related. . . 1395

Hepatic encephalopathy Hepatic encephalopathy in patients. . . 378 Effect of liver transplantation... 379 Changes in blood explain increased... 380

Hepatic vein thrombosis Liver transplantation for Bndd-Chiari... 1247

Hepatitis B Altered regulatory mechanisms which. . . 96 Predictors of hepatitis B v i rus . . . 97 S gene escape mutants as a cause. . . 174 Famciclovir treatment of hepatitis. . . 449 Lamivudine prophylaxis: a new strategy.. . 470 Survival after liver transplantation... 1255 Histepathological a n d . . . 1357

Hepatitis C Long-term outcome of hepatitis C . . . 112 Hepatitis C virus infection is not... 117 Outcome of liver retransplantutlon... 188 Hepatitis C viral infection and.., 1361

Hepatitis D Liver transplantation for patients. . . 94

Hepatitis, fu lminan t Severe neurological sequelae af ter . . . 383

Hepatitis G Hepatitis G virus in hepatitis C . . , 178

Hepatitis, viral Prevalence and acquisition of v i ra l . . . 92

Hepatocellular carcinoma Liver transplantation for smal l . . . 374 Treatment of hepatecellular carcinoma... 1237 Liver transplantation for hepatecellular... 1414

Hyperbilirubinemia Persistent unconjugated... 397

Hyperlipidemia Hyperlipidemia following liver transplant. . . 392 Serum lipid levels in pediatric... 393

Immunization Efficacy of vaccination against . . . 875

Immunology The effect of positive crossmatch... 1223

Intrahepatic cholestasis Case report: recurrence of progressive... 401

Isvhemia-reperfusion injury Enhanced liver calpain protease.. . 119 Alterations of epithelial cell polarity... 120 Graft function following l iver . . . 127 The role of apoptesis in the initial... 128 Minimal preservation-reperfusion... 1225

Liver biopsy Post-revascularizatian biopsy i n . . . 1358

Liver function tests Quantitative liver function testing. . . 1616

Methods Emergency auxiliary liver transplantation... 165 Auxiliary liver transplantation... 186 "Piggy-back ° liver transplantation... 390

5 6 0 A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1 9 9 5

L i v e r t r a n s p l a n t a t i o n ( c o n t i n u e d ) Outcome Causes of late mortality in survivors... 133 Absence of relationship between... 139 Impact of preservation injury o n . . . 402 Impact of positive crossmatch d u e . . . 1540

Pathology Proposal for a s tandardised. . . 413

Physiology Detection of albumin mRNA in blood. . . 131 Par~l flow aRer orthotopic l ive r . . . 132 Single-photon emission computed. . . 381 Endothelin homeostasis during l ive r . . . 405 Endothelin-1 and F2-isoprostane.. . 406 Distribution of inducible n i t r i c . , . 1019 Stability of cerebral perfusion. . . 1560 Arterial plasma amino acid patterns... 1570

Plasmapheresis Plasmapheresis in patients w i t h . . . 1411

Pneumocystis carinii Detection of Pneumocystis carinii . . . 1312

Porphyrias Follow-up after liver t ransplantat ion. . . 173

Primary biliary cirrhosis Selection and timing of l ive r . . . 1489

Prognosis Pretransplant body fat wasting predicts . . . 396 Is Mallory's body a prognostic fac tor . . . 1477

Racial differences Race is not a critical factor i n . . . 142

Rejection Assessment of histologic examination. . . 141 Risk factors for chronic rejection. . . 144 FK 506 is as effective as OKT3 f o r . . . 148 Ursodeoxycholic acid reduces hepa t ic . . . 170 FK506 (tacrolimus, Prograf TM) . . . 1167 The early diagnosis of chronic ductopenie.. . 1168 Changes in the activation s t a tu s . . . 1197 Chronic rejection following p r imary . . . 1309 Prediction of acute rejection i n . . . 1493 Incidence and outcome of OKT3 the rapy . . . 1496 Allograi~ rejection and lack o f . . . 1502

Renal function The effect of renal dysfunction. . . 1313

Renal transplantation Combined liver-kidney transplantat ion. . . 388

Sclerosing cholangitis Antineutrophi] cytoplasmic antibodies. . . 1139 Choledochocholedochostomy b i l i a ry . . . 1243

Sex differences Effect of donor gender on l ive r . . . 1169

Small bowel transplantation The pathology of the liver g ra f t s . . . 1582

T-tubes Diagnostic utility ofT-tube a f t e r . . . 1611

Thrombocytopenia Mechanisms of thrembocytopenia a f t e r . . . 123

TIPS The impact of transjugular intrahepat ic , . , 1180 Liver transplantation after t rans jugnlar . . . 1587

Vascular reconstruction Cryo-preserved vein graft fa i lures . . . 403

L i v e r t r a n s p l a n t a t i o n , e x p e r i m e n t a l Bioartifi¢ial liver

Preliminary evaluation of a n e w . . . 423 Cold storage organ preservation

Effect of calcium channel blockers . . . 446 Improvement oflivar graft viabil i ty. . . 1182

Cryopreservation Controlled rate freezing of hepatocytes. . . 420

Cytokine proflle Predominance of IL-4 mRNA expression.. . 440

Cytomegalovirus CMV infection of hepatocytes a n d . . . 434

Fatty liver, alcoholic ICAM-1 is elevated dramatical ly . . . 438 Inactivation of Kupffar cells minimizes. , . 439

Graft function Increased liver engraftment o f . . . 418 Antibiotic therapy for bac ter ia l . . . 1130 Femur fracture trauma to donors . . . 1468 In vitro performance of l ivers . . . 1481

Hepatic fibrosis Expression of c-met mRNA and TGF-~I . . . 504

Hepatocyte transplantation Amelioration of bilirubin conjugation. . . 417 Primary hepatocytes t ransplanted. . . 419 99m-Tc-labeled human serum a lbumin . . . 421 Hepatocyte transplant combined w i t h . . . 424 Isolated fetal porcine hepatocytes. . . 425 Allogeneic Kupffer cell is impor tan t . . . 426 The cole of MHC antigens and adhesion. . . 1364

L i v e r t r a n s p l a n t a t i o n , e x p e r i m e n t a l ( c o n t i n u e d )

Immune tolerance Precipitation of fatal rejection... 190 Rapid formation of donor cell.,. 1136

Ischemia-reperfusion injury Reperfusion after liver t ransplantat ion. . . 442 Impairment of taurocholato-dependent... 443 Beneficial effects of pentoxifylline... 1334 Protective effect of lidocaine aga ins t . . . 1344 Association between hyaluronic a c id . . . 1483

Organ preservation Effects of fasting and glucose. . . 441

Rearterialization Long-term outcome following orthotop~c... 1300

Survival Comparison of systemic and local . . . 1286

Transplant rejection Microclrrulatory impairment du r ing . . . 192

L i v e r t r a n s p l a n t a t i o n f o r h e p a t i t i s C

Cryoglobulinemia Cryoglobulinemia in liver t ransp lan t . . . 105

Economics Strategies for prevention of d e a t h . . . 877

HCV genotypes Quantitation ofintra-hepatic HCV-RNA... 1216

HCV+ donors Effect of donor hepatitis C seropositivity... 176 HCV genotypes and outcome in H C V . . . 177

Hepatitis C genotyping Hepatitis C virus diversity a n d . . . 108

Hepatitis C, recurrent Recurrence and outcome of hepat i t i s . . . 98 Hepatitis C virus infection recurrence. . . 99 Long-term histologic follow-up aRe r . . . 100 Severe recurrent HCV after l iver . . . 101 Interferon-alpha therapy for hepat i t i s . . . 103 OKT3 use associated with diminished.. . 104 Specific humaral immune response. . . 106 Serum eytokine levels in pa t ien ts . . . 107 HCV genotypes and quantitation o f . . . 109 Hepatitis C viral genotypes: association.. . 110 HCV-RNA titers in the early course . . . 111 Poor prognosis of patients retransplantod. . . 113 Early reinfection of and late H C V . . . 114 Hepatitis C virus reinfection a f t e r . . . 115 Increased infections in liver t ransp lan t . . . 116 HCV reinfection in liver t ransplanted. . . 175 Effect of interferon and r ibavir in . . . 722 Hepatitis C viral infection a n d . . . 1361

Immunology Anti-GOR in patients with chronic . . . 118 Diagnostic significance of IgM anti-HCV.. . 992 Does autoimmunity affect the outcome.. . 1262

Liver biopsy Serum HCV RNA levels and histological.. . 669

L i v e r ( x e n o ) t r a n s p l a n t a t i o n Hepatic metastasis of human colorectal.. . 373 Hyperacuto rejection of discordant. . . 427 Histopathology oflivar. . . 428 Study of CD4 and CD8 level a n d . . . 1271 A new and simplified technique f o r . . . 1388

L u c i f e r y e l l o w Carrler-mediated uptake of luci far . . . 810

L u n g Transplantation of hepatocytes marked. 1078

Lung transplantation Liver or combined lung and liver... 167

Lupus erythematosns Apoptosis and cell proliferation... 1512

Lymph nodes Enlargement of lymph node s within... 1232

Lymphocytes Activation

Antigen independent activation o f . . . 632 Changes in the activation s t a tu s . . . 1197

Cytokine profiles Binding of liver-derived lymphocytos... 84 Increased intrahepatic Thl cytokine... 461 Thl cytckine pattern and defective... 915 Immunodominant hepatitis C virus... 916

Hepatitis C Different quasi-species of hepat i t i s . . . 463 CD30-induction on T lymphocytes. . . 913 Different quasispecles of hepat i t i s . . . 927 Prognostic value of hepatitis C . . . 1014

Liver regeneration Changes in proliferative and cytotozic... 1137

Therapeutic use Autologous lymphocyte therapy f o r . . . 892

B l y m p h o c y t e s Identification of cross-subtype.. . 467 Hepatocyte growth factors-scatter. . . 1027

L A K l y m p h o c y t e s Possible involvement of t ransforming. . . 1306

N K C l y m p h o c y t e s Role of CD8 ÷ lymphocytes and natural... 491 Phenotypic and functional characterization... 923 Possible involvement of transforming.,. 1306

T lymphocytes CD30+

CD30-inducfion on T lymphocytes. . . 913 CD30+CD3+ Immunodomlnant hepatitis C virus... 916

Cell differentiation RAG1, RAG2 and TdT expression i n . . . 79

Hepatitis C Accumulation of HCV-core specific... 911 Cytokine expression and T-call subset... 914 Relevance of ultrastructural lymphocyte... 924

HepatoceUular injury Hypothyroidism inhibits experimentally. 1450

Lymphocyte activation Antigen independent activation o f . . . 632 Changes in the activation status . . . . 1197

T cell receptor Restriction of V beta gene u s a g e . . . 633 Analysis of the T cell antigen receptor . . . 1474

T l y m p h o c y t e s , C D 4 + Cell proliferation

Effective antigen presentation a n d . . . 81 Human intrahepatic biliary epithelial . . . 435

Hepatitis C Lymphocyte phenotypes in chronic . . . 462 Viral clearance during acute hepat i t i s . . . 912 Chronic hepatitis C virus infection. . . 932

Liver transplantation, experimental Study of CD4 and CD8 level and.- . . 1271

Primary biliary cirrhosis Cytokine responses to PPD in p r imary . . . 62

Thl Increased intrahepatic Thl cytokine. . . 461 Thl cytokine pattern and defective.. . 915 Requirement of Thl-like l iver . . ~ 1026

Thl/Th2 The role of THlfrH2 lymphocytes. . . 1025

Th2 Predominance of 1L-4 mRNA expression.. . 440

T l y m p h o c y t e s , C D 8 + Cell differentiation

CD8~a T lymphocytos. . . 80 HBV vs. HCV infection

Comparative analysis of the cytotoxic.. 909 Hepatitis B

The cytotoxlc T lymphocyte response. . . 466 Hepatitis C

Role ofCD8 + lymphocytes and n a t u r a l . . . 491 Defining the role of int rahepat ic . . . 724 Molecular mapping of an in t rahepat ic . . . 906 The peripheral blood cytotexio T . . . 907 Viral escape from the HLA-A2 restr ic ted. . . 908 Hepatitis C virns-spedfic cytotoxic... 910

L y m p h o m a De novo malignancy following orthotopie.. . 375 Epstoin-Barr virus-relatod post- transplant . . . 416 Infection by HCV and other lymphotropic.. . 981 Analysis of HCV infection in pat ients . . 1629

L y s o s o m e s Proliferation of hepatic lysosomes,. . 1067 Lysosomal enzymes as early a n d . . . 1102

M

M a c r o p h a g e c h e m o t a c t i c p r o t e i n o l Increased expression of p chemokines... 1030

M a c r o p h a g e i n f l a m m a t o r y p r o t e i n - 1 Increased expression of ~l chemokines. . . 1030

M a c r o p h a g e - s t i m u l a t i n g p r o t e i n Hepatic expression of hepatocyte. . . 1404

M a c r o p h a g e s Complement CIQ synthesis in r a t . : . 85 DNA strand break and fragmentat ion. . . 495 Phenotypic and functional characterization.. . 923 Uptake and metabolism in v ivo . . . 1073 Mediator production and phagocytic . . . 1199 A high-affinity peripheral benzodiazepine... 1354 Different receptors far endotoxin, . . 1405

HEPATOLOGY %701. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 5 6 1 A

M a g n e t i c r e s o n a n c e i m a g i n g Magnetic resonance... 1 MRI reliably detects macroregenerative... 313 Effect of liver transplantation.,. 379 MRI findings in chronic hepatic. . . 1289

M a g n e t i c r e s o n a n c e s p e c t r o s c o p y Assessment of in vivo hepatic. . . 68 Improvement of liver graft viability... 1182 In vitro proton (1H) magnetic. . . 1310

M a j o r b a s i c p r o t e i n Serum eosinophil granule-associated... 63

M a l a r i a Identification of human l iver . . . 733

M a l l o r y b o d i e s De novo expression ofnon-hepatoceliular... 766

M a l o n d i a l d e h y d e Acetaldehyde and malondialdehyde... 479

M a n g a n e s e The role of manganese in chronic... 217 Role of transferrin in the t issue. . . 1214

M a n n o s e b i n d i n g p r o t e i n Chronic hepatitis B virus infection... 627

M A P k i n a s e Inhibition of cell growth of human . . . 364 Role of signal transduction pathways. . . 371 Reperfusion after liver transplantation... 442 Cellular transformation induced.. . 509 Growth inhibition of myofihrablast-like... 688 MAP kinase and lipid-derived signal . . . 693 RAF and MAP klnase differentially... 743 Difference in activation of Raf/MEK/ERK1.. 1295

M a s s s p e c t r o m e t r y In situ detection of marker proteins.. . 57 Electrospray ionization-mass spectrometry... 856

M a t r i x m e t a l l o p r o t e i n a s e s Localization of 92kD gslatinase.. . 341 Cellular distribution of t issue. . . 342 Gene expression of matr ix . . . 517 Pentoxifylline inhibits the proliferation... 695 Expression of gelatinase A is increased,,. 1051 Membrane-type matrix metalloproteinase... 1052 Expression and activity of . . . 1053 Expression of metallopreteinases... 1054 Expression of meta]loproteinase... 1056

MDR g e n e s SEEALSO Multidrug resistance; P-glycoprotein Hepatocytos express an array of... 821 Bile canalicular vesicles are markedly... 840 Regulation of MDR2 P-giycoprotein... 864 Intrahepatie MDR3 P-glycoprotein... 1222

M e d i c i n e s , C h i n e s e h e r b a l Efficacy of Jigreen: an herbal d rug . . . 1270 Reduction of increased portal pressure. . . 1297

M E G X f o r m a t i o n Monoethylglycinexylidide and lidocaine.,. 560 Lidocaine metabolite formation i n . . . 1568 Quantitative liver function testing. . . 1616

M e n o p a u s e Iron hepatetoxicity in post~menopausal... 1284 Carbohydrate-deficient transferrin. . . 1550

m e t g e n e Immunolocalization of bcl-2 a n d . . . 122 A novel abl-like gene associated... 329 Expression of I-IGF and c-MET protein. . . 338 Expression of c-met mRNA and TGF-~I . . . 504 Hepatecyte growth factors-scatter... 1027

M e t a - a n a l y s i s Hepatocellular carcinoma

Meta-analysis of medical t reatments. . . 1394 Interferon therapy Meta-analysis of interferon randomized... 28 Treatment of chronic NANB and C... 185 Comparison of biochemical and virological... 1254

Variceal bleeding Meta-analysis of endoscopic l igatien. . . 580 Meta-analysis of propranolol p lus . . . 582

M e t a l l o p a n s t i m u l i n Expression of metallopanstimniin... 1248

M e t a l l o t h i o n e i n Induction of metallothionein mRNA.. . 780

M e t a s t a s i s Technical failures of cryosurgically... 4 Cryosurgery for hepatic metastases. . . 161 Utility and cost effectiveness o f . . . 164 Can flow cytometric DNA analysis. . . 317 Hepatic metastasis of human colorectal... 373 Overexpressien of laminin and collagen... 1048 Expression and activity of... 1053 Calcified liver metastases of Vipoma... 1526

M e t h i m a z o l e Methimazole slows hepatecyte streaming... 770

Methotrexate Methotrexate therapy of primary, . . 69 Two year histologie follow-up of . . . 70 Medium term treatment of PEC wi th . . . 71

M e t h y l e n e b l u e A new use for an old drug: methylene... 14

M e t h y l t r a n s f e r a s e s Demonstration and part ial . . . 791

M e t h y l x a n t h i n e s Inhibition of myofibroblastic... 714

M i c r o c i r c u l a t i o n Microcirculatery impairment during... 192 Impaired endothelial function in,.. 198 Role of endothelin-I in hepatic,.. 569 The regalatory mechanism by extracalhilar... 573 L-arginine minimizes reperfusion... 1099

Mieroeystin Expression in Xenopuz laevis oocytes.,. 751

Microsatellites Genetic mechanisms of tumorigenesis... 13 Assessment of microchimeriem following... 412 Loss of the DNA mismatch repair . . . 450 Physical mapping in t h e . . . 1058

M i c r o s o m e s Purification end characterization... 538 Hepatic microsomal UDP. . . 818 Functional identification of carrier. . . 826 NTCP is a candidate for the carrier. . . 863 Microsomal ethanol oxidizing system.. . 1430

M i c r o t u b u l e s Alcohol-induced alterations in t he . . . 478 Protein phosphatase 2A-mediated... 806 Microtubule-dependent bile acid. . . 1620

M i n o e y e l i n e Minocycline-inducod liver injury. . . 1383

M i t o c h o n d r i a Antibody to

Characterization of intrahepatic... 61 IgG and IgG3 levels of anti-M2... 1593

Drug effects Mechanisms of dideoxynucleoside... 1346

Ethanol Oxidation of DNA end proteins i n . . . 539

Genetics Cloning of the human mitochondrial... 773 Functional analysis of 5' regulatory... 775

Pathophysiology Impairment of taurocholate-dependent... 443 Biochemical events following partial... 516 Mechanism of defect in mitochondrial... 521 Mitochondrial abnormalities in Long. . . 1066 Cocaine-induced hepatic injury i n . . . 1085 Models for the dominant negative.. . 1618 Generation of hydrogen peroxide... 1084

Permeability Role of mitochonclrial free calcium... 1083 Calcium-induced mitechondrial... 1087 Induction of the permeability transition... 1106

Viral replication The mitechondrlon is the key erganalle... 1459

M o n o c l o n a l a n t i b o d i e s Effects of in vivo msnoc]onal... 429

M o n o e l o n a l g A m m o p a t h y Hepatitis C virus infection and . . . 987 Relevance of hepatitis C virus infection... 1385

M o n o c y t e s Role of interferon alpha on arachidonic... 248 Effect of interferon alpha on TNF-a. . . 250 HCV infection of peripheral blood... 925 Hepatocyte growth facters-scatter... 1027

M R P g e n e Cloning of a liver-specific MRP,. . 753 Expression and localization of t he . . . 754

M u c i n Prostaglandin E1 stimulates mucin. . . 15 Modulation of mucin end collagen... 1190

M u l t i d r u g r e s i s t a n c e SEEALSO MDR genes; P-glycoprotein Immunohistechemical study on expression... 335 Mechanisms whereby a synthetic... 361 Cloning of a llver-specific MRP. . , 753 Expression and localization of t he . . . 754 Multiple carriers involved in t h e . . . 812 Localization of the maltidrug resistance... 822 Assessment of isolated rat hepatecyte... 1160 Intrahepatic MDR3 P-glycoprotein... 1222 Biological signficance of P-glycoprotein... 1563

Mutation Glucose-6-phosphatase

Exon redefinition by a point mutation. . . 1077 Hemochromatos is Phenotype and genotype variability,.. 1060

Hepatitis B antigens Use of dominant negative mutants . . . 472 Absence of unique HBV mutation i n . . . 615 Serial analysis of hepatitis B v i rus . . . 621 HBV core proteins with central deletions... 643 Inhibition of viral replication... 648 Hepatitis B virus mutations associated... 1529 The relationship between pre-core/core... 1628

Hepatitis B core promoter HBV core promotor mutations cause . , . 614 Hepatitis B virus core promoter. . . 616

Hepatitis B pre-core antigen Mutations in the precoreJcore a n d . . . 346 Presence of hepatitis B virus precore.. . 645 High Incidence of HBV pre-core gene . . . 652 Method for detection of epsilon-secondary... 654 Survival after liver transplantation,.. 1255 Hepatitis B virus variants w i th . . . 1265 Hepatitis B virus pre-core mutat ion. , . 1413 Detection of hepatitis B virus precore.. . 1429 The relationship between hepatitis. . . 1567 Can hepatitis B virus precore mutan t . . . 1573 Quantitative analysis of wild-type.., 1583

Hepatitis B surface antigen Altered regulatory mechanisms which. . . 96 S gene escape mutants as a cause. . . 174 Mutagsnesis and expression ofHBsAg.. . 620 An epidemiological survey for hepatitis. . . 622 Natural occurring escape mutan t . . . 1604

Hepatitis B virus Falminant hepatitis associated with.,. 619 Core gene heterogeneity in HBV-DNA.,. 640 Sequencing analysis of the terminal.,. 642 Replication-defective HBV mutants... 1290 Immunologically negative hepatitis... 1523

Hepatitis C virus Hepatitis C virus diversity and,.. 108

Hepatocellular carcinoma p53 abnormalities in hepatoceUular... 332 Sequence-specific transcriptional... 333

Mannose binding protcin Chronic hepatitis B virus infection... 627

M x A p r o t e i n Expression of the interferon-induced... 883

M y a s t h e n i a g r a v i s Myasthenia gsavis and hepatitis ~.. 1275

myb g e n e Activation of hepatic stelhite ceils. . . 748

myc g e n e c-myc induction of hepatoma cell . . . 485 Impaired liver regeneration in transgenic.. . 506 Analysis of prolonged exposure t o . , . 795

M y o f i b r o b l a s t c e l l s Growth inhibition of myofibrchlast-like... 688 Pentoxifylline inhibits the proliferation.., 695 Recognition of two Spl binding si tes . . . 699 Reversal of activated lipocyte phenotype... 704 Heterogeneity ofprocollagen types . . . 708 Collagen VI serves as potent growth. . . 709 Identification of the antifihrogsnic... 718 HGF transcription is under a cell. ~. 1279

N

N a - b i l e a c i d c o t r a n s p o r t e r Identification of a dysfunctional... 727 Sex differences and hormonal regulation... 824 Further insights into the role o f . . . 842 Correct targeting of rat liver a n d , . . 846 Bile acids suppress the rat l iver , . . 847 Characterization of the human i leal . . . 848 Expression of the human Na÷-dependent... 849 Expression of the rat liver Ha +. .. 850 Characterization of the human Ha +. .. 851 Increased Na*/taurocholate (TC).. . 852 NTCP is a candidate for the carr ier . . . 853 Inflammatory cytokine regulation... 854

N a o H e x c h a n g e Activation of fat-stering cells. . . 829 Mechanism of extracollniar ATP-induced... 830 Amiloride, but not DIDS and NPPB. . . 835

N a - K - A T P a s e Increased hepatic NaK-ATPase activity.. . 828

N a - p u r i n e n u c l e o s i d e c o t r a n s p o r t The role of liver Na+/purine nucleozide.., 827

562A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

N a - t a u r o c h o l a t e c o t r a n s p o r t e r Characterization of the human i leal . . . 848 Expression of the human Na÷-depandent... 849 Expression of the rat liver Na ÷ . . . . 850 Characterization of the bnrn~n N a t . . 851 Increased Na+/taurocholate (TC). . . 852 NTCP is a candidate for the carr ier . . . 853

N a t r i u r e t i c h o r m o n e s Elevated levels of natrinretie hormones.. . 1465

N e p h c l o m e t r y Measurement of serum Gc protein. . . 409

N e p h r o t i c s y n d r o m e Effects of recombinant interferon... 1189

N e u t r o p h i l s Adenovirus-mediated expression of. :. 725 Mechanism of the adhesion and migration,.. 1023 Increases in intracellular calcium... 1105 Apoptesis and phagocytosis of circulating... 1532

Nimodipine Nimodipine, a dihydropyridine-type... 548

N i t r a t e s Portal and systemic hemodynamic... 595 Combination therapy of ni trates. . , 597

N i t r i c o x i d e Bile flow

Nitric oxide stimulates bile f low.. . 834 Nitric oxide-induced choleresis... 836

Biosynthesis Resistance to murine hepatitis v i rus . . . 1024 Effects of long-term alcohol... 1412

Inflammation Differential effects of nitric oxide.. . 1015 Role of nitric oxide in the hepatic. . . !016 Metabolic effect of nitric oxide.. . 1017

Pathophysiology Improving hepatic hemodynamic a n d . . . 431 Kupffer cell induces hepatocyte... 484 Nitric oxide and tumor necrosis... 486 DNA strand break and fragmentation... 495 Vasodilatien to nerve stimulation... 603 L-erginine minimizes reperfusion... 1099 Mediator production and phagocyti~... 1199

Physiology A critical balance between endothelins... 567 Endothelium-derived hyperpolarizing... 570 Nitric oxide preferentially upregulates.. . . 793 Stimulation of nitric oxide production... 1018 Nitric oxide-dependant and -independent... 1287

N i t r i c o x i d e s y n t h a s e Antagonists and inhibitors

Differential effects of nitric oxide.. . 1015 Ursodeoxycholic acid inhibits induction... 1020 Inhibition of hepatic nitric oxide... 1329

Gene expression Transcriptional activation of inducible... 196 The role of inducible NO synthase... 199 Altered pulmonary expression of . . . 457 Regulation of inducible nitric oxide.. . 571

Pathophysiology Endothelinm-dependent vasoralaxation... 246 Nitric oxide synthase activity i s . . . 606 Lack of inducible NOS expression... 607 Distribution of inducible nitric... 1019

Nitrosamines Does a pigment stone diet promote,.. 1420 The effect of 2,2'-dihydroxy-di-n... 1421

N o r f l o x a c i n ...............................................

Characteristics of the infections... 239 Is norfloxacin prophylaxis against . . . 240

N o s o c o m i a l i n f e c t i o n s Molecular evidence for nosocomial... 957 De nero hepatitis C virus infection... 959 Repeated transmission of HCV from. . . 962

N u c l e a r m e m b r a n e Autoantibodles against inner nuclear.. , 65 Autoantibodies against nucleoporin... 1608

N u t r i t i o n a l s t a t u s Effect ofischemia/reperfusion on , . 1101

O

O b e s i t y Obesity and gallstones: is dietary. . . 26 Overweight risk factor of alceheHc... 557 Up-regulation of mitochondrial aspartato. . . 825 Prevalence and risk factors for . . . 1362 The effect of gender on gallbladder... 1581

O c t r e o t i d e Effect of octrsotide on endogenous... 222 Insulin resistance in cirrhosis... 527 Subcutaneous octreotide for t h e . . . 1210 Hemodynamie effects of octrsotide... 1501 Calcified liver metastases ofVipoma... 1526 Octreotide induces a negative water . . . 1595

O K T 3 OKT3 use associated with diminished... 104 FK 506 is as effective as OKT3 for. :. 148 incidence and outcome of OKT3 therapy. . . 1496

2 ' - 5 ' - O l i g o a d e n y l a t e s y n t h e t a s e Correlation of hepatitis C v i rus . . . 279 Analysis of the early phase response... 281 Activation of interferon system.. , 464

O n c o g e n e s abl gene

A novel abl.like gene associated... 329 bcl.2 gene

Immunolocaiization of bcl-2 and . . . 122 bcl-2 protects from lethal hepatic. . . 483 Modulation of apoptosis-asseciated... 487 Differential expression of bcl-2 ... 1184

erb genes ErbB3, the major hepatic heregniin... 794

fos gene Impaired IL-l[3-induced hypothalamic... 1028

jun gene Reperfusion after liver transplantation... 442 Growth inhibition of myofibroblast-like... 688 Stimulation of c-jun kinase by flbrenectin,.. 746 Heparitinase and heparinase induce.. . 1318

met gene A novel abl-like gene associated... 329 Expression of HGF and c-MET protein.. . 338 Inhibition of neoplastic development... 451 c-myc induction of hepatema cell . . . 485 Expression of c-met mRNA and TGF-pl . . . 504 Hcpatecyts growth facters-scattsr... 1027

myc gene Impaired liver regeneration in transgenic... 506 Analysis of prolonged exposure t o . . . 795

raf genes RAF and MAP kinase differentially... 743 Difference in activation of Raf/MEK... 1295

ras genes p53 and k-ras gene mutations i n . . . 156 ras-transduced diethylnitrceamine... 203 Inhibition of cell growth of human . . . 364 Role of signal transduction pathways . . . . 371

O r g a n d o n o r s Effects ofintracellalur pH a n d . . . 1428 Femur fracture trauma to donors... 1468 In vitro performance of livers : . . 1481

O r g a n p r e s e r v a t i o n Drug effects

Beneficial effects of pentexifyllins .... 1334 Graft function

Effects of fasting and glucose... 441 Association between hyalurenic acid . . . 1483

Hepatoeyte transplantation Controlled rate freezing of hepatocytes.. 420

Hyperosmotic stress In vitro performance of l ivers . . . 1481

Injury Impact of preservation injury o n . . . 402

Intracellular pH Effects ofintracellular pH a n d . . . 1428

lschemia.reperfusion injury Loss of endothelial cell ecto-ATP... 437 Heat-shock protein 70 gane expression.. 445

O r g a n p r e s e r v a t i o n , c o l d s t o r a g e Extended cold ischaemia is not associated... 129 Donor organ cold ischemia time and... 191 Hepatic reperfusion damage af ter . . . 444 Effect of calcium channel blockers... 446 Improvement of liver graft viability... 1182 Effect ofischemic preconditioning... 1203 Cold preservation sensitizes hepatocytss... 1598

O r g a n i c a n i o n t r a n s p o r t e r Acetaminophen

Acetaminophan glucuranide transport. . . 817 Genetics

Expression in Xenopus laevis oocytes... 751 Cloning of a liver-specific MRP. . . 753 Expression and localization of t h e . . . 754 Sex differences and hormonal regulation... 824

Localization Localization of the multidrug resistance... 822

Multidrug resistance Multiple carriers involved in t h e . . . 812

O r g a n i c a n i o n t r a n s p o r t e r ( c o n t i n u e d )

Physiology Alteration of GSH homeostasis i n . . . 524 Polyspecifie steroid and drug transport. . . 530 Bile acid uptake in human hepateblastoma... 750 Differential processing of an organic.. . 823 Functional identification of carrier . . . 826

O r n i t h i n e d e c a r b o x y l a s e Novel ornithine decurboxylase protein.. . 1565

O s m o t i c p r e s s u r e Increased colloid osmotic pressure. . . 233

O s t e o p e n i a Cyclical etidronate versus sodium.. . 76

O s t e o p o r o s i s Vitamin D receptor polymorphisms... 731

O u t c o m e s r e s e a r c h Hepatitis C

Meta-analysis of interferon randomized... 28 Long-term course of IFN 2b t rea tment . . . 306 Prevalence and natural history o f . . . 960 Clinical experience with hepatitis. . . 963 Outcomes of heart transplant recipients... 964

Hepatocellular carcinoma Meta-analysis of medical t reatments. . . 1394

Hepatotoxieity Improved outcome from severe. . . 1110

Intrahepatic cholestasis Ursodeoxycholic acid therapy i n . . . 845

Liver transplantation The effects of postoperative complications... 140 Strategies for prevention of dea th . . . 877

O x i d a t i v e i n j u r y SEEALSO Free radicals; Hepatocellular,

Ischemia-reperfuslon injury Cell physiology

Bifunctional effect of tumor necrosis... 523 Gene expression of the antloxidants... 1082

Chemoembolization Changes in serum lipid peroxide... 1304

Cyclosporine Interactions of cyclosporine A a n d . . . 1104

Mitochondria Cocaine-induced hepatic injury i n . . . 1085

Pathophysiology c-myc induction of hepatoma cell . . . 485 Oxidation of DNA and proteins i n . . . 539 Glutathione as an important antioxidant... 564 Induction of human hepatic bi le . . . 777 Role of mitochondrlal free calcium... 1083 Generation of hydrogen peroxide... 1084 4-hydroxy-2,3-nonenal produc~on... 1463

Prevention Folyenylphosphatidylcholine decreases... 475 Fructose and other iron-chelating . . . . . 1081 Effects of vitamin E, ascerbic ac id . . . 1617

Stellate cells Activation of hepatic stenats cells. . . 748 Catalase inhibits collagen synthesis.. . 749

O x y g e n SEEALSO Free radicals Is oxygen tension a modulator o f . . . 458 Oxygen modulates the glucagon-dependent... 772 Oxygen regulates the expression... 774 Response to 100% inspired oxygen.. . 1339 Activation of Kupffer cells by a . . . 1631

P

P - g l y c o p r o t e i n SEEALSO MDR genes; Multidrug resistance Immunohistochemicai study on expression... 335 Localization of the multidrug resistance... 822 Bile canalicular vesicles are markedly : . . 840 Regulation of MDR2 P-glycoprotsin... 864 Biological signficance of P-glycopretoin... 1563

p 1 5 t u m o r s u p p r e s s o r g e n e Expression and regulation of p53 . . . " 334 Regulation of the p21/WAF1/CIP1/SDI1... 519 Cyclin-depandent kinase 4 inhibitors... 1205

p53 t u m o r s u p p r e s s o r g e n e Antagonists and inhibitors

Sodium butyrate reversibly blocks.. . 507 Antibody to

Antibodies to mutant p53 in cirrhotic... 1545 Cholangiocareinoma

Genetic mechanisms of tumorigenesis ~.. 13 p53 and k-ras gene mutations i n . . . 156

HEPATOLOGY Vol. 22, No. 4, P t . 2, 1995 S U B J E C T I N D E X 563A

p 5 3 t u m o r s u p p r e s s o r g e n e ( c o n t i n u e d )

Cyclins Possible mechanism of cyclin A . . . 337

Diagnostic use Ki-67 and p53 immunostalning methods. . . 323

DNA binding proteins Identification of proteins f rom. . , 330

Hepatitis C HCV proteins do not bind p53 o r . . . 350

Hepatocellular carcinoma p53 and Fas/APO-1 induction in hepatema. . . 200 p53 status, pX induced cell cycle.. . 202 p53 abnormalities in hepatecellular... 332 Sequence-specific transcriptional... 333 Expression and regulation of p53 . . . 334 Immunohistochemieal study on expression... 335 The clinicepathelogical study o f . . . 1307

Transfection Reeonstitution of wild-type p53 . . . 331

P a l m i t a t e s Lipid turnover in alcoholics before. . . 1291

P a n c r e a s The pancreas produces a-hydroxyethyl.. 549

P a n c r e a t i c c a n c e r Staging laparoscopy with laparoscopic.. 2 Spiral computed angiography for . . . 154

P a n c r e a t i c o d u o d e n e c t o m y Pancreatico-duodenectomy in patients.. 163

Pancreatitis Fs-isoprostane excretion in human... 12

Paracentesis SEE ALSO Ascites Reduction of esophageal variceal . . . 195 Sympathoadrenergic deactivation... 223 Comparison of the Caldwell Needle. . . 224 Hemodynamic changes in pat ients . . . 225 Increased colloid osmotic pressure. . . 233 Comparison of albumin, dextran-70... 456 TIPS and paracentesis for the t reatment , . . 762 Aminoacids subtraction by paracentesis... 1217 Effect of abdominal parasentesis.. . 1543

P a r k i n s o n d i s e a s e Parklnson's disease: a new r i sk . . . 1406

P a r v o v i r u s B19 Parvovirus B19 as a possible cause . . . 1351

P e d i a t r i c l i v e r d i s e a s e Autoimmune chronic active hepatitis

Validation of a scoring system for . . . 1470 Biliary atresia Hepatic artery resistance index... 11 Correlation of plasma fatty acid... 1221

Food allergy Life-threatening food allergy i n . . . 1345

Hemophil ia Safety and utility of percutaneous... 679

Hepatitis B vaccines Effect of a nationwide hepatitis, . . 468 Immunogenicity of alternative hepatitis. . . 1177

Hepatit is B, chronic Core gene heterogeneity in HBV-DNA... 640 Lymphoblasteid interferon-a... 879

Hepatitis C Interferon-alfa therapy of chronic... 39 Hepatitis C virus genotypes in se rum. . . 954 Different nucieotide diversity a n d . . . 955 Mother-te-child transmission o f . . . 967 Mother to infant transmission o f . . . 968

Hepatitis D Genotypic analysis and variability... 308

Hepatitis E Acute HEV infection in Egyptian. . . 305

Hepatitis, viral Acute hepatitis in western Amazon.. . 1252

Hepatocellular carcinoma Expression and regulation of p53... 334

Intrahepat ic cholestasis Case report: recurrence of progressive... 401 Ursodeoxycholic acid therapy i n . . . 845

Leukemia Prevalence and natural history of . . . 960

Liver transplantat ion Comparative study of pharmaeokinetic... 147 Serum lipid levels in pediatric.. . 393 Cryo-preserved vein graft failures. . . 403 Outcome of liver transplantation... 407 Progress in paediatric l iver . . . 1116 Biliary complications in 150 l iving. . . 1224 Minimal preservation-reperfusion... 1225 Hepatic hemodynamice in living related. . . 1395

P e d i a t r i c l i v e r d i s e a s e ( c o n t i n u e d ) Porphyrias

Hematin therapy in children wi th . . . 1075 Portal hypertension Surgical portosystemic shunt in... 153

Tyrosinemia Improvement in liver function and.., i076

Penciclovir Inhibitory effect of penciclovir.,. 890

Pentoxifylline Pentexifylline inhibits the proliferation... 695 Effect of PDGF, pentexifynine and. •. 696 Effect of pentoxifynine in a heteralogoas... 1292 Beneficial effects of pentexifTlline... 1334 Effects of simvastatin, pentexyfynine.,. 1440 Fibroproliferation in swine a n d . . . 1472 Role of adenosine receptors in t he . . . 1473

P e p t i d o g l y c a n - p o l y s a c c h a r i d e In vice IL-10 treatment suppresses . . . 1029 Gadolinium prevents hepatic granulomas... 1366

P e r i p h e r a l n e u r o p a t h y Peripheral neuropathy related t o . . . 1495

P e r o x i s o m e s Antibodies to ~nnor necrosis facter-c~... 362 Hepatic acinar expression of t he . . . 786 Clofibrate reduces bile acid synthesis,.. 860 Proliferation of hepatic lysosomes... 1067

P e t r o c h e m i c a l w o r k e r s Hepatic changes in workers f rom. . . 1196

P h e n o b a r b i t a l Intraeelinlar cascade controlling... 779

P h e n p r o c o u m o n Phenprocoumon for prevention of . . . 594 Phenproceumon-induced cirrhosis... 1549

P h e n y l e p h r i n e Glycine blocks the increase in intracellular... 864

P h l e b o t o m y Phlebotomy followed by u-interferon... 51 Randomized controlled trial of t he . . . 295 Hepatic stellate cell activation... 691

P h o s p h a t e s Assessment of in vivo hepatic.. . 68

P h o s p h a t i d i c a c i d s MAP kinase and lipid-derived signal. . . 693

P h o s p h a t i d y l c h o l i u e The effect of alteration of fa t ty . , . 17 Mechanisms whereby a synthetic... 361 Polyenylphosphatidylcholine decreases... 475 The bile canalicular membrane contains... 755 In vitro evidence that sterol.. . 756 Expression of a non-MDR2 coded l iver . . . 820 The effect of alteration of lecithin... 1548

P h o s p h a t i d y l i n o s i t o l Involvement of phosphatidylinositol... 809 Activation of phesphatidylinositel... 1513

P h o s p h o e n o l p y r u v a t e c a r b o x y k i n a s e s

Identification of cell.volume-responsive... 771 Oxygen modulates the glucagan-dependent... 772 Cloning of the human mitochondrial... 773 Oxygen regulates the expression... 774

P h o s p h o l i p a s e D Mechanisms whereby a synthetic.., 361

P h o s p h o l i p i d s Hepatic and gallbladder acyl-CoA... 16 Demonstration and part ial . . . 791 Bile caualicular vesicles are markedly. . . 840 Rapid and sustained decrease i n . . . 1614

P h o s p h o p r o t e i n p h o s p h a t a s e s Protein phosphatase 2A-mediated... 806

P h y l l a n t h u s a m a r u s Phyllanthus amarus interferes... 647

P I V K A - I I Clinicopathological significance... 322

P l a n t sterols Hepatic transport of unesterified... 534 Preferential sterol transport f rom. . . 536

P l a s m a The role of plasma in the disturbance... 802

P l a s m a p h e r e s i s Plasmapheresis in patients wi th . . . 1411

P l a s m i n o g e n a c t i v a t o r s Interferon increases extracellular,.. 685

Plasmodium falciparum Identification of human liver carboxyl... 733

P l a t e l e t - d e r i v e d g r o w t h f a c t o r Interferon-7-mediatod activation,.. 681 Effect of PDGF, pentexifylline a n d . . . 696 Role of platelet-derived growth. . . 697 Receptor tyresine kinase expression... 745

P l a t e l e t s Loss of endothelial cell ect~ATP.. , 437 The role of plasma in the disturbance... 802 Age and platelets: a simple index... 1486 Platelet concentrates have a very.., 1515

Pneumocystis carinii Detection of Pneumocystis carinii . . . 1312

Polyamines Allograft rejection and lack of . . . 1502

P o l y m e r a s e c h a i n r e a c t i o n Comparison of branched DNA probe . . . . 286 Low production of HBV and HCV i n . . . 639 Evaluation of two methods for . . . 1000 Comparison of two quantitative HCV. . . 1001 Quantitative detection of HCV RNA.. . 1002 Comparison of three PCR-based... 1003 Analytical evaluation of the Amplicor TM ... 1004 RIBA-3 or PCR as a complementary... 1005 Evaluation of Roche Amplicor HCV. . . 1235 Comparison ofHCV RNA levels b y . . . 1453 Comparative evaluation of HCV viremia . , . 1456 Comparison of two quantitative.,. 1500 Quantitative HCV RNA levels by PCR. . . 1571 Evaluation of the Amplicer HCV RNA.. . 1576 Interest of the in situ hybridization... 1600 Detection of hepatitis C virus using .... 1622

P o r p h y r i a s Follow-up after liver transplantation... 173 HCV type lb in patients with chronic... 976 Hematin therapy in children wi th . . . 1075 Estrogen and antioxidants i n . . . 1086

P o r t a l c i r c u l a t i o n Portal flow after orthotepic l iver . . . 132 Reproducibility of Doppler sonographic,.. 576 Actions of carvedilal, a vasodilating.,. 598 Study of qxepatotropkic" substances... 1363 Pcostaglandins and coagulation a n d . . . 1445 Ursodeoxycholic acid treatment augments. . . 1517

P o r t a l h y p e r t e n s i o n Drug effects

The calcium channel activator, Bay . . . 247 Clinical versus hemodynamic response... 596 Effects of simvastatin, pentexyfylline... 1440 Hemodynamic effects of octreotide... 1501

Esophageal varices Ursodeoxycholic acid delays t h e . . . 75 Propranolol does not decrease t h e . . . 193 Reduction of esophageal variceal. . . 195 Endoscopic sclerotherapy versus . . . 577 TIPSS versus variceal band ligntion... 578 Meta-analysis of endoscopic ligation... 530 Meta-analysis of propranolol p lus . . . 562 Prophylactic endoscopic variceal. . . 579 High resolution endoluminal sonography... 587 Efficacy of TIPS in the prevention... 759 TIPS versus scierotherapy + propranolol... 761 Hemodynamic effects of octreotide . . . . 1501 Daily modifications of splanchnic... 1541

Experimental models The role of inducible NO synthase. . . 199 Endothelium-dependent vasorelaxatien... 246 Combination therapy of ni trates. . . 597 Peripheral endotexemia and hyperdynamic... 601 Lack of inducible NOS expression... 607 The presence of blood in the stomach.. . 611 Levels of tumor necrosis fastor-a. . . 1401

Magnetic resonance spectroscopy In vitro proton (1H) magnetic. . . 1310

Pathophysiology Circulating tumor necrosis factor-~... 599 Vasodilation to nerve stimulation... 603 The effects of somatestatin on gastric... 612 Subcutaneous octreotide for the... 1210 Evaluation of mucosal blood flow... 1259 Nitric oxide-dependent and -independent... 1287 Inhibition of hepatic nitric oxide... 1329 Pathogenesis of portal hypertensive... 1479 Portal hypertension and black gallstone... 1507

Pediatric Surgical portosystemic shunt in.,, 153

Portal pressure Spontaneous reduction of portal... 194 The portal pressure-reducing effect... 197 Prolonged increase of portal pressure... 572 Effect of substance P and its receptor.. . 605 The presence of blood in the stomach.. . 611 Surgical resection of hepatecellular,.. 1164 Reduction of increased portal pressure. . . 1297

564A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1995

P o r t a l v e i n s The site of vascular obstruction... Outcome of TIPS in non-cavernomateus... Surgical resection of hepatocellular... Portal vein thrombosis in cirrhosis... Poor prognosis and limited therapeutic...

Portasystemic shunt Surgical portosystemic shunt in... Portacaval anastomosis results in .... Evidence that increased alcohol... Disruption of circadian locomotor... "Piggy-back" liver transplantation... Altered asialoglyceprotein receptor... CA 19-9 is not a reliable test in... Stability of cerebral perfusion...

Positron emission tomography Technical failures of cryosurgically... Utility and cost effectiveness of...

Posture The effect of posture on central... Systemic and regional hemodynamic...

Potassium channels Apoptesis, electrolyte transport... Choleretic action of giibenelamide...

Pravastatin Hyperlipidemia following liver transplant...

Predictors of response, interferon therapy

Acute hepatic fai lure Measurement of serum Ge protein. . .

Analysis Predictors of response to a lpha . . . Predictive factors of response t o . . . Does hepatitis C viral genotype.. .

Anti-HCV core antibodies Anti-HCV core antibody levels correspond...

Antibody formation E 1 antibody level monitoring predicts.. . Antibody response to hypervariable... Poor correlation of hepatitis activity... Prognosis of long-term resolvement... Significance of in vitro immunoglobniin...

Aspartate aminotransferase Serum aspartate aminotransferase..

Autoantibodies The development of auteantibodies...

Cirrhosis Cirrhosis doesn't influence response.. .

Cytohine profiles Disproportional secretion of IL-1 . . .

Hepatit is B, chronic HBV marker kinetics during therapy. . .

Hepatit is C virus density Differential flotation centrifugation...

Hepatit is C virus genome The mutual effect of genetic heterogeneity...

Hepatit is C virus genotypes Predictors of sustained response.. . Predictors of sustained biochemical... HCV genotype and serum 99K levels . . . Prognostic value of hepatitis C . . .

Hepatit is C virus RNA Identification of factors predicting. J. Loss ofHCV RNA at week 2 interferon... Early loss of minus HCV RNA st rand. . . Comparison of branched DNA probe. . . HCV RNA quantitatian using RT-PCR... Hepatic HCV-RNA does predict long-term... Prognostic markers for the response.. . Serial quantitative analysis o f . . . HCV genotypes and viremia in predicting. Comparison of HCV RNA levels b y . . . HCV RNA levels measured with a n . . . Predictive value of the detection... Evaluation of the Amplicor HCV RNA.. .

Hepatit is C, recurrent Features of relapse after a lpha . . .

Hepatit is D Interrelation between HBV, HDV a n d . . .

Interferon a receptor Correlation of hepatitis C v i rus . . .

Interferon, endogenous Resistance to interferon t reatment . . .

Interleukin-2 receptors Changes in serum soluble interleukin-2..

Interleukin-lO Serum levels of IL-10 and s-ICAM-1...

Iron The role of iron indices in predicting... Histology and hepatic iron content. . .

Liver transplantat ion Pretransplant body fat wasting predicts..

585 589

1164 1181 1380

153 215 220 221 390

1194 1441 1560

4 164

228 1155

482 837

392

409

271 272 278

1370

740 898 993 994

1505

664

262

1466

1118

884

289

253

274 275 276

1014

273 283 285 286 287 288

1154 1228

• 1288 1453 1454 1528 1576

1149

1386

279

742

919

741

296 737

396

P r e d i c t o r s o f r e s p o n s e , i n t e r f e r o n t h e r a p y ( c o n t i n u e d )

Meta.analysis Treatment of chronic NANB and C...

Platelets Age and platelets: a simple index•..

Primary biliary cirrhosis Predictors of unfavorable outcome...

Procollagen Evaluation of hepatic fibrogenesis...

VCAM.1 Serum levels of soluble vascular. . .

Viral replication "Breakthrough" during interferon...

Zinc Influence of serum zinc level t o . . .

P r e d n i s o n e Soluble intercellular adhesion molecule...

P r e g n a n c y Pregnancy and liver graft survival... Outcomes of multiple pregnancies... Increased Na+/taurecholate... Intrahepatic cholestasis of pregnancy... Prospective study of exogenous factors...

Primaquine Selective delivery of primaquine.,.

Primary biliary cirrhosis Apoptosis

Nuclear DNA fragmentation in biliary.. . Medium term treatment of PBC with... Immunohistechemical study of Fas...

Autoimmunity Characterization ofintrahepatic... Auteantibedies against inner nuclear... Overlap between type I auteimmune... Genetic predispositions for immunologic... Cyclin A as molecular target of ... IgG and IgG3 levels of anti-M2... Auteantlbodies against nucleoporin...

Bile acid transport Uptake of bile acids by isolated...

Bone density Cyclical etidronate versus sodium... Does long-term calcitenin, calcium... Vitamin D receptor polymorphisms...

CD4+ T cells Cytokine responses to PPD in primary. . .

Diagnosis In situ detection of marker proteins...

Disease severity Auteantibody against a heat shock...

Drug effects Retention of a bile acid analogue... Reduced expression of heat shock...

Drug therapy Methotrexate therapy of pr imary. . . Two year histelogic follow-up of . . . Soluble intercellular adhesion molecule... Predictors of unfavorable outcome... Increase oflipocyte number and...

Eosinophils Serum eosinophil granule-associated...

Ep idemiology Temporal and geographical variations...

Esophageal varices Ursodeoxycholic acid delays t he . . .

Genetics Increased expression of E251 i n . . .

ICAM-1 Pathogenetic origin of soluble ICAM-1...

Immunology Expression of E-ssiectin and E-selectin... Cloning of the variable regions.. . Antibodies against adhesion molecules... Analysis of the T cell antigen receptor...

Liver transplantation Calcitenin therapy does not prevent. . . Selection and timing of l iver . . . Prediction of acute rejection i n . . .

Magnetic resonance spectroscopy Assessment of in vice hepatic. . .

MDR3 gene Intrahepatic MDR3 P-giycoprotein...

Pathophysiology Histological course of primary biliary... Hypercoagulability in patients with... Plasma camitine pool and carnitine...

Portal vein thrombosis The site of vascalar obstruction...

Quality o f life Fatigue and quality of life in primary. . .

P r o c o l l a g e n Extracellular matrix proteins i n . . . 324 How are capsule and septum formed.. . 370

185 New prolyl 4-hydroxylase intdbiter.. . 694 Pentexifylline inhibits the proliferation... 695

1486 TNF-a stimulates a l ( I ) . . . 701 '~Deactivation" of activated.. . 703 Inhibition of rat Ite cell activation... 705

74 Heterogeneity of procoilagen types . . . 708 Elevated procollagen-III-peptide... 1433

1 4 9 7 Evaluation of hepatic fibregenesis... 1497 Significance of anti-HCV-core IgM. . . 1498

251 Interferon gamma treatment inhibits. . . 1506

31 Progesterone Prospective study of exogenous factors.. . 1138

1 3 4 1 P r o l i f e r a t i n g c e l l n u c l e a r a n t i g e n Differential expression of Bcl-2... 1184

72 P r o | y ] 4 - h y d r o x y l a s e Mechanism of action of HOE077.. . 689 New prolyl 4-hydrexylase inhibiter.. . 694

136 171 Promoters 852 Albumin

1115 Control of albumin gene expression... 784 1138 Aldehyde dehydrogenase

Functional analysis of 5' regulatery. . . 775 1 0 7 9 Collagen

Recognition of two Spl binding si tes . . . 699 Cyelin A

Possible mechanism of cyelin A . . . 337 58 Hepatitis B core antigen 71 HBV core promoter mutations cause . . . 614

1327 Absence Of unique HBV mutation i n . . . 615 Hepatitis B virus core promoter. . . 616

61 Hepatitis B virus mutations associated... 1529 65 Hepatitis C virus 90 Targeted inhibition of HCV promoter. . . 895

1 1 9 8 Laminin 1554 1593 A silencer element in the LAMC1... 782 1 6 0 8 Na-bUe acid eotransporter

Bile acids suppress the rat l iver . . . 847 1 5 1 1 Phosphoenolpyruvate carboxykinases

Identification of cen-volume-respansive... 771 76 Oxygen modulates the glucagon-dependent... 772 77 Procollagen

731 TNF-a stimulates a l ( I ) . . . 701 Retroviruses

62 Development of a novel retroviral. . . 360 UDP-glucuronosyltransferase

57 Persistent unconjugated hyperbilirubin... 397 Effect of butylated hydroxyteluene... 781

64 P r o p o x y p h e n e Liver and intestinal propoxyphene... 561

1212 Propranolol 1508 Propranolol does not decrease t h e . . . 193

Meta-analysis of propranolol p lus . . . 582 69 Portal and systemic hemodynamic... 595 70 Clinical versus hemodynamic response.. . 596 72 TIPS versus sclerotherapy + propranolol... 761 74 Characterization of the human Na +. .. 851

1 1 7 1 Propranolol elimination by r igh t . . . 1494

63 P r o s t a g l a n d i n s Fs-iSoprostane excretion in human . . . 12 Prosteglandin E1 stimulates mucin . . . 15

1109 Increased circulating Fs-isoprostanes... 554 Molecular cloning, expression a n d . . . 789

75 Glycine blocks the increase in intracellular... 804 Effects of lipopolysaccharide toxin. . . 1041

67 Prostaglandin E 1 for severe, ea r ly . . . 1331 Prostaglandius and coagulation a n d . . . 1445

60 P r o t e i n k i n a s e s Reperfusion after liver transplantation... 442

59 Protein kinase C activation/cellular... 531 66 Nitric oxide preferentially upregulates.. . 793

1 3 2 6 Tauroursodeoxycholic acid activates.. . 861 1474 The mechanism of serum amyloid A . . . 1042

P r o t e i n r e s t r i c t i o n 1282 Changes in proliferative and eytotoxie... 1137 1489 1493 P r u r i t u s

Pruritus in chronic hepatitis C . . . 975 68 Chronic cholestatic hepatitis C . . . 980

P u l m o n a r y a r t e r i o v e n o u s s h u n t i n g 1 2 2 2 Intrapulmonary shunting complicating... 1407

P u r i n e n u c l e o s i d e s 73 The role of liver Na÷/purine nucleceide... 827 78

1 3 3 6 P y o v e r d i n s Inhibition of iron toxicity in human . . . 1088

585 P y r u v a t e d e h y d r o g e n a s e In situ detection of marker proteins.. . 57

6 Characterization of intrahepatic... 61

HEPATOLOGY Vol. 22 , N o . 4, P t . 2, 1 9 9 5 S U B J E C T I N D E X 565A

QR

Q u a l i t y o f l i f e Fatigue and quality of life in p r imary . . . The effects of postoperative complications.

R a c i a l d i f f e r e n c e s Race is not a critical factor i n . . .

R a d i o n u c l i d e i m a g i n g The impact of spleen volume on sulfur . . .

R a d i o t h e r a p y Percutaneous intratumoral injection. . .

r a f genes RAF and MAP kinase differentially.. . Difference in activation of Raf/MEK.. .

R A G g e n e s RAG1, RAG2 and TdT expression i n . . .

R a p a m y c i n Comparison of systemic and local...

r a s g e n e s p53 and k-ras gene mutations i n . , . ras-transduced diethy]nitrosamine.. . Inhibition of cell growth of h u m a n . . . Role of signal transduction pa thways . . .

R e c e p t o r s Adenosine

Mechanism of extraceliular ATP-indured. Role of adenosine receptors in t he . .

Adrenergic Attenuation of cardiac ~-adrenergic.. .

Asialoglycoproteins A novel mRNA cis-acting e lement . . . Altered asialoglycoprotein receptor . . . Significance of auteantibodies i n . . .

Benzodiazepines A high-affinity peripheral benzo . . .

Dopamine The D2 dopamine receptor A1 al le le . . .

Endothelins Nitric oxide preferentially upregniates . . .

Endotoxin Different receptors for endotoxin. . .

Epidermal growth factor Analysis of prolonged exposure t o . . . Autephosphorylation of the epidermal . . .

Estrogens Variant liver estrogen receptor . . , Treatment with tamoxifen in pa t i en t s . . .

Fab Association of anti-Fab auteantibodies. . .

Glucocorticoids A novel c/s-acting element i n . . .

Hepatocyte growth factor Immunolocalization of bcl-2 a n d . . .

Heregulin ErbB3, the major hepatic heregul in . . .

Hyaluronie acid Hyaluronic acid binding abi l i ty . . . Expression of the cell adhes ion. . .

IGF-I Differential gene expression o f . . .

IGF-II Distribution of insulin-like g rowth . . .

lntegrins Expression and function ofintegrin...

Interferon a Correlation of hepatitis C v i r u s . . . Quantitative analysis of interferon. . .

lnterleukin-2 Changes in serum soluble interleukin-2..

Interleuhin-6 The soluble IL-6 receptor amplif ies. . .

/Ps Calcium and IPs regulate the calcium..

Lipoproteins Increasing hepatic cholesterol 7 a . . .

Muscar inic Cardiac contractility and muscarinic. .

Platelet-derived growth factor Role of platelet-derived g rowth . . . Receptor tyrosine kinase expression.. .

Prostaglandin F 2 Molecular cloning, expression and...

Purinergic Improving hepatic hemodynamic a n d . . Cloning, functional characterization.. . Modulation of intracellular ca lc ium. . .

Retinoie acid Induction of retinoic acid receptor. .

6 140

142

1293

356

743 1295

79

1286

156 203

3 6 4 371

830 1473

244

788 1194 1579

1354

556

793

1405

795 1439

336 1191

263

778

122

794

1564 1606

340

712

1047

279 918

919

1032

800

532

243

697 745

789

431 79O 801

792

R e c e p t o r s ( c o n t i n u e d ) Secretin

Bile acids modulate proliferative... 865 T cells Restriction of V beta gene usage... 633 Analysis of the T cell antigen receptor... 1474

Thrombin Upregulated expression of h u m a n , . . 683

Transferrin al-antitrypsin reduces t ransfercin. , . 1044 Localisation of ferritin, transferrin.,, 1143

Transforming growth factor [~ Transgenic mice expressing a Z n . . . 205 Characterization of TGF- ~ 1 . . . 1245 Cytokine mediated regulation o f . . . 1607

Tumor necrosis factor a Correlation of serial cytokine levels . . . 1038

Tyrosine kinases Receptor tyrosine kinase expression.. . 745

Vascular endothelial growth factor Differential expression of vascular . . . 511

Vi tamin D Vitamin D receptor polymorphisms... 731 Vitamin D receptor gene polymorpkism... 1267

R e n a l b l o o d f l o w Actions of carvedilol, a vasodilating.. . 598

R e n a l f a i l u r e Augmentin-induced hepate-renal fa i lure . . . 1173

R e n a l f u n c t i o n Circulating endothelin (ET)-I a n d . . : 231 Reduced filtration fraction a n d . . . 1163 The effect of renal dysfunction.. . 1313

R e n a l t r a n s p l a n t a t i o n Combined liver-kidney transplantat ion. . . 388 Chronic HCV infection in H D . . . 1175 In kidney graft recipients r ibavirine. . . 1187 Detection ofPneumocystis carinii.. : 1312 Immunologically negative hepat i t is . . . 1523

R e t i n o b l a s t o m a t u m o r s u p p r e s s o r g e n e

HCV proteins do not bind p53 o r . . . 350

R e t i n o i c a c i d Effects of dietary fat on ethanol-induced... 477 Diminished retinoic acid signaling... 715 Induction ofretinoic acid receptor... 792 Influence of all-trans and 9-cis . . . 1264

R e t r a n s p l a n t a t i o n Poor prognosis ofpatiente retransplanted. . . 113 Favourable clinical and H L A . . . 145 Outcome of liver retransplantation. . . 188

R e v e r s e t r a n s c r i p t a s e 2',3'-dideoxy-~-L-5'-fluorocytidine... 888 Inhibitory effect of penciclovir... 890

R e y e ' s s y n d r o m e Induction of the permeability t ransi t ion. . . 1106

R i b a v i r i n Two year course of ribavirin f o r . . . 48 A randomized controlled trial o f . . . 52 Combination treatment of a l p h a . . . 182 Effect of interferon and ribavirin . . . . 722 Hepatic iron deposition during r ibavir in . . . 736 Modulation of hepatitis C v i ru s . . . 738 In kidney graft recipients r ibavir ine. , . 1187

R i b o n u c l e o p r o t e i n s Inhibition of protein synthesis . . . 700 Pest-transcriptional regulat ion. . . 744

R i b o z y m e s SEE ALSO Gene therapy Three-dimensional models reveal . . . 309 Multimeric self-cleaving ribozyme.. . 474 Inhibition of hepatitis C virus-directed... 896 Study on the cDNA synthesis a n d . . . 1602

R N A Three-dimensional models revea l . . . 309 Comparison of glyceraldehyde-3-phosphate... 344 Multimeric self-cleaving ribozyme.. . 474 A novel mRNA cis-acting element . . . 788 Inhibition of hepatitis C virus-directed... 896 Study on the cDNA synthesis a n d . . . 1602

R o t a v i r u s e s Immunohistechemical studies o f . . . 1408

S

S a l i c y l a t e s Induction of the permeability t ransi t ion. . . 1106 The acute phase protein a lpha-1 . . . 1487

S a l m o n e l l a h e p a t i t i s Salmonella hepatitis: analysis o f . . . 312

S a r c o m a Liver resection for metastatic sarcomas. . . 1375 Liver resection for primary sarcomas. . . 1376

S C I D m i c e Hepatic metastasis of hnm~n colorectal. . . 373

S c l e r o s i n g c h o l a n g i t i s Diagnosis

Detection of antineutrophil cytoplasmic.. . 1140 ERCP

ERCP for primary sclarosing cholangit is . . . 9 Immunology

Are bile duct epithelial cells capable . . . 10 Genetic predispositions for immunologic.. . 1108 Immunization of mice with carbonic. . . 1261 Analysis of the T cell antigen receptor . . . 1474

Inflammatory bowel diseases Prevalence of primary sclerosing.. . 1480

Liver transplantation Antineutrophil cytoplasmic antibodies. . . 1139 Choledochocholedochostemy b i l i a ry . . . 1243 Calcitonin therapy does not p reven t . . . 1282 Prediction of acute rejection i n . . , 1493

Pathophysiology Hypercoagulability in patients with... 78 Pereral cholangioscopy after operations... 1333 Interferon-g~ mma production in primary... 1391

Therapy Management of primary sclerosing.., 3

Sclerotherapy SEE ALSO Varieeal bleeding; Varices, esophageal; Varlces, gastric Endoscopic sclerotherapy versus. . ~ 577 Prophylactic endoscopic variceal... 579 Meta-analysis of endoscopic l iga t ion . . . 580 Meta-analysis of propranolol p l u s . , . 582 TIPS versus sclerotherapy + propranolol . . . 761 MRI findings in chronic hepatic . . . 1289

S e c r e t i n Large but not small intrahepati c ... 211 Amiloride, but not DIDS and N P P B . . . 835 Bile acids modulate proliferative... 865

S e l e c t i n s Expression of E-selectin and F~selectin... 59 Endotoxemia induces E-selectin mRNA. . . 1037

S e p s i s SEE ALSO Endotoxin Human hepatecytes produce a f o rm . . . 83 Treatment with dietary sa tu ra ted . . . 476 Role of endothelin-1 in hepa t ic . . . 569 Nitric oxide-induced cholaresis. . . 836 Further insights into the role o f . . . 842 Stimulation of nitric oxide production... 1018 Endotexemia induces E-selectin mRNA... 1037 Kupffar cell pro-in0smmatery alterations... 1040 Leucine metabolism in liver of endotoxin... 1294 Early free serum Gc-globulin in... 1519 Circulating interleukin-10 levels . . , 1572

S e p t i c s h o c k Role of nitric oxide in the hepa t ic . . . 1016 Metabolic effect of nitric oxide . . . 1017 Release of soluble intercellular. . , 1021 Requirement of Thl-like l ive r . . . 1026

S e r i n e p r o t e i n a s e s Topoisomerase I inhibiters induce... 365

S i l i b i n i n Identification of the antifibrogenic.. . 718

S i m v a s t a t i n Effects of simvastatin, pentexyfyliine... 1440 HMG-CoA reductase inhibi ter . . . 1623

S i n g l e s t r a n d c o n f o r m a t i o n p o l y m o r p h i s m

Changes in genetic variability of. : . 255 Method for detection of epsflon-secendary,.. 654 Single-strand conformation polymorphism... 903 Rapid quasispecies analysis of the... 941

Sinusoidal endothelial cells Drug effects

Effect of calcium channel blockers. . . 446 Anticoagulant targeting endothelial... 575 Mannose-terminal glucocerehrosidase.., 1074 Effects of long-term alcohol . . . 1412

Pathophysiology Loss of endothelial cell ecto-ATP... 437 Chronic ethanol consumption impa i r s . . . 808 Liver endothelial cell dysfunction. . . 1022 Mechanism of the adhesion and migrat ion. . . 1023 Endotexemia induces E-selectin mRNA. . . 1037

566A SUBJECT INDEX HEPATOLOGY October 1995

Sinusoidal endothel ia l cel ls (continued)

Physiology Effective antigen presentation and : . . 81 Differential expression of vascular . . . 511 Heterogeneity of procollagen types . . . 708 Modulation ofintracellniar calcium... 801 Stimulation of nitric oxide production... 1018 Hyaluronic acid binding ability,. . 1564

Sinusoidal epithelium Perisinusoidal cell activation... 315 Polypeptide growth factors participate... 367 Apoptosis and phagocytosis of circulating. 1532

SjTgren's syndrome Prospective study of primary SjSgren... 984

Skeletal muscle metabo l i sm Severely disturbed hepatic and skeletal.. . 1335

Small bowel transplantat ion The pathology of the liver graf ts . . . 1582

Small in tes t ine The isoflavone genistein undergoes... 563 Identification of bilirubin UDP-GT.. . 819

Smooth muscle Altered intracellular signal transduction.. 245 Pathogenesis of TIPS stenosis... 593

Sodium SEEALSO Na-bile acid cotransporter;

Na-H exchange Effects of insulin on renal hemodynamics.. 227 The effect of posture on central . . . 228 Dissecting the factors involved.. . 229 Circulating endothelin (ET)-I a n d . . . 231 Elevated levels of natriuretic hormones.. . 1465

Somatos ta t in The effects of seumtostatin on gastric. . . 612

SPECT Single-photen emission computed... 381

Spermatozoa Absence of detectable HCV RNA i n . . . 1013

Sphinc tero tomy Peroral cholangloscopy after operations... 1333

Spironolactone Combination therapy of ni trates. . . 597 Effects of simvastatin, pentoxyfylline... 1440

Splanchnic blood f low The presence of blood in the stomach.. . 611 Daily modifications of splanchnic... 1541

Spleen Rapid formation of donor cel l . . . 1136 Precipitating antibodies to splenic... 1176 The impact of spleen volume on sulfur . . . 1293

Splenorenal shunt Conversion of failed transjugular. . . 160 Transgastric collateral vessels. . . 583

Spontaneous bacteria l per i toni t i s DNA fingerprinting demonstrates... 237 Intestinal bacterial overgrowth... 238 Is norfioxacin prophylaxis against . . . 240 Selective intestinal decontamination... 1268 Spontaneous bacterial peritonitis... 1396

Staphylococcal enterotox in Decreased constitutive mucine. . . 559

Staphylococcus Staphylococcus epidermidis is a n . . . 399

Stellate cells SEE ALSO Fibrosis

Activation Effects of dietary fat on ethanol-induced... 477 Expression and potential role o f . . . 687 Hepatic stollate cell activation... 691 Activation of cultured hepatic stellato... 692 New prolyl 4-hydroxylase inhibitor.. 694 Inhibition of protein synthesis.. . 700 '°Deactivation" of activated.. . 703 Activation of fat-storing cells. . . 829 Intercellular adhesion molecule-1... 1045 Contraction of collagenous bands . . . 1046 Correlation between hepatic stellate. 1488

Alcohol liver disease Novel expression of a unique Ito... 711

Cell adhesion Expression and function ofintogrin. 1047

Cell culture techniques Reversal of activated lipocyte phenotype... 704

Cell differentiation Epimorphin localizes in Ito cells. . . 513 HGF transcription is under a cel l . . . 1279

Stellate cel ls (continued) Cell proliferation

MAP kinase and lipid-derived signal. . . 693 Role of platelet-derived growth. . . 697 Serum transforming growth factor. . . 1359

Cytokine effects Intexferon-y-mediated activation... 681 Studies on the fibrogenic potential.., 719 induction of transforming growth... 1226 Interferon gamma treatment inhibits... 1506 Cytokine mediated regulation of... 1607

Drug effects Mechanism of action of HOE977.. . 689 Effect of PDGF, pentoxifylline a n d . . . 696 Inhibition of rat Ito cell activation... 705 Tranilast may inhibit collagen production... 710 Inhibition of myofibroblastic... 714 Identification of the antifibrogenic... 718 Increase oflipocyte number a n d . . . 1171 Influence of all-trans and 9-cis... 1264 Acetaldehyde increases transforming... 1461

Genetics Cell-specific transcription of the 459 TNF-a stimulates a l ( I ) . . . 701 5 lipoxygenase inhibitor suppresses... 707 Post-transcriptional regulation... 744 Receptor tyrosine kinase expression... 745 Zig, a novel zinc finger gene induced... 747

Hormone effects Effect of adrenomedullin, a novel . . . 716

Iron overload Vitamin E suppresses lipocyte activation... 690 Molecular and cellular aspects o f . . . 1057

Liver regeneration Cellular localization of hepatocyte... 503

Oxidative injury Activation of hepatic stollate cells. . . 748 Catalase inifibits collagen synthesis... 749

Pathophysiology Endothelin antagonism in experimental... 460 Distribution of insulin-like growth. . . 712 Up-regulation of mitechondrial aspartato.. . 825 Fibronectin isoform gene expression... 1049 Desmin expressing cells during. . . 1323

Physiology Complement C4 protein gene expression... 713 Diminished retinoic acid signaling... 715 RAF and MAP kinase differentially... 743 Stimulation of c-jun kinase by fibranectin... 746 Expression of gelatinase A is increased... 1051 Membrane-type matrix metallo.. . 1052

Stents Prospective long-term follow-up... 8 Mechanism of early biliary s tent . . . 1381 Endoscopic stenting of gallbladder... 1535

Steroid 27-hydroxylase Regulation of storol 27-hydroxylase... 857 Coordinate regulation of storol... 858

Sterol carrier prote in 2 In vitro evidence that sterol. . . 756

Stomach Transgastric collateral vessels. . . 583

Streptokinase Thrombectomy and intraoperative... 1195

Stromelysin Stimulation of c-jun ldnase by fibronectin... 746

Substance P Effect of substance P and its receptor... 605

Superoxide dismutase Interferon therapy induces superoxide.,. 56

SV40 large T antigen [CaS÷]i responses during proliferation... 512

Sympathet ic nervous system Effects of insulin on renal hemodynamics... 227

Syp protein Cellular transformation induced... 509

T

T cells SEE ALSO Lymphocytes

CD30+ CD30-induction on T lymphocytes... 913

CD30+CD3+ Irnmunodominant hepatitis C virus... 916

Cell differentiation RAG1, RAG2 and TdT expression i n . . . 79

T cells (continued) Hepatitis C

Accumulation of HCV-core specific... 911 Cytokine expression and T-cell subset . . . 914 Relevance of ultrastructura] lymphocyte... 924

Hepatocellular injury Hypothyroidism inhibits experimentally... 1459

Lymphocyte activation Antigen independent activation of . . . 632 Changes in the activation s ta tus . . . 1197

T cell receptor Restriction of V beta gene usage. . . 633 Analysis of the T cell antigen receptor.. . 1474

T cells, CD4+ Cell proliferation

Effective antigen presentation a n d . . . 81 Human intrahepatic biliary epithelial... 435

Hepatitis C Lymphocyte phenotypes in chronic... 462 Viral clearance during acute hepatitis... 912 Chronic hepatitis C virus infection... 932

Liver transplantation, experimental Study of CD4 and CD8 level a n d . . . 1271

Primary biliary cirrhosis Cytokine responses to PPD in pr imary. . . 62

Thl Increased intrahepatic Thl cytokine... 461 Thl cytokine pattern and defective... 915 Requirement of Thl-like l iver . . . 1026

Thl/Th2 The role of THlfPH2 lymphocytes... 1025

Th2 Predominance of IL-4 mRNA expression... 440

T cells, CD8+ Cell differentiation

CD8~a T lymphocytos... 80 HBV vs. HCV infection

Comparative analysis of the cytotexic... 909 Hepatitis B

The cytotoxic T lymphocyte response,. . 456 Hepatitis C

Role of CD8* lymphocytes and natura l . . . 491 Defining the role of intrahepatic.. . 724 Molecular mapping of an intrahepatic.. . 906 The peripheral blood cytotoxic T . , . 997 Viral escape from the HLA-A2 restricted... 908 Hepatitis C virus-specific cytotoxlc... 910 Study of CD4 and CD8 level a n d . . . 1271

T tubes Diagnostic utility ofT-tube af ter . . . 1611

Tamoxifen Paradoxical effects of tamoxifen... 562 Treatment with tamoxifen in pat ients . . . 1191 Tamoxifen inhibits the growth o f . . . 1475

TAP genes Analysis of gene and protein expression... 372

Taurocholate SEEALSO Bile acids and salts Impairment of taurocholato-dependent... 443 The bile canalicular membrane contains... 755 Bile acids suppress the rat l iver . . . 847 Characterization of the human i leal . , , 848 Selectively increased translocation... 863 Bile acids modulate proliferative.., 865 Retention of a bile acid analogue... 1212

Taurolithocholate Coordinated calcium signals in rat... 798 Bile acid-induced increase in cell... 1233

Tauroursodeoxycholate Interferon-alpha and tauroursedeoxycholic... 53 Tauroursedeoxycholic acid for the... 54 Tauroursodeoxychofic acid activates... 861 S-odenosy]methionine versus ursodeoxy... 1153

Tenascin Tenascin is a serum marker oflobniar... 1050

Terlipressin Terlipressin in the treatment o f . . . 236 Terlipressin enhances free wa te r . , , 1591

Terminal deoxynucleotidyl- transferase

RAG1, RAG2 and TdT expression in. 79

Testosterone Effect of antlandrogen t reatment . . , 359

Tetracycline Development of a novel retroviral. . . 360 Tetracycline-regulated expression... 625

Thalassemia Infection with the novel GB-C virus. . 448

HEPATOLOGY Vol. 22, No. 4, Pt. 2, 1995 SUBJECT INDEX 567A

T h e r a p e u t i c E R C P Prospective long-term follow-up.,. 8 ERCP for primary sclerosing cholangit is . . . 9 Mechanism of early bfliary s t en t . . . 1381 Endoscopic stenting of gal lbladder. . . 1535

T h r o m b i n Upregulated expression of h u m a n . . . 683

T h r o m b o c y t o p e n i a Mechanisms of thromhocytepenia a f t e r . . . 123

T h r o m b o e l a s t o g r a p h y Hypercoagnlability in patients w i t h . . . 78

T h r o m b o m o d u l i n Serum level of thromhomodulin a n d . . . 1246

T h r o m b o p l a s t i n Anticoagulant targeting endothelial . . . 575 Different receptors for endoteain. . . 1405

T h r o m b o x a n e s Effect of thromboxane inhibi t ion. . . 545

T h y m i d i n e k i n a s e Development of a novel re t roviral . . . 360

T h y m u s g l a n d Rapid formation of donor ce l l . . . 1136

T h y r o i d g l a n d Autoimmunity and thyroid dysfunction. . . 978

Thyroid hormone Hepatscellular thyroid hormone efflux... 728

T i g h t junctions Experimental colitis increases hepatecyte . . . 769

T I P S SEE Trans jugular intrahepat ic

portasystemic shunt

T i s s u e i n h i b i t o r s o f m e t a l l o p r o t e i n a s e s

Cellular distribution of t i s sue . . . 342 Expression of metalloprotelnases.. . 1054 High TIMP-1 expression results i n . . . 1055 Expression of metalloproteinase.. . 1056

T o m o g r a p h y , c o m p u t e d Clinical features suggesting development.. . 1527 Hepatic cyst computed tomography. . . 1619

T o p o i s o m e r a s e s Identification of proteins f rom. . . 330 Topoisomerase I inhibitors induce . . . 365

T r a n i l a s t Tranilast may inhibit collagen production. . . 710

T r a n s c r i p t i o n f a c t o r s SEEALSO Gene expression', Promoters

AP-1 Reperfusion a t~ r liver t ransplantat ion. . . 442

Binding sites Functional analysis of 5' regula tory . . . 775

C-EBPa Hepatocyto cell lines are der ived. . . 201 Control of albumin gene expression.. . 784 Recombinant adenovirus-mediated... 785

Hepatitis B virus Generation of tetracyclin-inducible... 653

H3VF 1/HNF4 NF-xB binding is e levated. . . 783

~LAP Control of albumin gene expression.. . 784

NF.I Recognition of two Spl binding s i tes . . . 699

A/F-z/ / Thiol regulation of endotoxin-induced... 520 Glutathione suppression of endotexin. . . 522 Bifunctional effect of tumor necrosis . . . 523 TNF-a stimulates a l ( I ) . . . 701 Tissue transglutaminase gene expression.. . 702 NF-xB binding is e levated. . . 783 Liver endothelial cell dysfunction. . . 1022 Antioxidants suppress endotexin-inducod... 1034 In vivo suppression of Kupffer . , . 1035 LPS-mediated NF-xB act ivat ion. . . 1036 Endotoxemia induces E-salectin mRNA. . . 1037 Activation of nuclear factor-r,B... 1098 The acute phase protein a lpha-1 . . . 1487

Spl Recognition of two Spl binding s i tes . . . 699 A silencer element in the L A M C t . . . 782

STAT APRF, increased nuclear b ind ing . . . 515 Interferon-y-mediated act ivat ion. . . 681

Zinc fingers Zf9, a novel zinc finger gene induced . . . 747 Expression of metallopanstimulin.. . 1248

T r a n s f e c t i o n SEEAL80 Gene therapy

Alpha fetoproteins Gene therapy ofhepatocellular carcinoma.. . 206

C-EBPa Recombinant adenovtrus-mediated... 785

Hems oxygenase Regulation of human hems oxygsnase-1.. . 776

Immunology Adenovirus-mediatsd expression o f . . . 725 Gene therapy studies in non-human. . . 1080 Characterization of TGF-~I . . . 1245

Insulin receptor substrate.1 Cellular transformation induced. . . 509

Na-bile acid cotransporter Bile acids suppress the rat l iver . . . 847 Expression of the human Na÷-dependent... 849 Characterization of the human Na ÷ . . . 851

p53 tumor suppressor gene Roconstitution of wild-type p 5 3 . . . 331

ras genes ras-transducod diethylnitrosamine-treated... 203

SV40 large T antigen [Ca2+] i responses during proliferation... 512

TIMP- 1 High TIMP-1 expression results i n . . . 1055

UDP-glucuronosyltransferase Prolonged expression of bilirubin-UDP... 453 Long-term correction of bi l i rubin. . . 1071

Vectors Development of a novel retroviral . . . 360 Cell ploidy-based fractionation.. . 452 High efficiency transfection o f . . . 787

T r a n s f e r r i n Diagnostic use

Carbohydrate deficient t ransferr in . . . 553 Carbohydrato-deficient t ransferr in . . . 1147

In pregnancy Carbohydrate-deficient t ransferr in . . . 1550

Pathophysiology Transferrin: a potent cholesterol... 24 Role of transferrin in the t i ssue . . . 1214

Receptors al-antitrypsin reduces t ransferr in . . . 1044 Localisation of ferritin, transferrin... 1143

T r a n s f o r m i n g g r o w t h f a c t o r a Polypeptide growth factors part icipate. . . 367 Are transforming growth factor a . . . 505 Impaired liver regeneration in t ransgenic. . . 506 Analysis of prolonged exposure t o . . . 795 Serum transforming growth factor . . . 1359 Transforming growth factor a l p h a . . . 1360

T r a n s f o r m i n g g r o w t h f a c t o r [~ Alcoholic cirrhosis

Serum undulin and collagen type ~.. 720 Antisense oligonucleotides Towards in vivo gene knock out... 1132

Apoptosis TGF-~I induction of apoptosis. , . 488

Cell physiology Effect of hepatitis B virus X g sne . . . 626 Transcriptional activation of a2( I ) . . . 698

Fibrogenesis Studies on the fibrogenic potential . . . 719

Gene expression Regulation of TGF-beta expression.. . 717 Identification of the antifibrogenic... 718 Increased intrahepatic mRNA expression.. . 1422 Acetaldehyde increases transforming. . . 1461 Oncogenes expression after b i l e . . . 1482 Cytokine mediated regulation o f . . . 1607

Hepatic fibrosis Expression of c-met mRNA and TGF-[31... 504 Plasma transforming growth f~tctsr-]3... 721 Induction of transforming growth . . . 1226 Transforming growth factor a l p h a . . . 1360

Hepatitis C Transforming growth facter-~l . . . 920

Hepatocellular carcinoma Prognostic significance of p la sma . . . 326

Hormone effects Effect of antiandrogen t rea tment . . . 359

Liver regeneration Kupffer cell depletion shifts t h e . . . 508

Receptors Transgenic mice expressing a Zn-inducible... 205 Characterization of TGF-~I . . . 1245

Regulation Apoptosis in the liver after • . . 490

Tumor immunology Possible involvement of t ransforming. . . 1306

T r a n s g e n i c a n i m a l s bcl.2 gene

Bcl-2 protects from lethal hepat ic . . . 483 Hepatic fibrosis

Transcriptional activation of a2 ( I ) . . . 698 Hepatitis B virus X protcin

Increased 8-hydroxy-2'-deoxyguanosine... 348 Cancer formation in WAP-HBV-X... 349

Hepatocyte growth factor Inhibition of neoplastic development.. . 451

Interleukin-6 The soluble IL-6 receptor amplif ies. . . 1032

Liver regeneration Impaired liver regeneration in t ransgenic . . . 506

myc gone Analysis of prolonged exposure t o . . . 795

PDGF receptor Role of platolet-derived g rowth . . . 697

TGF~ receptor Transgenic mice expressing a Zn-inducible... 205

T r a n s g l u t a m i n a s e Tissue transglutaminase gene expression.. . 702

T r a n s j u g u l a r i n t r a h e p a t i c p o r t a s y s t e m i c shunt

Anticoagulation TIPS: thrombogenicity and ea r ly . . . 592

Ascites Outcome after transjugular intrahepat ic . . . 234 TIPSS for refractory ascites a n d . , . 235 TIPS and paracentesis for the t rea tment . . . 762 Effectiveness oftransjugular intrahepat ic . . . 1531

Cirrhosis Hepatic extraction and systemic. , . 1298

Complications Conversion of failed t rans jugniar . , . 160 Does TIPS induce mechanical hemolysis?.. . 1442

Drug effects Portal and systemic hemodynamic. . . 595

Esophageal varices TIPS versus sclerotherapy + propranolol . . . 761

Hepatic encephalopathy Quantification of the extent o f . . . 757 MRI findings in chronic hepa t ic . . . 1289 Latent hepatic encephalopathy i n . . . 1478

Hepatic veno-occlusive disease Transjugular intrahepatic portal-systemic... 591

Liver transplantation The impact of transjugular intrahepat ic . . . 1180 Liver transplantation after transjugular. 1587

Magnetic resonance spectroscopy In vitro proton (1H) magnet ic . . . 1310

Occlusion Phenprocoumon for prevention o f . . . 594

Outcome TIPSS versus variceal band l igat ion. . . 578 Liver function after t rans jugular . . . 588 Outcome of TIPS in non-cavernomateus.. 589 Liver function after t rans jugular . . . 590 Clinical events following TIPS . . . 758

Physiology Dissecting the factors involved.. . 229 Increased colloid osmotic p ressure . . . 233 The influence of TIPS on por ta l . . . 760

Portal vein thrombosis Portal vein thrombosis in cirrhosis . . . 1181

Predictors of response Hepatic arterial resistance index . . . 1398

Stenosis Pathogenesis of TIPS stenosis: neoarterial. . . 593 The Achilles heel of TIPS, parenchymal . . . 763

Variceal bleeding Efficacy of TIPS in the prevention. . . 759

T r a n s p l a n t r e j e c t i o n SEE Graft rejection

T r a n s p l a n t a t i o n , b o n e m a r r o w Transjugular intrahepatic portal- systemic. . . 591 Orthotepic liver t ransplantat ion. . . 1499

T r a n s p l a n t a t i o n , h e a r t Liver or combined lung and l iver . . . 167 Clinical experience with hepat i t i s . . . 963 Outcomes of heart transplant recipients. . . 964

T r a n s p l a n t a t i o n , h e p a t o c y t e Acute hepatic failure

Critical analysis of intra-splenic. . . 387 Rapid integration and proliferation.. . 499

Bioartificial liver Preliminary evaluation of a n e w . . . 423

Crigler-Najjar syndrome Amelioration of biltrubin conjugation.. . 417 Primary hepatocytes t ransplanted. . . 419

568A S U B J E C T I N D E X HEPATOLOGY O c t o b e r 1 9 9 5

T r a n s p l a n t a t i o n , h e p a t o c y t e ( c o n t i n u e d )

Cryopreservation Controlled rate freezing of hepatecytes. . . 420

Graft function Increased liver engraftment o f . . . 418

Immunologic cytoxicity Hepatocyte transplant combined w i t h . . . 424 The role of MHC antigens and adhesion. . . 1364

Liver transplantation, experimental Isolated fetal porcine hepatecytes. . . 425

Methods Study of CD4 and CD8 level a n d . . . 1271

Radionuclide imaging Transplantation of hepatecytes m a r k e d . . . 1078

Rejection Anogeneie Kupffer cell is impor tan t . . . 426

Safety 99m-Tc-labeled human serum a lbumin . . . 421

T r a n s p l a n t a t i o n , l i v e r SEE Liver t ransplanta t ion

T r a n s p l a n t a t i o n , l u n g Liver or combined lung and l ive r . . . 167

T r a n s p l a n t a t i o n , r e n a l Combined liver-kidney t ransplantat ion. . . 388 Chronic HCV infection in I-1D... 1175 In kidney graft recipients r ibavir ine. . . 1187 Detection of Pneumocystis carinii , . . 1312 Immunologically negative hepat i t i s . . . 1523

T r a n s p l a n t a t i o n , s m a l l b o w e l The pathology of the liver g ra f t s . . . 1582

T r a n s p o r t e r a s s o c i a t e d w i t h a n t i g e n p r o c e s s i n g g e n e s

Analysis of gone and protein expression . . , 372

T r i g l y c e r i d e s Role of apolipoprotein E in intracel lular . . . 529

T r i m e t h o p r i m - s u l f a m e t h o x a z o l e Selective intestinal decontamination.. . 1268

T r i m e t h y l h e x a n o y l f e r r o c e n e Induction of heme oxygenase- 1 InRNA.. . 1350

T u m o r - a s s o c i a t e d a n t i g e n s CA-125 as a marker for detection.. 226 "Pseudo-ovarian carcinoma". . . 1240 CA 19-9 is not a reliable test i n . . . 1441

T u m o r b l o o d f l o w Alterations of blood supply to t he . . 316

T u m o r i m m u n o l o g y Analysis of gene and protein expressmn. . . 372 Possible involvement of t ransforming. . . 1306

T u m o r m a r k e r s Clinicepathological significance.. . 322

T u m o r n e c r o s i s f a c t o r a Antagonists and inhibitors

Tyrosine phosphorylation is impor tan t . . . 796 Antioxidante suppress endotexin-induced... 1034

Antibody to Antibodies to tumor necrosis facter-~. . . 362

Apoptosis Nitric oxide and tumor necrosis . . . 486 TNFa-induced apoptesis o f . . . 1093

Blood Circulating tumor necrosi s fac te r -a . . . 599 Levels of tumor necrosis fac tor -a . . . 1401

Cell physiology Bifunctional effect of tumor necrosis . . . 523 Apoptosis and clanal growth inhibi t ion. . . 1425

Drug effects Intrahepatic lymphocyte production. . . 1033

Gene expression Treatment with dietary sa tu ra ted . . . 476 In vivo suppression of Kupffcr . . . 1035

Gene regulation TNF-a stimulates a l ( I ) . . . 701

Hepatotoxieity S-adenosylmethionine deficiency... 1092

Interferon therapy Effect ofintcrferon alpha on T N F - a . . . 250

Kupffer cells Kupffer cell depletion shifts t h e . . . 508 Thiol regulation of endotexin-Induced... 520 Glutathione suppression of endotexin. . . 522 Endoeytesis is an essential s t e p . . . 1365

Pathophysiology Serum cytokine levels in pa t ien ts . , . 107 Role of tumor necrosis facter-aipha. . . 600 Further insights Into the role o f . . . 842 Different receptors for endotexin. . . 1405 Tumor necrosis factor alpha Increases. . . 1514

T u m o r s u p p r e s s o r g e n e s Interferon regulatory factor-1

Interferon regulatory faster-1 gene . . . 363 p15

Expression and regulation of p 5 3 . . . 334 Regulation of the p21/WAF1/CIP1/SDI1... 519 Cyclin-dependant kinase 4 inhibitors. . . 1205

p2~ Regulation of the p21/WAF1/CIP1/SDI1... 519

p53 Genetic mechanisms of tmnorigenesis. . . 13 p53 and k-ras gene mutations i n . . . 156 p53 and Fas/APO-linductlonin hepatema. . • 200 p53 status, pX induced cell cycle . . . 202 Ki-67 and p53 immunestaining methods . . . 323 Identification of proteins f rom. . . 330 Reconstitution of wild-type p 5 3 . . . 331 p53 abnormalities in hepatceellular. . . 332 Sequence-specific transcriptional. . . 333 Expression and regulation of p53. . . 334 Immunohistochemical study on expression . . . 335 Possible mechanism of cyclin A . . . 337 HCV proteins do not bind p53 o r . . . 350 Sodium butyrats reversibly blocks. . . 507 The clinicopathological study o f . . . 1307 Antibodies to mutant p53 in cirrhotic. . . 1545

Retinoblastoma HCV proteinsdo not bind p53 o r . . . 350

T u r n e r ' s s y n d r o m e Cholestasis associated with T u r n e r s . . . 1369

T y r o s i n e k i n a s e s Receptor tyrosine kinase expression.. . 745 Tyresine phosphorylatian is impor tan t . . . 796 Autephosphorylatlon of the epidermal. . . 1439

T y r o s i n e m i a Improvement in liver function a n d . . . 1076 Abnormalities in tyresine degradat ion. . , 1534

U

U D P - g l u c u r o n o s y l t r a n s f e r a s e Persistent unconjugated. . . 397 Prolonged expression of bilirubin-UDP... 453 Effect ofbutylated hydroxytoluene.. . 781 Hepatic microsoma] U D P . . . 818 Identification ofbilirubin UDP-GT.. . 819 Functional identification of car r ie r . . . 826 Correction of bilirubin glucuronidation.. . 1070 Leng-term correction of bi l i rubin. . . 1071

U l c e r a t i v e c o l i t i s Overlap between type 1 autoimmune. . . 90 Experimental colitis increases hepatecyte. . . 769

U l t r a s o u n d i m a g i n g Cholangiocarcinoma

Peripheral cholangiocarcinoma: detection.. . 1198 Cholelithiasis

Prevalence and risk factors f o r . . . 1362 Cirrhosis

Can cirrhosis be accurately diagnosed. . . 1278 Hepatic arteries

Clinical significance of t h e . . . 1178 Hepatocellular carcinoma

Clinical features suggesting development . . . . . . . Laparoscopy

Staging laparoscopy with laparoscopic.. . 2 Liver biopsy

The effect of ultrasonography o n . . . 1112 Liver donor screening

Maximal utilization of the "marginal ~ . . . 1299

U n d u l i n serum undulin and collagen t y p e . . . 720

U r s o d e o x y c b o l a t e Analogs and derivatives

Metabolism and enterohepatic circulation.. . 855 Study of human isoursodeoxycholic... 1389

Biosynthesis Hepatic cholesterol 7~-hydrexylase... 859

Cell physiology Nuclear DNA fragmentation in b i l ia ry . . . 58

Ethanol Chronic alcohol consmnption increases. . . 546

Hepatitis C Reduction of liver iron content . . . 1162 The effect of ursodeexycholic a c id . . . 1457

Hepatocellular injury 1153 S-adenosylmethionine versus . . .

Hepatotoxicity Bile salt toxicity is reduced b y . . . 1174

U r s o d e o x y c h o l a t e ( c o n t i n u e d ) Pharmacology

Ursodeexycholie acid inhibits induct ion. . . 1020 Effect of UDCA on liver iron s to re . . . 1368 Ursodeoxycholic acid treatment augments . . . 1517

Physiology Effect of bile acids on hepatocellular. . . 862 Retention of a bile acid analogue. . . 1212 Bile acid-induced increase in ce l l . . . 1233 Ursodeoxycholic acid reduces pro te in . . . 1592

Primary biliary cirrhosis Soluble intercellular adhesion molecule.. . 72 Histological course of primary b i l ia ry . . . 73 Predictors of unfavorable outcome. . . 74 Ursodeoxycholie acid delays t h e . . . 75 Reduced expression of heat shock . . . 1508

Therapeutic use Ursodeoxycholic acid reduces hepa t ic . . . 170 Ursodeoxycholic acid therapy i n . . . 845 Increase of lipocyte number a n d . . . 1171 Cholestasis associated with Turner ' s . . . 1369

V

V a l p r o i c a c i d Induction of the permeability t rans i t ion . . . 1106

V a r i a b l e r e g i o n s , i m m u n o g l o b u l i n g e n e s

Cloning of the variable reg ions . . . 66

V a r i c e a l b l e e d i n g SEEALSO Sclerotherapy; Transjugular

intrahepatic portasystemic shunt Surgical portosystemic shunt i n . . . 153 Spontaneous reduction of por t a l . . . 194 TIPSS versus variceal band l igat ion. . . 578 Meta-analysis of endoscopic l igat ion. . . 580 Meta-analysis of propranelol p l u s . . . 582 Increased portal and systemic fihrinolysis. •. 584 Variceal bleeding or refractory. . . 602 Subcutaneous octreotide for the . . . . 1210 Daily modifications of splancimic. . . 1541

V a r i c e a l l i g a t i o n Endoscopic sclerotherapy ve r sus . . . 577 TIPSS versus varicoal band l iga t ion . . . 578 Prophylactic endoscopic var icea l . . . 579 Meta-analysis of endoscopic l iga t ien . . . 580 Experiment of endoscopic var icea l . . . 581

V a r i c e s , e s o p h a g e a l Drug effects

Ureedeoxychelic acid delays t h e . . . 75 Propranolol does not decrease t h e . . . 193 Hemodynamic effects Of octreotlde.. . 1501

Endoscopic hemostasis Endoscopic sclerotherapy ve r sus . . . 577 Prophylactic endoscopic var icea l . . . 579

Endoscopic ul trasound High resolution end0blm~nal eonography. . . 587

Paracentesis Reduction of esophageal var icea l . . . 195

TIPS Efficacy of TIPS in the prevent ion. . . 759 TIPS versus sclerotherapy + propranalol . . . 761

V a r i c e s , g a s t r i c Experiment of endoscopic var icea l . . . 581 Efficacy of TIPS in the prevention. . . 759

V a s c u l a r e n d o t h e l i a l g r o w t h f a c t o r Expression ofvasculur endothelial . . . 339 Differential expression of vascu la r . . . 511

V a s c u l a r e n d o t h e l i u m Binding of liver-derived lymphocytes. . . 84 Impaired endothelial function i n . . . 198

V a s c u l a r g r a f t s Cryo-preserved vein graft fa i lures . . . 403

V a s c u l a r r e s i s t a n c e Hepatic artery resistance i ndex . . . 11 A critical balance between endothelins. . . 567 Role of endothelinm-derived... 568 Endothelium-derived hyperpolarizing.. . 570 Vasodilation to nerve st imulat ion. . . 603 Resting vasodilatery capacity i n . . . 604 The role of calcium channel inhibi t ion. . . 608 Nitric oxide-dependent and -independent. . . 1287

V a s c u l a r s m o o t h m u s c l e c e l l s Nitric oxide preferentially upregulates . . . 793

V a s o a c t i v e i n t e s t i n a l p e p t i d e cc-mitegenic effect of vaseactive.. ~ 518 VIP is a potent stimulus of bicarbonate . . . 752 Calcified liver metastases of VIPoma. . . 1526

HEPATOLOGY Vol. 22, No. 4, Pt. 2, 1995 SUBJECT INDEX 569A

Vasopressins Terlipressin in the treatment o f . . .

VCAM-1 Can soluble adhesion molecules b e . . . interferon reduces tissular cxpression... Serum levels of soluble vascular . . .

Vesicular t r a n s p o r t Alcohol-induced alterations in t h e . . . The bile canalicular membrane contains.. . Chronic ethanol administration increases.. Protein phosphatase 2A-mediated... Involvement of phosphatidylinositel... Maturational increase in canalicular.. . High affinity transporter of reduced. . . Acetaminophen glucuronide t ransport . . . Hepatic microsomal U D P . . .

Vidarab ine Outcome of prolonged arahinoside.. .

Videoendoscopy High resolution endoluminal sonography..

Vimentin Co-expression of cytokeratin 7 w i th . . .

VIPoma Co-mitogenic effect ofvasoactive.. . VIP is a potent stimulus of bicarbonate... Calcified liver metastases of VIPoma. . .

Viral replication Antagonists and inhibitors

Use of dominant negative mutan t s . . . Inhibition of hepatitis B v i r u s . . . Inhibition of viral replication... Lamivudine results in a complete... Inhibition of hepatitis B v i r a l . . , The effectiveness of ant isense. . .

Drug effects Reduction in hepatitis B virus quasispecies. 2',3'-Dideoxy-~-L-5'-fluorocytidine... Inhibitory effect of penciclovir...

236

126 249 251

478 755 797 806 809 814 815 817 818

1559

587

765

518 752

1526

472 473 648 886 891

1285

• 885 888 890

Viral replication (continued) Hepatitis B virus

Liver transplantation for pat ients . . . Routine evaluation of hepatitis... HBV core promotor mutations cause... Multiple enzyme activities of human... The mitechondrion is the key organelle... The relationship between hepatitis...

Hepatitis C virus Quantitation ofintra-hepatic HCV-RNA...

Hepatitis, viral Viral interference in double infection... What are epidemiological, biochemical...

Vitamin A Effects of dietary fat on ethanol-induced... Effects of dietary zinc on vitamin... Portal "watershed" at the...

Vitamin B Vitamin B deficiency results in...

Vitamin D Does long-term calcitonin, calcium... Vitamin D receptor polymorphisms... Vitamin D receptor gene polymorphism...

Vitamin E Vitamin E suppresses lipocyte activation... Effects of vitamin E, ascorhic acid...

WXYZ

X protein Characterization of a liver-specific... 623

94 Use of the yeast two-hybrid sys tem. . . 624 471 Tetracycline-regulated expression... 625 614 Effect of hepatitis B virus X gene . . . 626 651 Subcellular localization of hepat i t is . . . 1542

1 4 5 9 Xanthine oxidase 1567 Xanthine oxidase inhibition reduces. . . 844

1 2 1 6 Xenopus laevis oocytes Expression in Xenopus laevis oocytes... 751

694 Xenotransplantation 635 Hepatic metastasis of human colorectal,.. 373

Hyperacute rejection of discordant.. . 427 477 Histepathology of l ive r . . . 428

1462 Study of CD4 and CD8 level a n d . . . 1271 1630 A new and simplified technique fo r . , . 1388

Zinc 525 Transgenic mice expressing a Zn-inducible... 265

Influence of serum zinc level t o . . . 1341 Effects of dietary zinc on v i t amin . . . 1462

77 Zinc fingers 731

1267 Zf9, a novel zinc finger gene induced.. . 747 Expression of metallopanstimulin... 1248

Water Terlipresein enhances free water . . . 1591

Wilson's disease Conditionally immortalized hepatocytes... 1065 Mitechondrial abnormalities in Long. . , 1066 Proliferation of hepatic lysosomes... 1067 Identification of heterozygous carr iers . . . 1068

690 1617